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Abstract
Disease surveillance is the continuous collection, analysis, and interpretation of
health-related data. Information gained from routine HIV disease surveillance is vital to
national program managers deciding to implement new prevention or treatment
programs. In this dissertation, we describe methods for estimation of HIV incidence and
the prevalence of HIV drug resistance.
HIV incidence estimation is critical for identifying at-risk populations for targeted
interventions and measuring the effectiveness of these interventions. We provide an
in-depth literature review of the available options for estimating HIV incidence,
including cross-sectional assays. Next, we describe a novel cross-sectional assay for HIV
incidence estimation that discriminates between recent and long-term infections on the
basis of within-host viral diversity. Diversity is measured using a version of Shannons
entropy that we adapt to improve discriminatory ability. These adaptations include
breaking the within-host sequence alignment into smaller sections to allow for more
nuanced detection of within-host variability, and we suggest an algorithm for adjusting
for multiple HIV infections using clustering methods.
HIV drug resistance surveillance guides national programmatic managers
identifying effective treatment regimens for HIV-infected individuals in their countries.
We describe a large-scale consulting project with the World Health Organization to
redesign their guidance for pre-treatment and acquired HIV drug resistance surveillance
in low- and middle-income countries. Our consulting work prompted a variety of
iiiinteresting statistical questions that we address in a series of papers. We describe a novel
method for calculating sample sizes for two-stage clustered surveys in which the ﬁnite
population correction can be applied. Our method results in a sometimes dramatic
decrease in sample size while still achieving the desired precision. We introduce a novel
acquired HIV drug resistance outcome for measuring viral load suppression that
incorporates information on patient loss-to-follow-up. This outcome has increased
epidemiological utility over previously used outcomes. Finally, we evaluate methods for
conﬁdence interval estimation for proportions measured in surveys and provide
recommendations for their use.
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x1. IntroductionMy doctoral dissertation focuses on two important aspects of HIV-1 disease surveillance:
incidence estimation and monitoring of drug resistance. Disease surveillance is the con-
tinuous collection, analysis, and interpretation of health-related data, and disease surveil-
lance is critical for public health practice. Information gained from surveillance is vital
to national public health managers deciding to implement new prevention or treatment
programs. Because HIV/AIDS disproportionately affects under-served populations, lo-
gistical simplicity and low cost are very important factors in evaluating these surveillance
methods. Surveillance must be sufﬁciently feasible to be regularly executed in low- and
middle-income countries. Otherwise, countries may not implement these methods and
will lack the data necessary to make informed programmatic decisions.
In the Chapters 2 and 3, we describe our methods for estimation of HIV-1 incidence.
Incidence measures the rate of recent infections, and it is critical for understanding trans-
mission dynamics, identifying at-risk populations for targeted interventions, measuring
the effectiveness of community-level interventions, and calculating sample size require-
ments for randomized trials. In Chapter 2, we provide an in-depth literature review of
available options for estimating HIV incidence, emphasizing the serious challenges in
this ﬁeld. Standard follow-up of an HIV-negative cohort is prohibitively expensive, lo-
gistically complicated, and subject to biases. Other methods that involve repeated preva-
lence surveys require a variety of assumptions and are only applicable in generalized
epidemics. Ultimately, cross-sectional surveys that discriminate between recent and long-
term infections using a host or viral marker are most appealing. The majority of existing
assays measure immunological factors, but these assays have drawbacks including sub-
type variability and individuals who never test as long-term on the assay despite many
years of HIV infection (long-term non-progressors). Diversity-based assays are an emerg-
ing alternative; they rely on the immense increase in viral diversity that occurs within a
host over the course of an infection.
In Chapter 3, we describe a novel assay for discriminating between recent and long-term
infections using viral diversity. We adapt an existing diversity measure known as Shan-
2non’s entropy. Entropy is a concept from information theory, and it is used to measure the
variability in a multinomial outcome. After a person is infected with HIV, the virus mu-
tates resulting in a diverse range of sequence patterns within a single individual. Here,
the multinomial outcome of interest is each unique viral sequence pattern within an in-
dividual. In our paper, we demonstrate that by dividing the sequence alignment into
smaller sections before calculating entropy, we increase the discriminatory ability of the
assay as measured by the area under the receiver operator characteristic curve. In addi-
tion, weintroducea methodforadjustingforthepresence ofmultipleinfections. Multiple
infections confound the relationship between time since infection and diversity because
individuals recently infected with multiple viruses can have high diversity. We use clus-
tering methods to separate viral lineages and measure within-lineage entropy rather than
overall entropy.
In the Chapter 4, we describe a large-scale consulting project with the World Health Orga-
nization (WHO) to redesign their guidance for HIV drug resistance surveillance in low-
and middle-income countries. This guidance for surveillance in patients initiating treat-
ment (pre-treatment resistance) and patients on treatment (acquired drug resistance) will
be adapted by countries into fully realized survey protocols. These protocols will then
be implemented by the countries with limited support from the WHO. Thus, simplicity
and feasibility are critical for determining the success of this guidance. Nonetheless, we
emphasize the importance of collecting representative data and analyzing the data in a
statistically rigorous fashion. In a report included in this dissertation, we describe the
surveys and the statistical decisions made during the consulting process, focusing pri-
marily on sample size calculations and survey analysis. Guidance for the two surveys is
currently being published by the WHO.
Our consulting work prompted a variety of interesting statistical questions which we ad-
dress in a series of papers. In Chapter 5, we describe a novel method for calculating
sample sizes for two-stage clustered surveys in which the ﬁnite population correction
will be applied. We demonstrate dramatic decreases in sample size requirements while
3still achieving the desired precision. This paper has important implications for disease
surveillance in small countries or countries with concentrated epidemics. Using previ-
ously available methods, sample size requirements can be larger than the total eligible
population size in some countries. As a result, these countries do not feel able to properly
implement the survey and may not conduct the survey at all. Our method empowers
small countries to design drug resistance surveys that will work in their unique setting.
The sample size procedure introduced in the paper is already being implemented as a
core element of the WHO’s HIV drug resistance surveillance guidance.
In Chapter 6, we introduce a novel outcome for the acquired drug resistance survey. The
acquired drug resistance survey includes a cross-sectional assessment of viral load in pa-
tients on antiretroviral therapy for 12  3 months. As this measure excludes patients who
have died or been lost to follow-up, it is biased relative to the population-level prevalence
of viral load suppression. As a result, this measure can be misleading in the absence of
representative data on patient retention. A country may have high viral load suppres-
sion among retained patients, but they may have many patients lost to follow-up. If that
country implemented a program to improve patient retention, they may actually observe
a decrease in viral load suppression among retained patients because they have captured
some of the sickest patients who would have otherwise been lost. Through consulta-
tion with the WHO’s HIV drug resistance steering group, we constructed a new measure
of population-level viral load suppression that assumes that all patients who are lost to
follow-up are not virally suppressed. The outcome can be interpreted as a lower bound of
viral load suppression, and it has improved epidemiological utility over the unadjusted
outcome. In the paper, we derive the properties of this outcome, including point and
standard error estimators. We also derive the expected precision of this outcome under a
set of assumptions and assess sensitivity to these assumptions through a series of simu-
lations.
In Chapter 7, we evaluate methods for conﬁdence interval estimation for proportions
measured in surveys. Extensive literature has demonstrated that the Wald interval per-
4forms poorly in the independent and identically distributed setting. Alternative meth-
ods, including the Wilson, Jeffreys, and Agresti-Coull intervals, perform much better.
The Clopper-Pearson, or ‘exact,’ interval is another popular option, although it tends to
be unnecessarily wide and conservative. There is very little peer-reviewed evaluation of
these intervals in survey settings. In our paper, we describe seven methods for calculat-
ing conﬁdence intervals for proportions, including adaptions of the Jeffreys and Agresti-
Coull intervals that have never been applied in the existing literature. For each method,
we describe an approach that does and does not incorporate the design degrees of free-
dom into the calculations, suggesting a framework to increase logical consistency across
formulations. We evaluate these methods via an extensive simulation study. We demon-
strate the importance of adjusting for the design degrees of freedom, and we show that
the modiﬁed Jeffreys and Wilson intervals perform best in terms of conﬁdence interval
length and coverage. Finally, we address the topic of truncation, in which the effective
sample size from a clustered survey is not allowed to exceed the actual survey sample
size. We describe a discrepancy in the existing literature on truncation and provide our
recommendations for this setting.
52. The challenges of HIV incidence estimation
Natalie Exner2.1 Background
The ability to accurately estimate incidence, or the risk of acquiring infection within a
given period of time, is a critical component of any human immunodeﬁciency virus type
1 (HIV-1) disease surveillance program. A reliable estimate of incidence in a given pop-
ulation allows investigators to understand transmission dynamics, evaluate the perfor-
mance of prevention programs, and identify high-risk populations so as to efﬁciently
utilize resources (Rutherford et al., 2000). Accurate incidence estimates are also critical
when calculating sample size requirements during the design phase of prevention tri-
als. Despite the importance of this indicator, it is extremely difﬁcult to estimate HIV-1
incidence in practice (Family Health International, 2009). Methods currently available in-
cludedirectobservationofaseronegativecohort, back-calculationmethods, modelingthe
epidemic in the general population using serial prevalence surveys, and cross-sectional
assays which rely on the evolution of host or viral markers. All existing methods have se-
rious limitations, and the search for an estimator which is both unbiased and logistically
feasible continues.
Direct observation of a seronegative cohort was once considered the ‘gold standard’ for
the measurement of HIV-1 incidence. In practice, this method is rarely used because it
requires enormous sample sizes, making it both logistically complicated, prohibitively
expensive, and unsustainable even in resource-rich settings (Family Health International,
2009). Furthermore, there is potential for selection and follow-up bias because those who
are willing to enroll in such a trial and who are not lost to follow-up may not be represen-
tative of the general population. Brookmeyer et al. calculated two estimates of incidence
for two STD clinics in India (Brookmeyer et al., 1995). The cohort-based estimate was
markedly less than the combined cohort/cross-sectional estimate, and the difference in
these estimates was supported by signiﬁcant behavioral differences between those who
returned for follow-up and those who did not. Since individuals enrolled in a prevention
trial are counseled on risk reduction, it is reasonable to expect their HIV-1 incidence to
7be lower than that of the general population. Thus, direct observation of a seronegative
cohort is not an appropriate ‘gold standard’ for the estimation of HIV-1 incidence.
Until the mid-1990s, incidence could be back-calculated from AIDS surveillance data
using an estimate of the distribution of the viral incubation period (Brookmeyer, 1991).
Back-calculation methods from AIDS diagnoses require reliable disease surveillance data
as well as an accurately described incubation period (Gail and Brookmeyer, 1988). Be-
cause of the widespread use of highly active antiretroviral treatment (HAART), this
method is no longer in use, but some researchers use back-calculation from other events
besides AIDS diagnoses. Extended back-calculation models have been described using
a dichotomous measure of disease severity at time of HIV diagnosis (Hall et al., 2008),
CD4 cell count (Satten and Longini, 1994; Taffe et al., 2008), and the joint distribution of
two HIV antigens (Sommen et al., 2010). These methods require many assumptions, most
notably regarding testing behavior since they back-calculate from time of ﬁrst positive an-
tibody test (Karon et al., 2008). Because of the large amount of individual level variability
in CD4 and HIV antigen trajectories as well as the necessity for assumptions about homo-
geneity of testing behavior across individuals and time, these back-calculation methods
are not ideal for the estimation of HIV-1 incidence.
An alternative method infers incidence from changes in age-speciﬁc seroprevalence mea-
sured by serial surveys. The method works by dividing up the general population into
age cohorts so that these cohorts can be tracked through time across repeated surveys;
given the prevalence at the time of the last survey, the method accounts for deaths us-
ing assumptions about age-speciﬁc mortality, and then it calculates the number of new
infections that must have occurred in each cohort to achieve the observed prevalence in
the current survey (Hallett et al., 2008). The method can only be applied to generalized
epidemics in which large-scale demographic surveys are routinely carried out, and it can-
not be used to calculate incidence in sub-epidemics, such as among injection drug users
(Rehle et al., 2010). The accuracy of the estimate depends on the reliability of the sero-
prevalence surveys, which can be biased if they do not explicitly account for differential
8testing refusal, underrepresentation of mobile groups (Marston et al., 2008), and internal
migration (Hallett et al., 2008). Estimation of age-speciﬁc mortality is further complicated
by the roll-out of HAART and requires additional assumptions regarding age-speciﬁc
treatment initiation and the effect of treatment on survival (Rehle et al., 2010). Com-
puter packages, such as the Spectrum package (Stover, 2004; Stover et al., 2010), have
been developed to model age-speciﬁc incidence, but their results are only as good as the
seroprevalence data and assumptions on which they rely (Ghys et al., 2004). Thus, while
these models may serve as useful tools for understanding transmission dynamics, their
usefulness for accurately estimating incidence is limited (Sakarovitch et al., 2007).
2.2 Cross-sectional assays
Cross-sectional assays for recent HIV-1 infection are the most promising methods for inci-
dence estimation; they are cheaper, simpler, and prone to less bias than direct observation
of a cohort, and they require many fewer assumptions than back-calculation methods or
computer models. These assays distinguish between recent and long-term infections on
the basis of a host or viral marker; when the marker is below some threshold, the infec-
tion is classiﬁed as ‘recent’, and when the marker is above that threshold, the infection
is classiﬁed as ‘long-term.’ Incidence can be calculated from a cross-sectional survey as
I = P=! where P is the prevalence of recent infections within the at-risk population (i.e.
excluding long-term infections), and ! is the mean duration of the period when an infec-
tion is classiﬁed as ‘recent’, also called the window period (Rothman et al., 2008). This
estimator assumes constant incidence during the period before the survey at least as long
as the maximum plausible window period (Brookmeyer and Quinn, 1995). It also re-
quires an accurate estimate of the mean window period in the population of interest, and,
as a result, makes the implicit assumption that all individuals with HIV infection have
markers that will eventually cross the ‘recent/long-term’ threshold (Wang and Lagakos,
2009). Most existing assays rely on markers of evolution of the host immune system in
9response to HIV infection, though recent papers describe novel assays which exploit viral
characteristics.
The ﬁrst cross-sectional assay for recent infection was described in 1995 by Brookmeyer
and Quinn (1995). The assay relies on the presence of detectable p24 antigenemia during
the period before seroconversion. The survey ﬁrst identiﬁes and excludes all antibody
positive individuals, and then all antibody negative individuals are tested for p24. This
assay is not in use for two primary reasons: 1) the window period for p24 antigenemia
is very short (approximately 22.5 days from the ﬁrst report), and 2) the assay is used to
test antibody negative individuals. Even in a high prevalence setting, this assay will re-
quire enormous sample sizes to detect enough recent infections for a precise estimate of
incidence. The assay also has low sensitivity among individuals in the process of sero-
conversion (antibody indeterminate) (Hecht et al., 2002). A similar assay was developed
using detectable HIV-1 RNA during the pre-seroconversion period. While this assay has
better sensitivity and a slightly longer mean window period (Le Vu et al., 2009), it still re-
quires the testing of large samples of antibody negative individuals. Some authors have
proposed pooling algorithms for RNA testing to reduce costs (Brookmeyer, 1999; Quinn
et al., 2000), but, even with these cost-saving measures, the assay remains much more
expensive than an assay which is conducted using only antibody positive samples.
The ﬁrst test intended for use in seropositive individuals was described by Janssen et al.
(1998). By varying the laboratory procedure for the traditional antibody assay (higher
dilution, shorter incubation time, higher cutoff), they created a less-sensitive, or detuned,
assay, subsequently referred to as the Serological Testing Algorithm for Recent HIV Se-
roconversion (STARHS). As antibody levels increase during the early stages of infection,
seroconversion on the sensitive assay precedes seroconversion on the less-sensitive as-
say, and the time between these two events is described by the mean window period (129
days(95%CI:109-149days)intheinitialreportofasubtypeBcohort(Janssenetal.,1998)).
While this assay has signiﬁcant advantages over p24 and RNA testing in terms of cost and
feasibility, additional studies quickly identiﬁed its numerous limitations; the assay suffers
10from low internal consistency as demonstrated by high coefﬁcients of variation (>20%),
most likely because of the magnitude of the dilution (1:20,000) (Kothe et al., 2003); the
mean window period varies by HIV-1 subtype (Parekh et al., 2001; Wilson et al., 2004;
Young et al., 2003); the assay can misclassify those with advanced infection (Guy et al.,
2005; Parekh et al., 2001; Rawal et al., 2003; Wilson et al., 2004), those on antiretroviral
treatment (ART) (Killian et al., 2006; Rawal et al., 2003), and ‘elite suppressors’ (Laeyen-
decker et al., 2008); and there is evidence of individuals whose markers never cross the
less-sensitive threshold regardless of the length of follow-up (Young et al., 2003). As a
result, STARHS has low speciﬁcity which can lead to greatly overestimated measures of
incidence.
With the speciﬁc goal of addressing the subtype variability observed for STARHS, the
CDC developed the BED capture enzyme immunoassay (BED-CEIA) using gp41 se-
quences from HIV-1 subtypes B, E, and D (Parekh et al., 2002). The assay measures the
ratio of HIV-speciﬁc immunoglobulin G (IgG) to total IgG, a proportion which generally
increases during the ﬁrst two years after seroconversion (Parekh and McDougal, 2001).
While this assay has advantages over STARHS, including higher internal consistency
(Dobbs et al., 2004), lower cost, and commercial availability, a variety of studies have
demonstrated that the BED-CEIA has many of the same weaknesses as its predecessor,
including a non-zero fraction of the population who persistently test as ‘recent’ despite
demonstrated long-term infection (Hargrove et al., 2008; Karita et al., 2007), misclassi-
ﬁcation of those with advanced infection (Karon et al., 2008; Marinda et al., 2010), and
misclassiﬁcation of those on ART (Marinda et al., 2010). Furthermore, the mean window
period varies widely by subtype, either because of viral or host immunological factors
(Karita et al., 2007; Parekh et al., 2011). As a result, in 2005 UNAIDS recommended that
the BED-CEIA not be used in routine HIV-1 surveillance, including absolute incidence
estimation or monitoring trends (UNAIDS Reference Group on Estimates Modeling and
Projections, 2005).
Becauseofitspoorspeciﬁcity, usingtheBED-CEIAinahighprevalencesettingcanleadto
11signiﬁcant overestimation of incidence (Sakarovitch et al., 2007). A variety of estimators
have been proposed which adjust for imperfect sensitivity, short-term speciﬁcity (relating
to infections of duration longer than the window period ! but less than 2!), and long-
term speciﬁcity (relating to infections of duration greater than 2!). The ﬁrst adjusted es-
timator, proposed by McDougal et al. (2006), required calibration of four parameters: the
mean window period !, sensitivity , short-term speciﬁcity 1, and long-term speciﬁcity
2. This formula was further simpliﬁed by Hargrove et al. (2008) assuming that  = 1,
yielding only three parameters for calibration. McWalter and Welte (2008) constructed
an estimator that makes fewer assumptions than either McDougal or Hargrove and re-
quires calibration of only two parameters: the mean window period ! and long-term
speciﬁcity 2 (McWalter and Welte, 2009). Given the proportion of seropositive individ-
uals that register under the assay threshold P0, the true proportion of recent infections is
PT =
P0+2 1
2 . This adjusted prevalence can then be plugged into the traditional incidence
formula I = PT=!. Their estimator coincides with the maximum likelihood estimator
derived by Wang and Lagakos (2009).
Despite the mathematical justiﬁcation for the McWalter/Welte estimator, the use of ad-
justments for cross-sectional incidence estimates is hotly debated (i.e. which one, if any)
(Brookmeyer, 2009a,b; Hargrove, 2009; McDougal, 2009; Welte et al., 2009). Following the
2005 UNAIDS statement discouraging use of the BED-CEIA, the Global AIDS Coordina-
tor stated that the assay may be used as long as appropriate adjustments are made (Of-
ﬁce of Global AIDS Coordinator, 2006). In practice, these adjustments rely on accurate,
locally-derived estimates of the calibration parameters (Barnigh¨ ausen et al., 2008, 2010;
Kim et al., 2010; World Health Organization, 2009b), and if these calibration parameters
vary signiﬁcantly between populations or across time, it is unlikely that the BED-CEIA
will be of practical use (Hallett et al., 2009; Welte et al., 2010). One alternative proposed by
Wang and Lagakos is an augmented cross-sectional design which longitudinally follows
individuals who test as recent on the BED-CEIA with the goal of calculating an internal
estimate of long-term speciﬁcity; this method has the logistical challenges associated with
12individual follow-up, though to a much lesser extent than a complete cohort study, and
may be difﬁcult to implement in practice (Wang and Lagakos, 2010). Overall, despite the
initial promise of the BED-CEIA, extensive research has demonstrated that it is difﬁcult
to obtain accurate estimates of HIV-1 incidence using this assay alone.
Besides the STARHS and BED-CEIA, a variety of other assays have been developed to
exploit maturation of the host immune system during HIV-1 infection. Among the most
commonly used is the Avidity Index developed in 2003 (Suligoi et al., 2003). While the
originalpaperclaimedthattheassaywasrobusttoARTuseandthepresenceofadvanced
disease, subsequent studies have disproved these claims (Chawla et al., 2007; Sakarovitch
et al., 2007; Selleri et al., 2007). The IDE-V3 assay developed in 2005 measures antibodies
speciﬁc to four HIV-1 antigens, including the immunodominant epitope of gp41 (IDE)
and V3 peptides (Barin et al., 2005). This assay, also referred to as the enzyme immunoas-
say for recent infection (EIA-RI), is not appropriate for individuals initiated on ART dur-
ing early infection (Barin et al., 2005) and has overall low sensitivity (Le Vu et al., 2009;
Sakarovitch et al., 2007); there is also preliminary evidence of subtype variability (Le Vu
et al., 2009). Other assays include the anti-p24 IgG3 assay (Wilson et al., 2004), the line im-
munoassay (Sch¨ upbach et al., 2007), the particle agglutination assay (Hong et al., 2007),
and a new multi-subtype avidity-based assay developed by the CDC (Wei et al., 2010).
These assays are summarized in a review paper by the WHO Working Group on HIV
Incidence Assays (Busch et al., 2010). Overall, I believe that future evaluation of these im-
munoassays will reveal many of the same drawbacks as the existing immunoassays, in-
cluding low speciﬁcity and subtype variability. While immunoassays provide important
information regarding duration of infection, I do not think that they alone can provide
accurate and reliable estimates of HIV-1 incidence.
132.3 Diversity-based assays
An emerging alternative to immunoassays are diversity-based assays which exploit the
increase in viral diversity that occurs during the early stages of HIV-1 infection. The
majority of infections are seeded by a single founder virus (Keele, 2010), resulting in an
initial viral population with zero diversity. Because of the high error rate of the reverse
transcriptase enzyme (Ji and Loeb, 1994) and the rapid turnover rate in vivo (Ho et al.,
1995; Wei et al., 1995), the virus is able to rapidly diversify within its new host (Cofﬁn,
1995). There is strong evidence that viral genetic diversity increases linearly with time
during this initial phase of HIV-1 infection (Frost et al., 2005; Kearney et al., 2009; Lee
et al., 2008, 2009; Shankarappa et al., 1999). This accumulation of mutations has also been
described using a Poisson distribution (Keele et al., 2008; Lee et al., 2009; Leitner and
Albert, 1999). The envelope (env) gene, which codes for the viral surface proteins that
interact with the host immune system, has the greatest potential for diversity within the
HIV-1 genome. Variability in env is adaptive in that it helps the virus evade host im-
mune pressures (Holmes et al., 1992). In fact, unlike other regions of the genome, there is
compelling evidence that env is under positive, or diversifying, selection, promoting vari-
ability in the host viral population rather than selecting for only the ‘ﬁttest’ quasispecies
(Bonhoeffer et al., 1995; Ganeshan et al., 1997; Overbaugh and Bangham, 2001; Piantadosi
et al., 2009; Poss et al., 1998; Yamaguchi and Gojobori, 1997). Overall, diversity-based as-
says of recent infection are promising because of the immense within-host variability of
the HIV-1 genome.
A variety of diversity-based assays have been described in the recent literature. There is
one which uses the fraction of ambiguous nucleotide calls obtained during bulk sequenc-
ing of the pol gene as a proxy for overall diversity (Kouyos et al., 2011; Wilson et al., 2011;
Andersson et al., 2013). Using a Swiss subtype B cohort, they found evidence that this
fraction increases linearly during the ﬁrst eight years of infection (Kouyos et al., 2011).
The advantage of this type of test is that it is easily implementable as bulk sequencing of
14this region is already part of standard genotypic resistance testing procedures. It also has
certain disadvantages: nucleotide ambiguity is inherently a binary measure and may not
adequately describe the diversity present at a particular position; the lower limit of detec-
tion is typically 20% (Kouyos et al., 2011), meaning the assay will underestimate diversity
if there are minority quasispecies in the population; and, while diversity in pol correlates
with diversity in other regions, genetic bottlenecking could occur in response to selective
pressures, thereby reducing speciﬁcity. Another recent assay suggests measuring diver-
sity in multiple regions of the genome, including env, pol, and gag, to increase robustness
against such genetic bottlenecking (Cousins et al., 2011). This assay uses high resolution
melting (HRM), which measures diversity without sequencing using the melting charac-
teristics of DNA duplexes (Towler et al., 2010). Again, the advantage of this assay is its
implementability, being in a 96-well plate format and taking only a few minutes to run.
A disadvantage not addressed is the likely increased sensitivity to insertions/deletions
that DNA-duplex-based assays, such as the heteroduplex mobility assay (HMA), exhibit
(Delwart et al., 2002, 1994, 1993; Sagar et al., 2004). Most of all, none of the diversity-based
assaysdescribedthusfarareabletodistinguishbetweensingle-viruslong-terminfections
and multiple-virus recent infections.
The presence of infections seeded by multiple founder viruses provides a signiﬁcant chal-
lenge for diversity-based assays. Though the majority of infections are thought to be
founded by a single virus, a non-negligible proportion are founded by two or more viri-
ons. This proportion appears to be related to mode of infection (Ritola et al., 2004; Tem-
pleton et al., 2009), and there may exist effect modiﬁers, such as the presence of inﬂamma-
tory genital infections (Abrahams et al., 2009; Haaland et al., 2009). Various studies have
yielded a remarkably consistent estimate of 80% of heterosexual transmissions involving
single virus transmission (Abrahams et al., 2009; Grobler et al., 2004; Keele et al., 2008;
Salazar-Gonzalez et al., 2008), although there may be a higher risk for male-to-female
versus female-to-male transmission (Delwart et al., 2002; Long et al., 2000). Many reports
from men who have sex with men have demonstrated very little multiplicity of infection
15(Delwart et al., 1997; Gottlieb et al., 2004; Shankarappa et al., 1998), though this has not
been consistent across all studies (Kearney et al., 2009; Ritola et al., 2004). As might be ex-
pected because of the lack of a mucosal barrier, parenteral transmission, such as through
injection drug use, is associated with a much higher proportion of multiple infections (Bar
et al., 2010; Templeton et al., 2009). Simple measures of diversity, such as the fraction of
ambiguous nucleotides or the HRM score, cannot discriminate between single and multi-
pleinfections; asaresult, theywillsufferfromreducedsensitivitybecauserecentmultiple
infections will appear long-term by virtue of their high levels of diversity. Since the un-
derlying proportion of multiple infections is related to mode of transmission, which may
vary across samples, it is unlikely that these incidence estimates can be reliably adjusted
for their imperfect sensitivity.
Overall, multiply infected individuals have high viral diversity, even at the earliest
stages of infection. Interestingly, there is evidence to suggest that the individual lineages
founded by each of the separate virions have very low initial diversity. This has been
recognized in studies which have sequenced quasispecies from individuals recently in-
fected with multiple viral strains (Long et al., 2000; Salazar-Gonzalez et al., 2008). These
sublineages conform to a Poisson distribution when analyzed individually (Keele et al.,
2008). Thus, the challenges associated with multiplicity of infection may be overcome if
the viral population can be separated into related sublineages and the diversity measured
within these clusters.
The most recent diversity-based assay described in the literature uses features of the dis-
tribution of pairwise Hamming distances of env sequences (Park et al., 2011). These se-
quences are obtained using single genome ampliﬁcation and direct sequencing, a method
which reduces Taq polymerase errors, Taq polymerase mediated template switching, and
non-proportional representation of target sequences (Keele et al., 2008). The authors use
the tenth percentile of the distance distribution to discriminate between recent and long-
term infections, with the reasoning that the proportion of similar sequences will decline
with time. Their method appears to be robust to a variety of different factors, including
16viral subtype and multiplicity of infection. No studies have yet evaluated these claims
using different data sets (Allam et al., 2011).
2.4 Discussion
Despite the immense effort to develop an accurate and reliable estimator for HIV-1 inci-
dence, no method has emerged that is sufﬁciently sensitive, speciﬁc, and robust to differ-
ences in host and viral characteristics. Cross-sectional assays, which require the fewest
assumptions and are logistically most feasible, are likely to be the best option, but they are
not without their challenges. Immunoassays, such as the BED-CEIA and the Avidity In-
dex, suffer from low speciﬁcity resulting from ART use, chronic disease, and the presence
of long-term non-progressors in the population. Diversity-based assays are emerging as
a new alternative to immunoassays. Because of the added complication of multiplicity
of infection, simple measures of diversity are unlikely to be successful in distinguishing
between recent and long-term infections. I believe that sequencing of the viral popula-
tion using single genome ampliﬁcation and direct sequencing will be necessary to fully
characterize the diversity within an individual. Eventually, these assays will need to be
evaluated for their performance in the presence of ART and chronic infection. Overall,
it is unlikely that a single assay will work well enough for use in research or routine
surveillance; thus, focus is now shifting to multiassay algorithms (MAAs) which incor-
porate different measures, such as viral characteristics, host immune response, and use
of antiretrovirals (Brookmeyer et al., 2013a,b; Moyo et al., 2014). An accurate measure of
viral diversity could be incorporated as a reﬁning step at the end of such an algorithm to
improve HIV-1 incidence estimation (Cousins et al., 2014).
173. Adapting entropy to measure within-host viral diversity
for use in a cross-sectional HIV-1 incidence assay
Natalie Exner and Marcello PaganoAbstract
HIV-1 incidence can be estimated using cross-sectional assays that discriminate between
recent and long-term infections on the basis of host or viral characteristics. Because of the
limitations of existing immunological assays, assays measuring within-host viral diver-
sity are potentially useful because diversity generally increases with time since infection.
One such assay described in the literature is the 10th percentile (Q10) of the within-host
pairwise Hamming distance distribution. A standard measure of viral diversity is Shan-
nons entropy which either quantiﬁes the variability in the sequence patterns within the
alignment or summarizes the variability at each position in the gene/region. We propose
subdividing the gene/region of interest into sections of moderate length and calculating
entropy as a weighted average of the entropy in each section. Such a method is hampered
when an individual has been multiply infected. To overcome this shortcoming, we pro-
pose a clustering based method that separates the sample into unique sub-lineages before
measuring entropy, if there is evidence of multiple infections. To evaluate our approach,
we analyze envelope sequence data from a longitudinal subtype C infection cohort in
Botswana comprised of 8 acute and 34 recent infections. Sequences were obtained using
single genome ampliﬁcation followed by direct sequencing. We demonstrate that using
sections of moderate length and adjusting for multiple infections results in signiﬁcantly
improved discriminatory ability of the assay relative to either pre-existing entropy-based
measure (using the whole alignment or each position) or the Q10 method.
3.1 Introduction
An accurate estimator of HIV-1 incidence is critical for understanding transmission dy-
namics, evaluating the performance of prevention programs, and identifying high-risk
populations for targeted interventions (Rutherford et al., 2000). Cross-sectional surveys
for incidence estimation are promising for a variety of reasons, including increased feasi-
19bility and reduced selection bias as compared to direct observation of an HIV-1 negative
cohort (Brookmeyer and Quinn, 1995). To accurately estimate incidence cross-sectionally,
an assay must be able to distinguish between recent and long-term infections on the basis
of a measured host or viral marker. Current HIV incidence assays that rely on changes
in host immunological factors during early stages of infection, such as the BED-CEIA
(Parekh et al., 2002) and the Avidity Index (Suligoi et al., 2003), have critical limitations,
including misclassiﬁcation of those with advanced infection (Karon et al., 2008; Marinda
et al., 2010), misclassiﬁcation of those on ART (Marinda et al., 2010), and variability in
performance across subtypes (Karita et al., 2007; Parekh et al., 2011).
An emerging alternative to immunoassays are diversity-based assays that exploit the in-
crease in viral diversity that occurs during the early stages of HIV-1 infection. Numerous
studies have demonstrated that within-host viral diversity increases over the course of
HIV infection (Frost et al., 2005; Kearney et al., 2009; Lee et al., 2008, 2009; Shankarappa
etal.,1999); thus, within-hostviraldiversityisapotentialpredictoroftimesinceinfection.
A range of diversity-based assays have been described in the recent literature, including
a measure of the fraction of ambiguous nucleotide calls obtained during bulk sequencing
(Kouyos et al., 2011) and a high-resolution melting (HRM) assay that measures diver-
sity without sequencing using the melting characteristics of DNA duplexes (Towler et al.,
2010). These assays are readily implementable, but one key limitation is their inability to
accurately classify individuals recently infected with multiple viruses. While the initial
diversity in a single infection is zero, this initial diversity can be very high when there are
multiple founding viruses, thereby confounding the relationship between diversity and
time since infection. It is estimated that 20% of heterosexual infections are founded by
multiple viruses (Abrahams et al., 2009; Keele et al., 2008; Salazar-Gonzalez et al., 2008),
with higher rates observed for parenteral infections (Bar et al., 2010; Templeton et al.,
2009). Another recently described diversity-based assay uses the 10th percentile of the
distribution of within-host pairwise Hamming distances obtained via single genome am-
pliﬁcation (Park et al., 2011). The authors suggest that this method has high sensitivity
20and speciﬁcity and is robust to the presence of multiple infections.
We propose an alternative measure of within-host viral diversity also using data from
single genome ampliﬁcation and direct sequencing. Our measure is an adaptation of a
standard measure of viral diversity – normalized Shannons entropy. Entropy is a concept
from information theory that measures variability in a multinomial outcome (Shannon,
1948). There are two common ways in which entropy is calculated for viral sequences. In
the ﬁrst approach, the multinomial outcomes are the observed viral sequence patterns in
an alignment (henceforth referred to as the whole alignment approach) (Sato et al., 1998;
Wang et al., 1998). Entropy (H) can be deﬁned as:
H =  

1
logN
 n X
i=1
pi logpi
where N is the total number of sequences, n is the number of distinct sequence patterns,
and pi is the proportion of sequences consisting of each distinct sequence pattern. The
measure is normalized by the quantity logN, which is the maximal entropy for a set of N
sequences. Entropy is equal to 0 when all sequences are identical and is equal to 1 when
all sequences are distinct.
The second approach entails calculating the entropy at position j, where n is the number
of distinct bases (or amino acids) at each position and pij is the prevalence of base i (or
amino acid i) at position j; the entropy of the alignment is then the average entropy over
all positions (henceforth referred to as the position approach) (Korber et al., 1994).
We argue that it is possible to improve the ability of entropy to discriminate between
recent and long-term infections by modifying how the quantity is calculated. We demon-
strate that the whole alignment approach described above is not well-suited for discrim-
ination because, by this deﬁnition, two sequences varying by only a single nucleotide
have distinct patterns. As a result, this method is not sufﬁciently nuanced to measure the
range of similarities that can occur between sequences. In addition, we demonstrate that
the second version of Shannons entropy the position approach is also not well-suited for
discrimination because it over-represents highly correlated positions. We propose a novel
21method that subdivides the viral gene into smaller sections, calculates entropy in each in-
dividual section, and combines results across all sections. The optimal section length is
a compromise between the two extreme lengths deﬁned by the whole alignment and the
position methods, and can be determined by its discriminating capabilities.
As can be anticipated, a multiply-infected individual will exhibit more variability than a
singly-infected individual, both infected at the same time, and as a result, judging time
since infection by looking at the diversity will be complicated by the multiplicity of the
infection. To address this problem, we also propose an approach for identifying multi-
ple infections using standard clustering techniques. We suggest that viral diversity be
measured within distinct sub-lineages rather than across all sequences to reduce the con-
founding effect of multiple infections. This approach is motivated by evidence that the
separate sub-lineages in a multiple infection evolve independently (Keele et al., 2008).
Thus, the diversity within each sub-lineage may be comparable to the diversity accumu-
lated within a single infection. We evaluate our proposed methods using data from a
primary HIV-1 subtype C infection cohort in Botswana (Novitsky et al., 2009). The cohort
includes eight acutely infected and thirty-four recently infected individuals followed lon-
gitudinally through 500 days post-seroconversion. We demonstrate improved discrimi-
natory ability of our approach when comparing it to the 10th percentile (abbreviated as
Q10) (Park et al., 2011) of the pairwise Hamming distance distribution.
3.2 Materials and methods
3.2.1 Sequence data
We analyze viral sequences from the Tshedimoso study, a primary HIV-1 subtype C in-
fection cohort in Botswana comprised of eight acutely infected individuals (Fiebig stage
II) and thirty-four recently infected individuals (Fiebig stage IV or V) (Novitsky et al.,
2009). For acutely infected subjects, time of seroconversion was estimated as the mid-
22point between the last seronegative test and the ﬁrst seropositive test; for recently infected
patients, time of seroconversion was estimated using Fiebig staging (Fiebig et al., 2003).
Subjects were followed longitudinally through 500 days post-seroconversion. At each
time point, sequences from the envelope gene were obtained using single genome am-
pliﬁcation followed by direct sequencing (Novitsky et al., 2009). After aligning the se-
quences, hypermutants were removed from the sample using Hypermut 2.0 (Rose and
Korber, 2000). The total length of the alignment was 1377 nucleotides. Only samples with
at least 5 sequences collected were considered for analysis. The 42 subjects were observed
at a total of 197 time points with a median of 11 sequences per time point (range 5, 32).
From the aligned sample of HIV-1 viral sequences, for each subject at each time point we
calculate the 10th percentile of the pairwise Hamming distance distribution (Q10).
3.2.2 Proposed method
Our methods require an aligned sample of HIV-1 viral sequences obtained cross-
sectionally from a single host. Each sequence can represent a single region, multiple
regions, a single gene, or multiple genes. For the sequences to be representative of the un-
derlying viral population, they are obtained using single genome ampliﬁcation followed
by direct sequencing.
(1) Sectioned entropy
Given an alignment of sequences with multiple sequences per individual, we subdivide
the aligned sample into smaller sections. For each individuals set of aligned sequences,
we calculate the entropy separately for each section, and then we average across the sec-
tions to obtain an overall score (see Figure 3.1). By calculating diversity in this way, iso-
lated polymorphisms do not disproportionately contribute to entropy because they are
countered by the lack of diversity in other sections. The score is a weighted average with
weights equal to the length of the section (after removing all gap-only sites in the sam-
23ple). The length and location of these sections can be determined in a variety of ways. We
select a simple division of the sample into approximately even sections of L nucleotides,
testing a variety of values for L (ranging from 50 to 500), but the method can easily be
adapted for more biologically motivated divisions, such as breaking up the sample into
functional domains, or ﬂexible weighting of regions.
Figure 3.1: Highlighter plot example of sectioned entropy procedure. The alignment of sequences
within a host is subdivided into sections of a pre-determined length. Entropy is measured within
each section, and the overall entropy score is a weighted average of the section-speciﬁc entropy
measures.
(2) Adjusting for multiplicity of infection
Next, we propose an algorithm to reduce confounding due to the presence of multiple
infections. Multiple infections can be characterized by a high degree of clustering among
the sequences within a patient. After dividing the alignment into sections, we test each
individuals sequences for the presence of multiple infections using clustering methods.
If present, we separate the sample into distinct sub-lineages, measure the entropy in each
sub-lineage, and combine information across sub-lineages to obtain the entropy for that
section (see Figure 3.2). By measuring entropy within sub-lineages rather than across
sub-lineages, we reduce the risk of over-estimating diversity at early stages of infection
whenwewouldexpectlowvariabilitywithinsub-lineagesbutpotentiallyhighvariability
across sub-lineages. Because within-host recombination can dilute the strength of cluster-
ing, clustering is assessed in each section separately to allow sequences within an indi-
vidual to group with different sub-lineages across sections. The clustering procedure is
24repeated for all sections, and the overall score is the average entropy across all sections.
Figure 3.2: Highlighter plot example of adjustment for multiplicity of infection procedure. Within
each section, clustering methods are applied to separate sequences within a host into distinct sub-
lineages. Entropy is measured within each sub-lineage and combined across sub-lineages.
To test for the presence of clustering within an individual in an aligned section, we use
Hamming Distance (or any other genetic distance metric) to calculate a matrix of pair-
wise distances for all of the sequences within a host, and then we compare the maximum
observed pairwise distance to a moderately low threshold (3%) because sequences with
a maximum pairwise distance below this are unlikely to be multiply infected. Among
sequences with a sufﬁciently high maximum pairwise distance we use an automatable
procedure employing a measure known as the silhouette width to determine the opti-
mal number of clusters given the observed data (Kaufman and Rousseeuw, 1990). This
procedure can return a value of 1, 2, 3 or 4 clusters, with 1 cluster indicating no signiﬁ-
cant clustering. To apply this procedure, ﬁrst use the k-means algorithm on the matrix of
within-host pairwise distances to cluster sequences into k = 2, 3, and 4 groups (Kaufman
and Rousseeuw, 1990). For each value of k, calculate the average silhouette width. Sil-
houette width is a measure of the adequacy of clustering that can take values between 0
and 1, with an average silhouette width above 0.70 indicating a strong structure. Average
silhouette width maximizes when the number of clusters is optimal. Silhouette width is
deﬁned as:
s(i) =
b(i)   a(i)
max[a(i);b(i)]
where, for sequence i, a(i) is the average distance to other sequences in its cluster, and
b(i) is the average distance to sequences in the nearest cluster, with nearest deﬁned as
25having the minimum average distance to sequence i. The average silhouette width is
the average over all sequences i. Since silhouette width is not calculated for k = 1, the
optimal number of clusters k is the value of k that yields the maximum silhouette width,
conditional on that maximum being above 0.70; otherwise, k is equal to 1.
Given the calculated number of clusters k for that section, we subdivide the sequences
intosub-lineagesusingk-meansclustering. Wethenmeasureentropyineachsub-lineage,
and these entropy scores are pooled across sub-lineages, weighting proportional to the
number of sequences in each sub-lineage minus 1 (since diversity is trivially zero from
a sample of size 1 and should not contribute to the overall diversity). Letting HK be the
entropy in the kth sub-lineage, the overall entropy in that section is:
H =
Pk
k=1(nk   1)Hk
Pk
k=1(nk   1)
As before, the overall entropy score is a weighted average of the entropy values across all
sections, weighted by section length.
3.2.3 Statistical analyses
We calculate each approachs discriminatory ability at 180 days post-seroconversion via
the area under the curve (AUC) of the receiver operator characteristic (ROC) curve and
an associated 95% conﬁdence interval. We employ a non-parametric approach to adjust
for clustering of the data by subject because subjects are observed repeatedly over time
(Obuchowski,1997). Todirectlycomparetwodifferentapproachesusingthesamesample
of clustered data, we apply a similar method to calculate the absolute difference in AUC
and a 95% conﬁdence interval for this difference (Obuchowski, 1997).The analyses were
carried out using R (R Core Team, 2012).
263.3 Results
For all subjects at all time points, we calculate entropy using the whole alignment ap-
proach, the position approach, and the section approach, dividing the alignment into
sections roughly of length L = 50 through L = 500 nucleotides (in increments of 50) with
and without adjusting for multiplicity of infection using the Silhouette method described.
In Figure 3.3 we plot entropy score trajectories for each of the 42 subjects against time
since seroconversion using whole alignment entropy (L = 1377) and sectioned entropy
for three additional values of L (50, 300, and 500 nucleotides) without adjusting for mul-
tiplicity of infection (plotted with LOESS curve 95% conﬁdence band). Although there is
heterogeneity in the level of diversity across individuals, the trajectories tend to increase
with time for all measures. The whole alignment approach attains a maximal value even
at the earliest time points for some samples. After introducing sectioning, the entropy
scores decrease and are less likely to attain the maximal value. As a result, we observe
a more pronounced relationship between time and diversity. When the sections are very
small (i.e., L = 50), the entropy scores tend to be lower because there are more gene
regions with few or no mutations.
In Figure 3.4 we plot diversity trajectories for each of the 42 subjects using Shannons
entropyforL = 250withandwithoutadjustmentformultiplicityofinfectionagainsttime
since seroconversion. The adjustment method results in slightly decreased variability in
the trajectories, as evidenced by a tightening of the 95% conﬁdence interval band. Even
after adjusting for multiplicity of infection, some early infections with high entropy scores
persist.
Table 3.1 summarizes the results of the clustered ROC analyses measuring discriminatory
ability at 180 days post-seroconversion using the whole alignment approach, the posi-
tion approach, and the section approach, dividing the alignment into sections of length
L = 50 through L = 500 nucleotides (in increments of 50) with and without adjusting for
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(d) Sectioned Entropy, L=50
Time, days post−seroconversion
E
n
t
r
o
p
y
 
S
c
o
r
e
0
0.2
0.4
0.6
0.8
1
0 100 200 300 400 500
Figure 3.3: Entropy score trajectories and LOESS line for the env gene of 42 acutely and recently
HIV-infected subjects. (a) Whole alignment approach. (b) Sectioning procedure is applied with
L = 500 without adjustment for multiplicity of infection. (c) Sectioning procedure is applied with
L = 250 without adjustment for multiplicity of infection. (d) Sectioning procedure is applied with
L = 50 without adjustment for multiplicity of infection.
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Figure 3.4: Entropy score trajectories and LOESS line for the env gene of 42 acutely and recently
HIV-infected subjects. (a) Sectioning procedure is applied with L = 250 without adjustment for
multiplicity of infection. (b) Sectioning procedure is applied with L = 250 with adjustment for
multiplicity of infection.
multiplicity of infection using the Silhouette method described. Note that the Silhouette
method is not applied to the position approach because clustering cannot be assessed in
a region of length L = 1. Among the methods considered, the minimal AUC is 68.3% for
the whole alignment approach adjusting for multiplicity of infection, and the maximal
AUC is 79.3% for the sectioned entropy approach with L = 250 adjusting for multiplic-
ity of infection. The AUCs for the whole alignment approach are lower than any AUC
obtained via the sectioned approach. With one exception (L = 50 with adjustment), all
combinations of the sectioned approach have a signiﬁcantly higher AUC than the whole
alignment approach. The AUCs for the position approach are lower than any AUC ob-
tained via the section approach. This difference is statistically signiﬁcant for L = 150,
200, and 250 (without adjustment) and L = 250 (with adjustment). Note that statistical
signiﬁcance is determined using the matched AUC procedure described previously; thus,
certain approaches do not achieve statistical signiﬁcance despite having higher AUC val-
ues. Furthermore, the statistical procedure incorporates the observed covariance between
theapproaches. Becausetheapproachesusethesameunderlyingdata, thecovariancecan
29be very high. Thus, a signiﬁcant difference can be detected between methods even when
there is a lot of overlap in the conﬁdence intervals.
Table 3.1: Estimated area under the curve for discriminating between infections ¡180 and 180 days
post-seroconversion on the basis of within-host viral diversity in env. Diversity is measured using
whole alignment entropy, sectioned entropy, or position entropy, either adjusted or unadjusted for
multiplicity of infection.
Not Adjusted for Adjusted for
Multiplicity of Infection Multiplicity of Infection
AUC 95% CI AUC 95% CI
Whole Alignment (L = 1377) 68.8% (61.5%, 76.0%) 68.3% (61.0%, 75.6%)
Sectioned (L = 500) 77.8%* (70.8%, 84.8%) 78.3%* (71.5%, 85.2%)
Sectioned (L = 450) 78.0%* (71.0%, 85.0%) 78.9%* (71.9%, 85.8%)
Sectioned (L = 400) 77.8%* (71.0%, 84.7%) 78.6%* (71.8%, 85.5%)
Sectioned (L = 350) 77.8%* (70.9%, 84.7%) 78.3%* (71.7%, 85.0%)
Sectioned (L = 300) 76.8%* (69.8%, 83.8%) 77.4%* (70.3%, 84.4%)
Sectioned (L = 250) 78.4%*y (71.3%, 85.6%) 79.3%*y (72.3%, 86.2%)
Sectioned (L = 200) 77.9%*y (70.7%, 84.9%) 79.0%* (72.0%, 86.0%)
Sectioned (L = 150) 77.9%*y (70.5%, 85.2%) 78.8%* (71.9%, 85.6%)
Sectioned (L = 100) 76.7%* (69.4%, 83.9%) 78.2%* (71.0%, 85.4%)
Sectioned (L = 50) 76.2%* (68.6%, 83.8%) 74.7% (66.9%, 82.4%)
Position (L = 1) 73.7% (66.1%, 81.3%) n/a n/a
* indicates that the AUC is signiﬁcantly higher than that of the unadjusted whole alignment approach.
y indicates that the AUC is signiﬁcantly higher than that of the unadjusted position approach.
In Figure 3.5 we plot diversity trajectories for each of the 42 subjects using the Ham-
ming Distance Q10 approach. Q10 tends to increase with time since seroconversion in
this population. We observe some individuals with high measurements at early time
points. These patients are almost exclusively patients with documented multiple infec-
tions (Novitsky et al., 2011). The sample includes one very high outlier at 469 days post-
30seroconversion for a patient with a multiple infection. There are also patients with low
values of Q10 persisting beyond 300 days post-seroconversion. The AUC for the Q10
method in this sample is 74.5% with 95% conﬁdence interval (67.2%, 81.9%). The whole
alignment approaches (unadjusted and adjusted) have a signiﬁcantly lower AUC than
the Q10 method. Nearly all combinations of the sectioned approach have a signiﬁcantly
higher AUC than the Q10 method (unadjusted L = 200, 250, 350, 400, 450, and 500, and
adjusted L = 100, 150, 200, 250, 350, 400, 450 and 500). The maximal difference is with
the sectioned entropy with L = 250 and adjusting for multiplicity of infection; here the
absolute difference is 4.7%, with 95% conﬁdence interval (1.9%, 7.5%).
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Figure3.5: Q10trajectoriesandLOESSlinefortheenvgeneof42acutelyandrecentlyHIV-infected
subjects. (a) All trajectories. (b) Detail.
3.4 Discussion
We propose a new measure of within-host HIV-1 viral diversity for use in cross-sectional
incidence estimation. To generate this measure, we describe two simple adjustments to
Shannons entropy with the goal of improving our ability to discriminate between infec-
tions before and after 180 days post-seroconversion. For the ﬁrst proposed adjustment,
31we divide the alignment into sections of length L (recommended L = 250) and calculate
overall entropy as an average of the section-speciﬁc entropy values. For the second ad-
justment, we use clustering methods to separate samples into distinct viral sub-lineages
before measuring entropy. Both of these adjustments improve the discriminatory abil-
ity of entropy as evidenced by changes in AUC. We evaluate an existing diversity-based
measure using the 10th percentile (Q10) of the within-subject pairwise Hamming distance
distribution. We found that most combinations of sectioned entropy had signiﬁcantly im-
proved discriminatory ability over Q10 in this cohort of acutely and recently infected
subtype C patients from Botswana.
The results of our research provide insight into the relationship between diversity and
the size of the gene/region of interest. Traditionally, entropy is either measured as the
variability in the patterns in the whole alignment, or entropy can be calculated as the av-
erage entropy over all positions in the gene/region. Both of these approaches represent
extreme values for L, the length of the region in which we calculate entropy; in the for-
mer, L is equal to the total length of the gene/region; in the latter, L is equal to 1. Our
research suggests that the optimal L is a compromise between these two extremes. If L is
too large, we fail to capture similarities between sequences, and a sample can reach max-
imal entropy even if it is very homogeneous. If L is too small, we over-represent highly
correlated polymorphisms, leading to undesirable behavior of the measure and poorer
prediction. If we select a larger L, related mutations that fall in the same section do not
contribute disproportionately to overall diversity.
There are limitations to this method. First, there is heterogeneity in the accumulation of
diversity across individuals. As a result, this method is unlikely to be useful for predict-
ing time since infection in individuals (i.e. clinical use), but it has applicability at the
population-level, such as in the estimation of HIV-1 incidence. Second, this method re-
quires single genome ampliﬁcation and direct sequencing for each sample, tools which
are expensive and time-intensive. We believe that (1) the ﬁnancial and labor costs will
decrease as technology improves, and (2) that the lack of reliable alternatives at any cost,
32despite the importance of the problem, suggests that this research is worth pursuing. In
addition, we propose that this assay is best used as part of a multi-assay algorithm (MAA)
in which patients are screened using less expensive cross-sectional assays, such as viral
load testing, BED-CEIA, or antibody avidity (Brookmeyer et al., 2013a); thus, genotyp-
ing would only be necessary for the small fraction of individuals who test as recent on
all screening assays, and the measurement of diversity would be a reﬁning step in the
algorithm.
An additional limitation is that, while the adjustment for multiplicity of infection does
slightly improve measurement of some multiple infections, some early infections have
persistently high diversity levels even after adjustment. These cases tend to be individu-
als infected with multiple related viruses (Novitsky et al., 2011) that do not clearly cluster
and are very difﬁcult to distinguish from long-term single infections without additional
information. Furthermore, inter-lineage recombination does occur in multiple infections.
The motivation for evaluating clustering in each section rather than evaluating clustering
in the entire alignment is the presence of recombination, which results in recombinant
sequences clustering with different sub-lineages in different regions. Dividing the sam-
ple into sections before measuring clustering reduces the impact of recombination, but
recombination breakpoints which do not fall exactly in line with section breakpoints can
weaken the approach. We tested incorporating information on estimated recombination
breakpoints as identiﬁed by the program RDP3 (Martin et al., 2010), but this adds an ad-
ditional layer of complexity without improving overall performance (data not shown).
There may be a better way to incorporate this information.
Our procedure can be generalized for other methods of measuring diversity. For example,
the discriminatory ability of Q10 may improve if the gene/region is ﬁrst divided into
smaller sections and/or separated into distinct sub-lineages using clustering methods.
This question merits further investigation.
334. WHO HIV drug resistance surveillance consulting
project report
Natalie Exner and Marcello PaganoAbstract
In this report, we describe our large-scale consulting project for the World Health Orga-
nization (WHO), focusing on the statistical challenges that arose and solutions identiﬁed.
The WHO is currently in the process of redesigning their guidance for the surveillance
of HIV drug resistance (HIVDR) in low- and middle-income countries. The guidance
describes recommendations for monitoring two aspects of HIVDR that are of interest to
country program directors: (1) resistance in individuals starting antiretroviral therapy
(ART), referred to as pre-treatment drug resistance (PDR), and (2) resistance in individu-
als on ART for at 12  3 months and  48 months, referred to as acquired drug resistance
(ADR). Descriptions of our proposed approach for these two surveys is currently being
prepared for publication by the WHO, and the methodology described within will then
be adapted by in-country researchers into survey design protocols that will meet the par-
ticular needs of that country.
4.1 Introduction
In our work as statistical consultants designing surveillance systems for HIV drug resis-
tance in low- and middle-income countries, we faced a variety of challenges. The ﬁrst
major challenge is the likely limited technical capacity of in-country researchers who
will be executing these surveys. Thus, the survey design, implementation, and analy-
sis must be exceedingly simple. The second major challenge is the extreme diversity of
HIV epidemics across all low- and middle-income countries. Among the countries we
have consulted with, one country has more than 4,000 HIV sites, while another has only
5. Some countries have generalized HIV epidemics, while others have epidemics that are
highly concentrated among particular risk groups. Some countries have electronic medi-
cal records that have detailed information on all patients that can be queried at a national
level, while others have paper-based systems that cannot be accessed without visiting
35each site individually. Thus, it is important that the design is sufﬁciently ﬂexible that it
can be adapted for use in any country. The third major challenge is feasibility. The pro-
posed designs can not be too costly or logistically complicated. Longitudinal follow-up,
which was an element of the previous version of these protocols, is no longer considered
feasible. For small countries, the designs cannot require sampling more patients than
would be eligible during the survey period. Feasibility is critical because it can be the dif-
ference between the survey being implemented, or not. These are just some of the many
challenges that arose during this consulting process.
Ultimately, ourgoalistoimprovetheabilityofprogrammanagerstomakeinformeddeci-
sionsabouttheircountry’spreventionandtreatmentprogramsthroughtheuseofsurveil-
lance data with sufﬁcient precision and quality. To elevate the quality of the surveillance
data, we employ principled statistical methodology and epidemiological expertise while
being mindful of the constraints described above. Where possible, we opted for the sim-
plest methodology without sacriﬁcing rigor. We recognize that if we were to make the de-
sign more complex, we could get closer to the ideal statistical result. In practice, though,
the more complex the design, the less likely that the survey will be done properly and
the less likely that the survey will be done at all. We developed Excel-based tools with
limited input required by the user to assist in the survey design process, and, with only
few exceptions, we developed primary outcomes that can be easily analyzed in Stata or
other survey-based statistical software. Our goal is to empower in-country researchers to
collect and analyze their own data with limited external assistance to build capacity to
make decisions about their national HIV programs.
The core of this report is divided into two sections, covering each of the survey design
protocols. We focus on the statistical challenges and our proposed solutions. Some solu-
tions are standard, while others required development of new methodology. We describe
all in turn.
364.2 Pre-treatment drug resistance (PDR)
Section 4.2.1: Background
Section 4.2.2: Survey overview
Section 4.2.2.1: Sampling frame Construction
Section 4.2.2.2: Site stratiﬁcation
Section 4.2.2.3: Site sampling
Section 4.2.2.4: Patient sampling
Section 4.2.3: sample size calculations
Section 4.2.3.1: Effective sample size
Section 4.2.3.2: Design effect due to clustering of the outcome by site
Section 4.2.3.3: Design effect due to imperfect information weighting
Section 4.2.3.4: Calculating the sample size
Section 4.2.3.5: Incorporating the ﬁnite population correction
Section 4.2.3.6: Sample size calculations when all sites are sampled
Section 4.2.4: Data analysis
Section 4.2.4.1: Site sampling weight
Section 4.2.4.2: Outcome 1a
Section 4.2.4.3: Outcomes 1b and 1c
Section 4.2.4.4: Outcomes 2a, 2b, and 2c
37Section 4.2.4.5: Regional aggregation
4.2.1 Background
In high-income countries, physicians can identify appropriate treatment regimens for pa-
tients initiating antiretroviral therapy (ART) using results from routine genotypic HIV
drug resistance testing. In low- and middle-income countries, the current cost of geno-
typic testing is prohibitive. Thus, a public health approach must be applied in which
all patients are initiated on a single ﬁrst-line regimen. Nationally representative surveil-
lance of HIVDR in populations initiating ART is critical to inform the selection of an
effective ﬁrst-line regimen. HIVDR among patients initiating ART may be attributable to
transmitted drug resistance, meaning that patients are infected with an already resistant
viral strain, or resistance may be acquired due to previous exposure to ARV, in the con-
text of prevention of mother to child transmission (PMTCT) programs, pre-exposure pro-
phylaxis (PrEP), post-exposure prophylaxis (PEP), or previous disclosed or undisclosed
antiretroviral therapy. Regardless of the origin of the drug resistance mutations, it is
important for a country to understand both the prevalence and type of drug resistance
circulating because of the important country and global implications for population-level
treatment outcomes.
In the previous surveillance methodology described by the WHO in 2006, the pre-
treatment resistance survey and the acquired drug resistance survey were part of a single
longitudinal survey (Jordan et al., 2008). After an initial pilot testing period, the WHO
recommended that 10 to 15 representative ART sites be sampled, and one third of these
sites be surveyed each year on a three-year cycle. The survey conducted at each site was
a longitudinal survey following patients through the ﬁrst 12 months of therapy. Patients
were assessed for HIVDR prior to ART initiation and at 12 months (or before the switch
to second-line therapy). We discuss the baseline survey here and reserve discussion of
the 12 month follow-up survey for the section on acquired drug resistance.
38Between2006 and2010, forty surveyswereperformed in12countries usingthisstandard-
ized protocol (World Health Organization, 2012a, p. 29). During survey implementation,
a variety of challenges emerged. First and foremost, the longitudinal nature of the survey
made it logistically challenging, especially in settings with decentralized service-delivery
models and in areas of concentrated or low prevalence epidemics (World Health Organi-
zation, 2012b, p. 7). Secondly, the duration of the survey meant that it took at least a year
and a half from survey initiation until results were available (World Health Organization,
2012a, p. 32). The lag was too long to provide timely information to ART program man-
agers. Another challenge of the previous survey was the lack of standardized guidance
on how to sample sites in a representative fashion. A pilot study in Namibia was run in
which sites were classiﬁed based on region and disease burden (high/low), and only one
site was sampled per stratum. Design choices like this make surveys less efﬁcient.
To increase survey feasibility, the WHO decided to replace the single longitudinal study
with two cross-sectional surveys (World Health Organization, 2012b, p. 7); the ﬁrst is a
survey of patients initiating treatment to measure pre-treatment drug resistance (PDR),
and second is a survey of patients on treatment for at least 123 and 48 months to
measure acquired drug resistance (ADR). They approached us for statistical guidance as
they developed these protocols. In the following section, we describe the proposal for the
PDR survey. The ADR survey is described in Section 4.3.
4.2.2 Survey overview
For the surveillance of pre-treatment drug resistance (PDR), we propose a two-stage clus-
tered survey where the primary sampling units (PSUs) are sites where patients initiate
ART, and the secondary sampling units (SSUs) are patients initiating treatment at these
sites during the 6 month survey period. The survey duration was chosen to be six months
because it is short enough to provide timely information to program managers but long
enough so that small countries can enroll enough eligible patients. Sites are selected pro-
39portional to some measure of size, as described in Section 4.2.2.1, using systematic sam-
pling, as described in Section 4.2.2.3. Eligible patients initiating therapy are enrolled at
each sampled site until a predetermined patient quota is achieved, as described in Sec-
tion 4.2.2.4. These patients are asked about any prior exposure to antiretroviral drugs
(ARVs), and specimen samples are genotyped to test for the presence of HIV drug resis-
tance mutations. After the site-speciﬁc quota is achieved, sites continue to screen patients
for presence and type of prior exposure, as described in Section 4.2.2.4.
The primary outcomes of the survey are listed below. Outcome 1 measures HIV drug
resistance among different groups of patients. Outcome 2 measures the prevalence of
prior exposure to ARVs.
1a. Prevalence of HIV drug resistance among all initiators, regardless of prior exposure
to ARVs
1b. Prevalence of HIV drug resistance among ART initiators without prior exposure to
ARVs
1c. Prevalence of HIV drug resistance among individuals initiating ART with NNRTI-
based regimens without prior exposure to ARVs
2a. Proportion of all ART initiators without prior exposure to ARVs
2b. Proportion of all ART initiators with prior exposure to ARVs
2c. Proportion of all ART initiators with unknown prior exposure to ARVs
These outcomes were determined through discussions involving the WHO and partners.
They were selected because of their relevance to national program managers.
404.2.2.1 Sampling frame construction
Prior to sampling sites, the country must construct their sampling frame. The sampling
frame is a list of all ART sites in the country where patients initiate treatment and the
relative sizes of these sites. Ideally, site size is estimated as the number of treatment
initiators observed at that site during a recent time period, such as the previous 6 months.
If sampling is performed proportional to the number of initiators enrolled at each site
during a previous time period, we refer to this as Probability Proportional to Size, or
PPS, sampling. Technically, the sampling is PPES (Probability Proportional to Estimated
Size) because the number of initiators enrolled at each site is expected to vary over time
(Yansaneh, 2005, p. 17), but we refer to it as PPS to distinguish it from the other option we
present. If information on the number of initiators enrolled at each site during a previous
time period is not available, the country can perform Probability Proportional to Proxy
Size, or PPPS, sampling. In PPPS sampling, the proxy measure is some measure of site
size, generally the number of patients enrolled at that site during a recent time period.
This will not be exactly proportional to the number of initiators, but it is a reasonable
alternative that will distinguish between large, medium, and small sites. We expect PPPS
sampling to be less efﬁcient than PPS sampling. We describe how the choice between PPS
and PPPS affects the sample size calculations during our discussion of the design effect
(see Section 4.2.3.3).
To improve feasibility of the survey, we provide guidance for the exclusion of sites that
are either very small or difﬁcult to access. Very small sites are sites that would initiate
very few patients during the 6 month period. Difﬁcult to access sites are sites that the
country decides a priori that they would not reasonably be able to include if selected
duringsampling. Thismightincludesiteslocatedinareasofpoliticalinstabilityorinvery
remote geographic areas. Though it could induce bias to exclude either very small sites
or difﬁcult to access sites, it is better to encourage countries to make these assessments
prior to sampling and to do so in a principled way. We suggest that sites that are excluded
41should not represent more than 10% of the patient population. Thus, if more than 10% of
the patient population is treated at very small sites, then at least some of these sites should
be included in the sampling frame. The 10% threshold was identiﬁed as a compromise
to improve feasibility while limiting bias. If the absolute difference in PDR prevalence
between the excluded sites and included sites is 10% (which would be very high in this
setting), the absolute bias would be no more than 1%.
4.2.2.2 Site stratiﬁcation
We did not actively encourage stratiﬁcation (also referred to as explicit stratiﬁcation), in
which separate sampling frames are constructed for each stratum. While we recognize
that stratiﬁcation can improve the efﬁciency of the survey, our decision stemmed from a
variety of factors. The primary reason is the broad range of potential stratifying factors.
Countries with generalized epidemics may be interested in very different factors than
countries with concentrated epidemics, and so on. To provide usable statistical guidance
and tools for survey design for all of the possible scenarios that may arise would place
too much of a burden on the WHO. Suggesting a standard and relatively simple strategy
increases the likelihood that the survey will be designed properly while also limiting
dependence on external assistance. Other reasons for not encouraging stratiﬁcation are
the fact that it can be difﬁcult to proportionally allocate sites to strata when there are few
sites being sampled overall or when there are many strata. The extreme is the setting
when one site per stratum is sampled, in which the efﬁciency gain from stratiﬁcation is
more or less lost because standard variance estimation becomes impossible. Finally, from
the existing surveys, there was no evidence that pre-treatment drug resistance varied
widely on any site-level factor (urban vs. rural, etc). Thus, it would be hard to justify the
additional complexity without some suggestions of a gain in precision.
Nonetheless, we do provide some guidance on how to perform stratiﬁcation for countries
interested. This is available in one of the report annexes. We emphasize the importance of
42limiting the number of stratifying variables, combining similar strata if any one stratum is
too small, and sampling at least two sites per stratum. In our guidance, we describe how
to perform sample size calculations by allocating the effective sample size proportionally
to the strata. If the primary goal of the country is just to guarantee a certain degree of
regional representation (i.e. at least one site per region), we provide a short method that
can be used to assess how many sites must be sampled to guarantee at least one site per
region when using systematic sampling with implicit stratiﬁcation (see Section 4.2.2.3).
Brieﬂy, the method shows countries how to check that the systematic sampling interval
is smaller than the size of the smallest region. If so, then each region will be sampled at
least once regardless of the systematic sampling random starting point. If the sampling
interval is too large, then either more sites must be sampled or small regions should be
combined with other similar regions.
4.2.2.3 Site sampling
In the ﬁrst stage of sampling, it is recommended that 15-40 sites are sampled via system-
atic sampling using probabilities proportional to estimated site size (Wolter, 2007, sect.
8.6). This will lead to a nationally representative selection of sites in the country. The
exact number of sites to be sampled should be determined by the country. The number
is a compromise between efﬁciency (it is more statistically efﬁcient to sample more sites)
and feasibility (it is more logistically complicated and expensive to sample more sites).
In countries where there are 15 or fewer sites, all sites should be included in the survey.
The survey is then a one-stage stratiﬁed survey of patients within sites, which is more ef-
ﬁcient than a two-stage clustered survey. In countries where there are more than 15 sites,
these countries have the option of including all sites or taking a sub-sample (the standard
design described above).
Systematic sampling was selected because it is routinely used in surveys in the devel-
oping world (Family Health International, 2000, p. 38). It also has the added beneﬁt
43of allowing countries to employ implicit stratiﬁcation to improve representativeness. In
implicit stratiﬁcation, the systematic sampling frame is ordered on some factor before
sampling. We suggest ordering by geographic region and also size within geographic
region. In this way, there is an increased likelihood that sites will be sampled from each
of the geographic regions. One negative consequence of systematic sampling is that, in
some countries, large sites may be sampled more than once. In this case, we ask that sites
just sample proportionally more patients from these sites.
4.2.2.4 Patient sampling
In the sites sampled, consecutive eligible patients initiating ART on or after a pre-
deﬁned survey start date are enrolled until the predetermined sample size for each site
is achieved. We assume that consecutive patients are independent and that there are no
time trends during the 6 month period. All individuals initiating ART are eligible to be
enrolled, irrespective of their prior ART history. Specimens are collected from enrolled
patients prior to ART initiation, and these specimens are sent to the laboratory for HIV
drug resistance genotyping. Each site should contribute roughly the same number of
specimens to the sample. In practice, this may not occur because of laboratory failure or
sites being too small to achieve the predetermined sample size. This is accounted for in
the survey weights (see Section 4.2.4.2).
After the predetermined sample size is achieved, sites must continue to screen initiators
for prior ARV exposure. The goal of this continued screening process is two-fold. First
of all, this improves the precision of Outcomes 2a, 2b, and 2c, which measures the pro-
portion of patients in each prior ARV exposure category. Second and more importantly,
the estimated site sizes used for systematic sampling were approximations to improve
the efﬁciency of sampling. In order to appropriately adjust the survey sampling weights,
the sampled sites must report the actual number of ART initiators observed during the 6
month survey period. Thus, even if a site is able to achieve its patient enrollment quota in
44one day, it must continue to screen initiators for 6 months. Because of serious push-back
from collaborators and funding partners, a compromise was reached that sites can screen
initiators for a minimum of 3 months and then extrapolate to determine the 6 month eli-
gible population size. This requires the assumption that there are no changes in the rate
of ART initiation over the 6 month survey period.
4.2.3 Sample size calculations
The survey sample size is powered to achieve sufﬁciently precise results for Outcome
1b, which is the prevalence of HIV drug resistance among initiators without prior expo-
sure to ARVs. A conﬁdence interval of half-width of 5% is suggested as an appropriate
compromise between feasibility and precision.
Below we provide a comprehensive description of our proposed sample size calculations
and justiﬁcations for assumed values and methods used. Nonetheless, it is not necessary
for in-country researchers to understand the methodology below to generate an appropri-
ate survey design. To improve feasibility, Excel-based tools for sample size calculations
were constructed. These tools require limited user input, with the majority of assumed
values internalized in locked cells. We believe this will reduce the likelihood of miscalcu-
lations during the survey design process.
4.2.3.1 Effective sample size
To determine the necessary sample size for the survey, we start by determining the ef-
fective sample size for estimating the prevalence of HIV drug resistance among initiators
sampled. The effective sample size refers to the number of patients, keff, we would need
to sample to achieve a desired conﬁdence interval half-width if we were conducting a
simple random sample. The effective sample size is determined by the prevalence of the
outcome and the desired width of the conﬁdence interval. The effective sample size is
then multiplied by the estimated design effect to yield the actual sample size of the sur-
45vey.
Note: Because the method for calculating a conﬁdence interval in the setting of clustered
surveys uses a t distribution with degrees of freedom equal to the design degrees of free-
dom (Korn and Graubard, 1999, p. 62), our effective sample size is also a function of the
number of sites sampled. When the design degrees of freedom are large (around 40 or
greater), it is standard to assume that z0:975  tdf;0:975 as this simpliﬁes calculations. This
is only appropriate when the design degrees of freedom are large. Since this design re-
quires sampling of around 15-40 sites, the design degrees of freedom will be small, and
it is thus inadvisable to make this simpliﬁcation. The consequence of using this simpliﬁ-
cation would be an underestimation of the total sample size required to achieve a given
conﬁdence interval half-width.
To determine the effective sample size, consider the following formula for a Wald-type
conﬁdence interval. Here, e pDR refers to the assumed prevalence of HIVDR among initia-
tors. Available evidence suggests that it is reasonable to conservatively assume an esti-
mated prevalence of HIVDR among all treatment initiators of 10%. This ﬁgure, which is
greater than the 5% generally reported in the literature, including in the 2012 WHO HIV
Drug Resistance Report, is used as a conservative measure of expected HIVDR preva-
lence because higher levels of pretreatment HIVDR – approximating 10% – have been
documented in some regions. n refers to the number of sites sampled, and df are the
design degrees of freedom:
95% CI =
 
e pDR   tdf;0:975
s
e pDR(1   e pDR)
keff
; e pDR + tdf;0:975
s
e pDR(1   e pDR)
keff
!
The design degrees of freedom are deﬁned as df = (# of sites sampled) – (# strata) (Korn
and Graubard, 1999, p. 62). If stratiﬁcation is not used, df = n   1. The half-width of this
conﬁdence interval is:
46L = tdf;0:975
s
e pDR(1   e pDR)
keff
The effective sample size can be calculated using the following formula:
keff =
t2
df;0:975e pDR(1   e pDR)
L2
keff should be rounded up to the nearest integer.
The effective sample size must be inﬂated by the design effect to determine the actual
sample size The elements of the study design that contribute to the design effect are (1)
clustering of the outcome by site (DEFFclust, see Section 4.2.3.2), and (2) imperfect in-
formation from using data from a previous year or from a slightly different population
(DEFFinfo, see 4.2.3.3).
4.2.3.2 Design effect due to clustering of the outcome by site
It is ﬁrst necessary to calculate the design effect due to clustering of the outcome. The
similarity of HIVDR outcomes of initiators within sites is measured via the intracluster
correlation coefﬁcient, or ICC. If m is the number of patients sampled per site and ICCDR
is the estimated intracluster correlation for the HIVDR outcome, the design effect due to
clustering can be estimated using the following formula:
DEFFclust = 1 + (m   1)ICCDR
In order to estimate the ICC, global data from WHO’s HIV Drug Resistance Report 2012
were used. For each site in each country, the estimated probability of drug resistance for
treatment initiators was used to calculate the ICC using an analysis of variance estimator
(Ridout et al., 1999). Although ICC is deﬁned as capturing the clustering of outcomes by
47sites within the same country, sites in the data-set were collapsed across different coun-
tries.
For the outcome of pre-treatment HIVDR, the estimated ICC using data from the 2012
WHO Drug Resistance Report is ICCDR;raw = 0:005. The observed prevalence of pre-
treatment HIVDR in the global data is 4.5%. As the assumed prevalence of HIVDR among
initiators is 10%, and since the ICC and prevalence are generally correlated, the ICC
was adjusted to reﬂect the assumed prevalence (Guillford et al. 2005). To perform this
adjustment, a linear model predicting natural log of ICC by the natural log of prevalence
was applied. The equation is
ICCDR = exp

0:91  ln

e pDR
0:045

 ICCDR;raw
It is important to note that there are limitations to these estimates. First of all, the ICC
estimates are based on only the data available in the global report. A 95% conﬁdence in-
terval can be constructed for ICCDR;raw using Searle’s method (Searle, 1971; Ukoumunne,
2002), and the resulting interval extends from 0.000598 to 0.0131; thus, the interval is very
wide, reﬂecting the uncertainty in the estimate. Thus, as the survey is implemented, it is
important that the data obtained be used to better inform the estimate of ICC for future
iterations of the survey.
4.2.3.3 Design effect due to imperfect weighting information
As described in Section 4.2.2.1, countries may either use PPS or PPPS sampling. The sur-
vey is maximally efﬁcient when the estimated site sizes are perfectly proportional to the
true site sizes. Otherwise, there is an inﬂation in the variance. To estimate the effect of
imperfect information on the design effect, we use a formula estimating the variance con-
tribution for disproportionate weights (Kalton et al., 2005, eq. 23). The design effect can
be approximated by DEFFinfo = 1 + cv2(weights), where cv() refers to the coefﬁcient
48of variation and weights are the survey weights. For PPS sampling, it is estimated that
DEFFinfo = 1:10. For PPPS sampling, it is estimated that DEFFinfo = 1:50. This cor-
responds to inﬂating the sample size by 10% and 50%, respectively, to account for the
imperfect information. These numbers were calculated from observing the differences in
population sizes between treatment initiators and patients on ART at sites in an African
country over a two year period. These numbers are approximations, and the true values
may also be very country speciﬁc. As the survey is carried out, it is recommended that
these values be re-evaluated and adjusted as necessary for future iterations of the survey.
The design effect is also inﬂuenced by other sources of variability. For example, different
sites will have different levels of genotyping failure. This will induce additional variabil-
ity in the weights. It is estimated that this source of design effect will be small, so it is
ignored in the calculations to increase the simplicity of the design.
4.2.3.4 Calculating the sample size
The design effect for HIVDR is estimated using the following formula (Park and Lee,
2004):
DEFF = DEFFclust  DEFFinfo
Given the calculated effective sample size (keff, see Section 4.2.3.1), intracluster correla-
tion (ICC, see Section 4.2.3.2), and design effect due to imperfect information (DEFFinfo,
see Section 4.2.3.3), solve the following equation for m, the number of initiators to be
sampled per site:
m =
1   ICCDR h
n
DEFFinfokeff   ICCDR
i
If such an m does not exist, or if the calculated value of m is too large to be practical in
a particular setting, consider increasing the number of sites sampled, n. Because of the
49design effect, sampling a larger number of sites will require fewer samples per site, and
it will also require a smaller overall sample size
The sample size needs to be adjusted for two additional parameters: (i) Laboratory fail-
ure when genotyping. Based on data from the 2012 WHO HIV Drug Resistance Report,
the expected genotyping failure rate is assumed to be 10%. Thus, we need to divide the
required sample size by 0.90. (ii) Expected proportion of initiators without prior expo-
sure to ARVs. In order to retain statistical power at the analysis stage when considering
only patients without prior ARV exposure, the sample size needs to be adjusted for the
expected proportion of initiators without prior ARV exposure. It is assumed that 75% of
initiators will have not had prior exposure to ARVs, so we need to divide the required
sample size by 0.75. This should be the last step in the sample size calculations.
msamp =
m
0:90  0:75
4.2.3.5 Incorporating the ﬁnite population correction
Countries can apply the ﬁnite population correction at the analysis stage to reﬂect the fact
that either a signiﬁcant portion of sites in the sampling frame are included in the sample
or that a signiﬁcant portion of eligible patients within a particular site are included in
the sample; the result is a reduction in the variance (see Chapter 5 for a more in-depth
discussion of this topic). Currently, the standard method for performing sample size cal-
culations in small countries that will be applying the ﬁnite population correction is to
reduce the effective sample size (World Health Organization, 2009a). We demonstrate
that this method can be inaccurate and lead to an overestimate of the sample size.
We show that the formula for the design effect due to clustering can be revised to incor-
porate the predicted effect of the ﬁnite population corrections which will be applied at
the analysis stage. The design effect due to clustering in the absence of ﬁnite population
50corrections is DEFFclust = 1 + (m   1)ICCV LS where m is the number of patients sam-
pled per site and ICC is the intracluster correlation. For a country with N total sites in
the sampling frame and an average of M eligible patients per site, it can be shown that
the design effect due to clustering can be approximated by Chapter 5:
DEFFclust 

1  
m
M

+

1  
n
N

m  

1  
m
M

ICCDR
The average number of eligible patients per site can be estimated as the total number of
eligible patients (estimated from available data) divided by the total number of sites in
the sampling frame (M = M=N where M =
PN
i=1 Mi). It can be shown that the neces-
sary number of patients per site to be sampled per site to achieve a desired precision is
(Chapter 5):
m =
1   ICCDR
n
DEFFinfokeff   ICCDR
 
1   n
N

+ N
M (1   ICCDR)
The sample size must then be adjusted for expected genotyping failure and the expected
proportion of initiators without prior exposure to ARVs.
4.2.3.6 Sample size calculations when all sites are sampled
If all sites in the sampling frame will be included in the survey, the following modiﬁca-
tions can be made to the sample size calculations (using notation previously described).
Brieﬂy, the survey effective sample size is calculated, and this effective sample size is
multiplied by a design effect due to imperfect information, the expected laboratory fail-
ure, and the expected proportion of initiators without prior ARVs exposure. It is not
necessary to multiply the calculations by a design effect due to clustering because all sites
in the sampling frame are included in the survey. The effective sample size necessary to
achieve a conﬁdence interval of half-width L is:
51keff =
3:84e pDR(1   e pDR)
L2
If the ﬁnite population correction is incorporated into the calculations (where M is the to-
tal eligible population size in the country), then the effective sample size can be calculated
using the following equation (Lohr, 2010, eq. 2.25):
keff =
M  3:84e pDR(1   e pDR)
L2  M + 3:84e pDR(1   e pDR)
Because information on patient enrollment from a prior time period will be used to al-
locate the sample, it is recommended that the sample size be inﬂated slightly to account
for imperfect information; this is equivalent to adjusting for a design effect for dispropor-
tionate weighting (see 4.2.3.3). Next, the sample size should be inﬂated by the amount of
expected laboratory success rate (90%) and the expected proportion of initiators without
prior ARV exposure (75%). Thus, the actual sample size for the PPS-equivalent design is:
kact =
keff  DEFFinfo
0:90  0:75
The actual sample size is then allocated to the sites proportional to the number of eligible
patients expected to be observed during the survey period. For each site, the sample size
of that site is equal to the total sample size, kact, times expected patient accrual at that site
divided by the expected patient accrual for all sites included in the survey. For example,
if 25% of patients in a country attend a particular site, 25% of the sample size should be
allocated to that site. The per site sample sizes are rounded to the nearest whole number.
4.2.4 Data analysis
Data analysis is conducted using a design-based framework. We calculate each of the out-
comes as a ratio, where the denominator is an estimate of the number of eligible patients
52in the country during the survey period, and the numerator is an estimate of the number
of such patients with the outcome of interest.
Directions for the data analysis are provided for the Stata SVY package in Stata (Stat-
aCorp, 2013). Support includes detailed instructions on how to enter the data into a
spreadsheet, step-by-step directions for reading the data into Stata, and step-by-step di-
rections for analyzing the data using drop-down menus with limited use of the command
line. We also provide a sample data set and a worked out example.
Even if Stata is not used to conduct the analysis, the Stata SVY manual section on Variance
Estimation contains all necessary formulae for calculating the prevalence, variance, and
95% conﬁdence interval of each outcome (StataCorp, 2013).
4.2.4.1 Site sampling weight
Once an appropriate design is identiﬁed, sites will be sampled using either PPS or PPPS
systematic sampling. In PPS, site size is estimated using prior data on the number of
initiators by site. In PPPS, site size is estimated using prior data on the number of patients
on ART by site. For site i, the estimated site size in the sampling frame (from either PPS
or PPPS) is denoted as f Mi. If the predetermined number of sites to be selected is n? (note
that this may be different from the number of unique sites sampled, n, because sites may
be sampled twice), the probability that a site is selected is equal to n?f Mi divided by the
total size of all sites in the sampling frame, f M =
PN
j=1 f Mj. Thus, the site sampling weight
is equal to the following, where SI = f M=n? is the sampling interval from systematic
sampling:
wsite;i =
f M
n?f Mi
=
SI
f Mi
If all sites are included in the survey, the site sampling weight is equal to 1 for all sites.
If a stratiﬁed survey is conducted, site weights should be constructed separately for each
53sampling frame.
As described in Section 4.2.2.4, Mi is a count of the number of eligible patients attending
site i observed during the 6 month survey period.
4.2.4.2 Outcome 1a
Outcome 1a is the overall prevalence of HIVDR among all ART initiators, regardless of
prior ARV exposure. The site sampling weight is deﬁned in Section 4.2.4.1. The patient
sampling weight for all initiators in site i is deﬁned as Mi divided by the number of
initiators with genotyped data available from that site, mi. The overall weight is the
product of the site and patient sampling weights:
w1i = wsite;i 
Mi
mi
For a setting without stratiﬁcation, the prevalence, b p1a, is estimated using a ratio, letting
b ti indicate the number of initiators observed with HIVDR at site i:
b p1a =
Pn
i=1 w1ib ti Pn
i=1 w1imi
=
b T
c M
The denominator of the ratio, c M, is an estimate of the total number of individuals initiat-
ing ART during the 6 month survey period in the country. (If sites are excluded from the
sampling frame, it is technically an estimate of the number of eligible individuals in sites
in the sampling frame.) The numerator, b T, is an estimate of the total number of these ART
initiators with any HIVDR mutations.
The variance is calculated using Taylor series linearization. Brieﬂy, the variance of the
ratio is expressed as a linear combination of the variance of the numerator, the variance
of the denominator, and the covariance of the two (Lohr, 2010, sect. 9.1). The variance of
the numerator total is (StataCorp, 2013, sect. variance estimation, eq. 2):
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The variance of the denominator total and the covariance term follow similarly, and they
are described in the Stata documentation. The formulae are also generalized for surveys
with stratiﬁcation. The variance of b p1a is the following (StataCorp, 2013, p. 187):
d var(b p1a) =
1
c M2
(
d var(b T)   2
b T
c M
c cov(b T; c M) +
b T 2
c M2
d var(c M)
)
A 95% conﬁdence interval can be calculated using a standard Wald formula or by a Logit
transformation (see Chapter 7 for more details). The latter is currently the default in Stata.
4.2.4.3 Outcomes 1b and 1c
Outcome 1b and Outcome 1c are subpopulation analyses of Outcome 1a. Outcome 1b is
the prevalence of HIVDR among ART initiators without prior exposure to ARVs. Data
analysis is conducted using the same sampling weights described for Outcome 1a. The
population is restricted to patients without prior exposure to ARVs using the subpopu-
lation command in Stata (StataCorp, 2013, sect. subpopulation estimation). Brieﬂy, the
difference between a subpopulation analysis and a conditional analysis is that the former
sets survey weights equal to zero for those not in the subpopulation and the latter entirely
excludes these patients entirely (West et al., 2008). This distinction is relevant when a site
has, by chance, no initiators eligible for the subpopulation analysis.
4.2.4.4 Outcomes 2a, 2b, and 2c
Outcomes 2a, 2b, and 2c are the prevalence of no prior exposure, yes prior exposure,
and unknown prior exposure to ARVs, respectively, among all ART initiators. The site
55sampling weight is deﬁned in Section 4.2.4.1. The patient sampling weight for site i is
deﬁned as Mi divided by the number of initiators with recorded exposure status available
from that site. The overall weight is the product of the site and patient sampling weights.
The prevalence of each category is estimated using a ratio.
4.2.4.5 Regional aggregation
The WHO desired a framework for aggregating data across countries in a similar region
to increase precision. For example, for the global report, the WHO may aggregate data on
the prevalence of HIVDR among patients from Latin American countries with prior ex-
posure to prevention of mother to child transmission (PMTCT) drugs. Aggregating data
requires the assumption that the survey designs are comparable; speciﬁcally, the surveys
should be conducted in a relatively limited time frame in order for their aggregation to
be defensible because of possible time trends.
This analysis can be readily achieved by treating countries as ﬁxed strata and analyzing
the data using a combined ratio estimate (S¨ arndal et al., 2013, eq. 7.3.13) (Wu, 1985). We
provide the methodology for aggregating data across H countries (indexed h = 1;:::;H).
The outcome for country h is the following:
b ph =
b Th
c Mh
The aggregated point estimate, b p, is the following:
b p =
b T
c M
=
PH
h=1 b Th
PH
h=1 c Mh
Essentially, the point estimate combines information across countries, weighting by the
size of the eligible population, c Mh, as estimated by their national survey. In addition, this
approach does not require the eligible population sizes to be known with certainty. The
variance of b p can be calculated using Taylor Series linearization (as in Section 4.2.4.2):
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1
c M2
(
d var(b T)   2
b T
c M
c cov(b T; c M) +
b T 2
c M2
d var(c M)
)
As we assume that the surveys are independent across countries:
d var(b T) =
H X
h=1
d var(b Th)
d var(c M) =
H X
h=1
d var(c Mh)
c cov(b T; c M) =
H X
h=1
c cov(b Th; c Mh)
One additional issue is data sharing. If all of the raw data is available from each coun-
try, this analysis can be easily conducted in Stata treating country as a ﬁxed stratiﬁcation
variable. As it is unlikely that all countries will share their raw data, the WHO can still
perform this aggregation procedure as long as they have the following elements for their
outcome of interest: (1) b Th, (2) c Mh, (3) d var(b Th), (4) d var(c Mh), and (5) c cov(b Th; c Mh). These
values can be readily returned from Stata using the total commands in the SVY frame-
work (StataCorp, 2013). Thus, this represents only a few additional commands beyond
the standard analysis for each outcome of interest in the global report (see Section 4.3.4).
4.3 Acquired drug resistance (ADR)
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4.3.1 Background
As described in Section 4.2.1, in an effort to improve feasibility, the WHO has opted to
replace the previously recommended single longitudinal survey of patients from baseline
through 12 months on therapy with two cross-sectional studies. The ﬁrst cross-sectional
study is a baseline survey to assess pre-treatment drug resistance (PDR) among patients
58initiating ART (see Section 4.2 for comprehensive description of the PDR survey). The
second cross-sectional study is a survey of patients on ART to assess acquired drug resis-
tance (ADR). We describe the ADR survey in this section.
In the previously used longitudinal protocol, patients were assessed for HIVDR prior to
ART initiation and at 12 months (or before the switch to second-line therapy). Because of
the longitudinal nature of the survey, some patients transferred out, died, stopped ther-
apy, or were lost to follow-up before the survey end date. At the 12 month time point,
the primary outcomes were (1) HIV drug resistance prevention (deﬁned as viral load <
1000 copies/mL), (2) HIV drug resistance, and (3) possible drug resistance (included in
this category are people lost to follow-up, individuals who stopped antiretroviral ther-
apy, those for whom drug resistance cannot be assessed, and those with viral load greater
than 1000 copies/mL 12 months after therapy initiation but no drug resistance mutations
detected). These outcomes excluded patients with documented transfer to other sites and
documented deaths. Deaths were excluded because it was assumed that individuals who
died within 12 months of the start of treatment were unlikely to have died because of
drug-resistant HIV (Jordan et al., 2008, box 4). Outcomes were calculated as raw per-
centages among the relevant populations, and there was no adjustment for weighting or
clustering.
By using a cross-sectional design, the survey has increased feasibility, and it can be
adapted to include patients on therapy for longer periods of time; this would not be
possible with a longitudinal study. Nonetheless, cross-sectional studies have important
limitations. A cross-sectional survey excludes patients who are no longer receiving ART
at the study site and therefore cannot be observed because they have died, been lost to
follow-up or have stopped treatment. This “survivor bias” can signiﬁcantly impact the in-
terpretation of the primary outcome. Without accounting for within country or country-
to-country variability in retention patterns, there are many important confounding fac-
tors, making it challenging to meaningfully a) assess changes in the national estimate of
observed viral load suppression (VLS, viral load < 1000 copies/mL) over time, b) com-
59pare these estimates against a global standard, or c) compare estimates across countries.
We describe our approach adjusting for this survivor bias in Section 4.3.2.
The updated acquired drug resistance survey includes outcomes related to viral load sup-
pression, HIV drug resistance and retention outcomes. These are important outcomes
for the monitoring of acquired HIV drug resistance. For patients achieving viral load
suppression, it is assumed that, because the treatment regimen is successful, there is no
”effective” drug resistance. If a country observes suboptimal levels of virological sup-
pression, they may initiate additional investigations to identify the source of these fail-
ures. In addition, information on retention is collected to improve the epidemiologic
utility of the viral load suppression outcome. Among patients with virological failure,
the country is also interested in the proportion of patients failing ﬁrst-line ART without
evidence of drug resistance mutations; patients failing therapy without evidence of resis-
tance mutations would beneﬁt from programmatic measures aimed at improving adher-
ence, whereas a high proportion of patients failing with drug resistance mutations might
suggest a need for a change in ﬁrst- or second-line treatment regimens (World Health
Organization, 2012b).
4.3.2 Survey overview
The acquired drug resistance (ADR) survey protocol has signiﬁcant overlap with the (pre-
treatment drug resistance) PDR survey protocol, and we refer readers to equivalent sec-
tions in the PDR portion of this document to reduce redundancy. For ADR surveillance,
we propose a two-stage clustered survey where the primary sampling units (PSUs) are
sites where adult patients receive ART, and the secondary sampling units (SSUs) are eli-
gible patients receiving treatment at these sites during the 6 month survey period. Similar
to the PDR survey protocol, sites are selected proportional to some measure of size using
systematic sampling (see Sections 4.2.2, 4.3.2.1 and 4.3.2.3). Patient eligibility is deter-
mined by duration on therapy. The WHO has identiﬁed an early and a late time point
60for the ADR survey. The early time point targets adults who have been on ART for 12
(3) months during the survey period, and the late time point targets adults who have
been on ART for at least 48 months. These time points were selected based on clinical
relevance, consistency with a the previous survey and a preexisting 12 month retention
indicator, and feasibility; it can be difﬁcult to enroll patients if the time windows are too
narrow. Countries may choose to conduct the survey at a single time point or both time
points simultaneously. This decision will depend on budget and programmatic needs.
For the measurement of viral load suppression and drug resistance outcomes, eligible
patients on ART are enrolled at each sampled site until a predetermined patient quota
is achieved for each time point, as described in Section 4.3.2.4. These patients are asked
about any prior exposure to antiretroviral drugs (ARVs), and specimen samples are geno-
typed to test for the presence of HIV drug resistance mutations. After the site-speciﬁc
quota is achieved, sites continue to screen patients for presence and type of prior expo-
sure, as described in Section 4.2.2.4.
Because of the limitations of cross-sectional data described in Section 4.3.1, we have con-
vinced the WHO of the importance of collecting data on retention. Data collection will be
done by a retrospective chart review among patients at the sites sampled, and we adopt
the preexisting PEPFAR/UNGASS indicator deﬁnition of 12 month retention (UNAIDS,
2011, sect 4.2). Currently, the indicator is measured via census only, and thus represen-
tative data on retention is very rarely available from low- and middle-income countries.
If analyzed properly, the survey yields a nationally representative estimate of retention
without requiring a census. For the early time point, we propose a method for combining
informationonpatientVLSandretentionintoanewoutcomethatwearguehasimproved
epidemiologic utility. The motivation, deﬁnition, and properties of this outcome are de-
scribed in an additional paper (Chapter 6). Brieﬂy, if we assume that all patients who
are lost to follow-up are not virologically suppressed, we can estimate population-level
VLS as the product of VLS observed among retained patients and the prevalence of reten-
tion. We do not collect data on retention for the late time point because it is open-ended,
61and thus the expected prevalence of retention is not meaningful because eventually all
patients are lost to follow-up or die.
The primary outcomes of the survey are listed below. Outcome 1 measures HIV drug
resistance among different groups of patients. Outcome 2 measures the prevalence of
prior exposure to ARVs.
1a. Prevalence of VLS (VL < 1000 copies/mL) among individuals on ART
1b. Prevalence of VLS among individuals on ﬁrst-line ART
1c. Prevalence of VLS among individuals on NNRTI-based ﬁrst-line ART
2a. Nationally representative measure of retention at 12 months (early time point only)
2b. Prevalence of VLS among individuals on ART, adjusted for retention (early time point
only)
3a. Prevalence of HIVDR among individuals on ART with VL > 1000 copies/mL
3b. Prevalence of HIVDR among individuals on ﬁrst-line ART with VL > 1000
copies/mL
3c. Prevalence of HIVDR among individuals on NNRTI-based ﬁrst-line ART with VL >
1000 copies/mL
4. Prevalence of HIVDR among individuals on ART
These outcomes were determined through discussions involving the WHO and partners.
They were selected because of their relevance to national program managers.
4.3.2.1 Sampling frame construction
Prior to sampling sites, the country must construct their sampling frame. The sampling
frame is a list of all ART sites in the country where patients receive treatment and the
62relative sizes of these sites. The relative size of the sites is equal to the number of pa-
tients on treatment at the site during a previous time period. We refer to this method of
sampling as Probability Proportional to Proxy Size, or PPPS, sampling (also described in
Section 4.2.2.1). Countries with sites that opened recently may have few or no patients on
treatment for  48 months. If a country is only implementing the survey at the later time
point, the country can choose to exclude sites that are not expected to observe patients
on treatment for  48 months from the sampling frame. If a country is implementing
both time points, we propose a stratiﬁcation scheme to limit patient under-enrollment
(see Section 4.3.2.2).
As described for the PDR survey, we provide guidance for the exclusion of sites that are
either very small or difﬁcult to access (see Section 4.2.2.1).
4.3.2.2 Site stratiﬁcation
As described for the PDR survey, we do not actively encourage explicit stratiﬁcation (see
Section 4.2.2.2). One important exception is if a country has many recently opened ART
sites and is planning to implement both survey time points. In this setting, the country
riskssamplingmanyrecentlyopenedARTsitesandsigniﬁcantlyunder-enrollingpatients
for the late time point. To avoid this scenario, we provide statistical guidance for a strati-
ﬁed design in which sites are grouped into two categories indicating their ability to enroll
patients on treatment for  48 months. In practice, this grouping will likely separate re-
cently opened (new) sites and old sites. From the old sites, patients are enrolled for both
the early (123 months) time point and the late ( 48 months) time point (see Table 4.1).
From the new sites, patients are enrolled for only the early time point. Thus, to identify
a suitable strategy, the country ﬁrst identiﬁes a design such that they can enroll sufﬁcient
patients on treatment for  48 months among the old sites only. Then, the country iden-
tiﬁes how many additional new sites they must sample to have a reasonable stratiﬁed
design for the early time point. This can be achieved via an already developed Excel-base
63Table 4.1: Sampling strategy for both time points
Early Time Point Late Time Point
123 mos.  48 mos.
New Sites First Stratum n/a
Old Sites Second Stratum Only Stratum
sample size calculator.
4.3.2.3 Site sampling
Site sampling is conducted in the same manner as described for PDR (see Section 4.2.2.3).
4.3.2.4 Patient sampling for viral load suppression/HIVDR
In the sites sampled, consecutive eligible patients on ART for 12  3 or  48 months
(depending on which time points are implemented) on or after a pre-deﬁned survey start
date are enrolled until the predetermined sample size for each time point at each site is
achieved. Specimens are collected from enrolled patients, and these specimens are sent
to the laboratory for viral load testing. Specimens with viral load > 1000 copies/mL are
sent to the laboratory for HIV drug resistance genotyping.
After the predetermined sample size is achieved, sites must continue to screen patients to
assess their eligibility for the survey. As described for the PDR survey, the primary goal is
to determine the total number of eligible patients observed at that site during the survey
period for proper weighting (see Section 4.2.2.4). For the early time point, this is the total
number of unique patients on treatment for 123 months observed at the site during the
6 month survey period. For the late time point, this is the total number of unique patients
on treatment for  48 months observed at the site during the 6 month survey period. As
for the PDR survey, we require that screening continues for a minimum of three months
regardless of the time necessary to complete enrollment.
644.3.2.5 Patient sampling for retention
For the early time point only, in order to obtain a measure of retention for patients on
treatment, countries perform a retrospective chart review at the sites sampled. To conduct
this chart review, countries list patients at the site who will have been on therapy for
exactly 12 months during the survey period. The total number of eligible records at that
site must be recorded. Next, a random sample of these patients is selected for assessment
of retention. This sample can be obtained via systematic sampling (e.g., every 10th record
beyond a random start point) (Lohr, 2010, sect. 2.7). 12 month retention is deﬁned as the
patient being retained on ART at exactly 12 months after treatment initiation (UNAIDS,
2011, sect. 4.2). Patients who have stopped treatment, died, or been lost to follow-up are
not considered retained. Patients with documented transfer to another site are excluded
from the sample. The inherent assumption is that these transferred patients have the
same prevalence of retention and viral load suppression after transferring care as patients
who did not transfer, and excluding them from the sample will properly implement these
assumptions.
4.3.3 Sample size calculations
The survey sample size is powered to achieve sufﬁciently precise results for Outcome 1b,
whichistheprevalenceofVLSamongindividualsonﬁrst-lineART.Iftheearlytimepoint
sample is conducted, the survey is also powered to achieve sufﬁciently precise results for
Outcome 2a, which is the prevalence of 12-month retention among all individuals. For
both outcomes, a conﬁdence interval of half-width of 5% to 6% is suggested as an
appropriate compromise between feasibility and precision. The survey is not powered
to achieve sufﬁciently precise results for Outcome 3a, which is the prevalence of HIV
drug resistance outcomes among patients failing therapy. While this was originally the
outcome of interest, the sample sizes were prohibitively large because this outcome is
only measured among patients with viral suppression failure, which is approximately
6515%to30%ofthepopulation, dependingon thetimepoint. Thispopulationalsoexcludes
all viral ampliﬁcation and genotyping failures. As a result, the overall sample sizes must
be very large to collect usable data on a sufﬁcient number of patients failing therapy.
As described for the PDR survey, sample size tools are available for countries designing
these surveys (see Section 4.2.3).
4.3.3.1 Calculating the sample size for viral load suppression survey
Sample size calculations for the viral load suppression portion of the survey proceed sim-
ilarly to those described for the PDR survey (see Section 4.2.3).
To calculate the effective sample size for the early time point, the suggested assumed
prevalence of VLS is e pV LS = 0:85 with suggested precision L = 0:05 (see Section 4.2.3.1).
For the late time point, the suggested assumed prevalence of VLS is e pV LS = 0:70 with
suggested precision L = 0:06.
In order to estimate the intracluster correlation, global data from WHO’s Global HIVDR
Report 2012 were used (WHO 2012a, table 9). For each site in each country, the estimated
probability of viral load suppression was calculated at the 12 month time point after cen-
soring patients with documented transfer to another site. As before, ICC is estimated
using an analysis of variance estimator (see Section 4.2.3.2). Using the raw data, with
observed prevalence of viral load suppression of 89% at 12 months after treatment initi-
ation, the estimated ICC is very low (ICCV LS;raw = 0:0032). The 95% conﬁdence interval
for this quantity is -0.001425 to 0.01339; thus, the interval is very wide, reﬂecting the un-
certainty in the estimate. For the assumed prevalence of 85% at the 12-24 month time
point, the multiplicative factor is 1.34, resulting in an estimated ICC of ICCV LS;early =
1:34  0:0032  0:004. As the assumed prevalence of viral load suppression for the 48+
month time point is 70%, the estimated ICC is ICCV LS;48+ = 2:15  0:0032  0:008.
As PPPS sampling is used for this survey, the estimated design effect due to dispropor-
66tionate weighting is DEFFinfo = 1:50 (see Section 4.2.3.3).
To calculate the necessary sample size, the same procedure described in Section 4.2.3.4
can be used. For the ADR survey, the sample size needs to be adjusted for two additional
parameters (note that this is in lieu of adjusting for genotyping failure and prevalence
of prior ARV exposure as described for the PDR survey): (i) Laboratory failure when
measuring viral load. For example, if we expect a 15% ampliﬁcation failure rate, we need
to divide the required sample size by 0.85. (ii) Expected proportion of patients sampled
receiving a ﬁrst-line regimen. In order to retain statistical power at the analysis stage
when considering patients on ﬁrst-line regimen only, the sample size needs to be adjusted
for the expected proportion of patients sampled receiving a ﬁrst-line regimen. For the
sake of simplicity, it is assumed that 95% of patients sampled will be receiving a ﬁrst-line
regimen.
The same procedure for incorporating the ﬁnite population correction into sample size
calculations can be used for the ADR survey (see Section 4.2.3.5).
If all sites in the sampling frame will be included in the survey, the same procedure de-
scribed for the PDR survey can be applied (see Section 4.2.3.6). The necessary assumed
values for each time point are provided in this section.
4.3.3.2 Calculating the sample size for retention survey
The same procedure described for the viral load suppression outcome can be used to
calculate necessary sample sizes to achieve a particular conﬁdence interval width for the
estimated retention at 12 months (see Section 4.3.2.4). The following parameters should
be used: estimated prevalence of retention at 12 months is assumed to be 85%, i.e. ~ pRET =
0:85. The estimated intracluster correlation coefﬁcient from global data is ICCRET;raw =
0:0713 with an observed prevalence of 12 month retention of 76.6%. For the assumed
prevalence of 85% at the 12 month time point, the estimated ICC is ICCRET = 0:667 
0:0713  0:0475. The assumed DEFFinfo = 1:5 because PPPS sampling is used.
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expected prevalence of documented transfer, assumed to be 5%, since these patients will
be censored from the calculations. Thus, the sample size should be divided 0.95. If de-
sired, the ﬁnite population correction can be incorporated using the formulas described
above. The total eligible population size is an estimate of the number of patients who
initiated therapy 12 months prior to survey initiation.
4.3.3.3 Predicted precision of adjusted viral load suppression outcome
Given a particular sample size for the viral load measure, and given a particular sample
size for the retention measure, the predicted variance and conﬁdence interval width for
theadjustedviralloadsuppressionoutcome(Outcome2b)canbecalculated; assumptions
and derivations are provided in Chapter 6. Let m be the number of patients sampled per
site for the viral load suppression measure (excluding ampliﬁcation failures), let s be the
number of patients per site for the retention measure (excluding documented transfers),
and let M be the total number of patients who initiated treatment in the year prior to the
survey initiation.
Without applying the ﬁnite population corrections, the predicted variance is the follow-
ing:
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If the ﬁnite population corrections are applied, the predicted variance is the following:
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The predicted conﬁdence interval half-width is then tn 1;0:975
p
var(^ pADJ). Generaliza-
tions for stratiﬁed data or settings where all sites are included are described in Chapter
6.
4.3.4 Data analysis
Data analysis for the ADR survey has the same key features as the PDR survey (see Sec-
tion 4.2.4). The key difference is that Stata cannot directly calculate Outcome 2b, which is
the adjusted VLS measure. Nonetheless, we have provided directions for how to conduct
this data analysis in Stata with a few additional commands. A worked out example is
provided in the guidance. Data analysis is conducted using a design-based framework.
We calculate each of the outcomes as a ratio, where the denominator is an estimate of the
number of eligible patients in the country during the survey period, and the numerator
is an estimate of the number of such patients with the outcome of interest.
4.3.4.1 Site sampling weight
The calculation of the site sampling weight follows the same procedure as described for
PDR (see Section 4.2.4.1)
69As described in Section 4.3.2.4, Mi is a count of the number of eligible patients for the
VLS/HIVDR survey attending site i observed during the 6 month survey period. As
described in Section 4.3.2.5, Si is a count of the number of eligible records for retention
review at site i.
4.3.4.2 Outcomes 1a, 1b, and 1c
Outcome 1a measures population-level viral load suppression (VL<1000 copies/mL)
among individuals who have been on ART for 123 (or  48) months and who have
been retained in care. Outcome 1a, therefore, is not adjusted to take into account the pro-
portion of people who no longer attend sites because they have been lost to care, have
died or have stopped treatment. The site sampling weight is deﬁned in Section 4.3.4.1.
The patient sampling weight for site i is deﬁned as Mi divided by the number of patients
on treatment for 12 (or 48) months with ampliﬁed viral load data available from that
site, mi. The overall weight is the product of the site and patient sampling weights:
w1i = wsite;i 
Mi
mi
The point estimator, variance estimator, and conﬁdence interval estimator are as de-
scribed in Section 4.2.4.2.
Outcomes 1b and 1c are subpopulation analyses of Outcome 1a (see Section 4.2.4.3).
4.3.4.3 Outcome 2a
Outcome 2a measures population-level retention at 12 months (see Section 4.3.1). The site
sampling weight is deﬁned in Section 4.3.4.1. The patient sampling weight for site i is
deﬁned as Si divided by the number of patients on treatment for 12 (or 48) months with
ampliﬁed viral load data available from that site, si. The overall weight is the product
of the site and patient sampling weights. The point estimator, variance estimator, and
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4.3.4.4 Outcome 2b
Outcome 2b measures viral load suppression (VL<1000 copies/mL) at 12 months among
individuals sampled, adjusted for non-retention. This estimator assumes that all patients
who are not retained in care at 12 months are not achieving viral load suppression. The
adjusted proportion of patients on treatment for 12 months with viral load suppression
is estimated using a ratio estimator. Ratio estimators are used to construct prevalence
estimates in settings where both the numerator (total number of patients on treatment
for 12 months in the country with viral load suppression) and the denominator (total
number of patients on treatment for 12-24 months who are still retained in care in the
country) must be estimated. The following formula for a ratio estimator is used, where
^ pV LS;i is a site-speciﬁc estimate of VLS (Outcome 1a), and ^ pRET;i is a site-speciﬁc estimate
of retention (Outcome 2a):
^ pADJ =
Pn
i=1 wsite;iSi^ pV LS;i^ pRET;i Pn
i=1 wsite;iSi
The associated variance estimator is described in Chapter 6.
4.3.4.5 Outcomes 3a, 3b, and 3c
Outcome 3a measures the prevalence of HIV drug resistance among individuals sampled
onARTfor123(or48)monthswithviralloadsgreaterthan1000copies/mL.Outcome
3a is a subpopulation analysis of the overall data because the population is restricted to
those individuals without viral load suppression. The site sampling weight is deﬁned
in Section 4.3.4.1. The patient sampling weight is the same as deﬁned for Outcome 1a
(see Section 4.3.4.2). For all HIV drug resistance outcomes, we must also deﬁne a non-
response weight to compensate for genotyping failure. For all individuals with observed
71genotype, their non-response sampling weight is deﬁned as the number of patients with
observed viral load failure at their site divided by the number of patients with observed
viral load failure and observed genotype at their site. The non-response weight assumes
that genotyping failure is unrelated to the presence of HIV drug resistance mutations. For
all individuals with missing genotype, their non-response sampling weight is missing.
For all individuals with viral load suppression, their non-response weight is equal to 1.
The overall weight is the product of the site, patient and non-response sampling weights.
For Outcome 3a, the population is restricted to patients without viral load suppression
using the subpopulation command in Stata (see Section 4.2.4.3). To analyze Outcomes 3b
and 3c, users can input additional subpopulation speciﬁcations using the “and” operator.
4.3.4.6 Outcome 4
Outcome 4 is the prevalence of HIV drug resistance among all individuals sampled on
ART for 123 (or  48) months. Data analysis is conducted using the same sampling
weights described for Outcome 3a (see Section 4.3.4.5), though the population is not re-
stricted for Outcome 4. The point estimator, variance estimator, and conﬁdence interval
estimator are as described in Section 4.2.4.2.
4.3.4.7 Regional aggregation
Results can be aggregated as described in Section 4.2.4.5.
4.4 Discussion
In the above document we describe our proposed methodology for the surveillance of
pre-treatment drug resistance (PDR) and acquired drug resistance (ADR) in low- and
middle-income countries. This work is the product of a large-scale consultation project
72with the World Health Organization. This methodology is currently being published by
the WHO and will be implemented by countries this year. We believe that the proposed
methodology is statistically rigorous while still maintaining feasibility. We have already
received very positive feedback from partners that the methods are intuitive and repre-
sent a signiﬁcant improvement over previous versions.
735. The use of the ﬁnite population correction in survey
design for national disease surveillance
Natalie Exner, Shira Mitchell, and Marcello PaganoAbstract
The ﬁnite population correction (fpc) is a factor that can be applied to deﬂate the variance
in settings where a large fraction (>5%) of the eligible population is included in a survey.
It is appropriate to the use the fpc when the results of the survey will not be generalized
beyond the eligible population. For countries conducting national disease surveillance
to inform programmatic function, the fpc can dramatically reduce the variance of survey
outcomes. When designing a survey, the fpc can be ignored or a simple fpc represent-
ing the fraction of the eligible survey population sampled can be incorporated into the
sample size calculations. Applying the fpc results in a decrease in the survey sample
size while still achieving the desired precision. We propose a novel method for calculat-
ing the sample size for a two-stage clustered survey that predicts the magnitude of the
ﬁrst- and second-stage fpcs as elements of the design effect. The result is an even greater
decrease in required sample size. Via a series of simulations, we demonstrate that our
proposed sample size calculation method achieves the desired precision even when the
required sample size is dramatically smaller than that returned by the existing methods.
Our method has important implications for surveillance in resource-limited settings in
which reducing the overall survey cost and increasing feasibility are especially critical to
national program managers.
5.1 Introduction
When conducting national disease surveillance in a small country, the ﬁnite population
correctionfactor(fpc)canhaveadramaticeffectontheestimatedprecisionofsurveillance
outcomes. The fpc is used to reﬂect the fact that samples are taken without replacement
from a ﬁnite population. The fpc is equal to one minus the fraction of the population
sampled, and it ordinarily multiplies the variance estimator (Lohr, 2010, eq. 2.9). If only
a small proportion of the population is sampled, the fpc will be approximately one and
75can safely be ignored; otherwise, the variance will be reduced. The fpc is useful when the
sample size is large relative to the population size (say, >5%). It is appropriate to use the
fpc when survey results will not be generalized beyond the eligible survey population
(Kish, 1965, sect. 2.3). For national disease surveillance, survey results are only used for
monitoring programmatic function, and thus the fpc is appropriate in this setting. For
in-country researchers with limited technological expertise, the statistical software Stata
allows users to specify the fpc at each level of sampling when analyzing multi-stage sur-
veys (StataCorp, 2013). The resulting standard error estimates are reduced accordingly,
withtheﬁrststageﬁnite population correctionreducingtheestimatedﬁrststagevariance,
and so on.
When planning to conduct disease surveillance to estimate the prevalence of an outcome
by using a two-stage clustered survey, one must calculate the sample size required to
achieve a certain precision. This effort is, of course, complicated by the fact that the preci-
sion is affected by the prevalence being estimated. One common approach is to assume a
value for the prevalence, possibly based on historical or other relevant information, and
ﬁrst calculate the required sample size as if one were taking a simple random sample with
replacement. This sample size, known as the effective sample size, is then multiplied by
an estimate of the design effect to yield the actual survey sample size. We can thus see that
the design effect measures the relative variance of a survey with a particular design, such
as a two-stage clustered survey, as compared to a simple random sample (Kish, 1995).
In a small country, the actual sample sizes calculated using this approach may be exces-
sively large, approaching or even exceeding the total number of eligible survey partic-
ipants. One common solution is to calculate the effective sample size assuming that a
simple random sample is conducted without replacement. The simple random sample
variance is deﬂated by an fpc equal to one minus the effective sample size divided by the
total size of the eligible population (World Health Organization, 2009a). This smaller ef-
fective sample size is then multiplied by the design effect, resulting in an overall smaller
actual survey sample size. In small countries, the actual sample size calculated with the
76fpc may be signiﬁcantly smaller than the one without, reﬂecting the fact that a signiﬁcant
proportion of the total eligible population will be included in the survey.
In this report, we describe an alternative approach for performing sample size calcula-
tions for two-stage clustered surveys. Rather than adjusting with a single fpc equal to
one minus the effective sample size divided by the total population size, we propose an
approach that more accurately mirrors the ultimate survey analysis in which an fpc is
applied at each stage of the design. We demonstrate how to predict the magnitude of the
ﬁrst and second stage fpcs and how they can then be incorporated into the sample size
calculations. As might be expected, the result is an even greater decrease in the estimated
sample size while still preserving the overall desired precision. We demonstrate, by sim-
ulation, that the standard approach with a single fpc tends to overestimate the sample
size necessary to achieve a particular precision. This work is motivated by the develop-
ment of a generalizable survey protocol for HIV drug resistance surveillance in low- and
middle-income countries. In resource limited settings, cost and feasibility are major fac-
tors in survey design; thus an approach that yields smaller sample sizes while preserving
overall precision is desirable and has great applicability. In Section 5.2, we describe our
calculations for the prediction of the effect of the ﬁnite population correction on variance
estimation. In Section 5.3, we discuss three methods for sample size calculations for two-
stage clustered surveys. In Section 5.4, we describe a simulation study to compare these
three methods. Finally, we discuss our conclusions in Section 5.5.
5.2 Prediction of fpc effect
5.2.1 Notation
Divide a population into N primary sampling units (PSUs), and Mi secondary sampling
units (SSUs) within each PSUi, i 2 1;:::;N with overall population size M =
PN
i=1 Mi.
Let pi indicate the PSU mean of the outcome of interest in PSUi. Thus, the overall preva-
77lence is p =
PN
i=1
Mi
M pi.
To estimate p, we perform a two-stage clustered survey using probability proportional to
size (PPS) sampling in which larger PSUs are more likely to be sampled, and an equal
number of SSUs are sampled from each PSU, expecting that the smallest PSU is larger
than the required sample size per PSU. n PSUs and m SSUs per PSU are sampled without
replacement. Let b ti indicate the number of successes among the m SSUs sampled from
PSUi, and thus the observed prevalence of the outcome is b pi = b ti=m. Letting w be the
sampling weight for each SSU selected (constant across all PSUs and SSUs), we construct
a ratio estimator b p deﬁned below (Lohr, 2010, eq. 6.33):
b p =
Pn
i=1 wb ti Pn
i=1 wm
5.2.2 Inﬁnite population setting
The variance of this estimator can be decomposed into two parts, with the ﬁrst corre-
sponding to sampling n of N total PSUs using PPS sampling, and the second correspond-
ing to sampling m of Mi total SSUs from each selected PSU using simple random sam-
pling. Assuming that n  N and m  Mi 8i and that Mi and pi are independent, the
variance can be approximated as follows, where V arPSU measures the variance of the
PSU means (see Appendix A.1.1):
V ar(b p) =

1
n

V arPSU +

1
nm

p(1   p)[1   ICC]
The intracluster (or intraclass) correlation coefﬁcient (ICC) provides a quantitative mea-
sure of the similarity between SSUs within PSUs (Ridout et al., 1999). The numerator of
the ICC represents the between PSU variability, and the denominator represents the sum
of the between PSU and within PSU variabilities (Donner and Koval, 1980, p. 1). In order
to calculate variances, we assume an underlying beta-binomial model for the data; in the
78ﬁrst stage the PSU means are sampled from a beta distribution, and the second stage SSU
outcomes are sampled from a binomial distribution with the PSU mean generated in the
ﬁrst stage. The ICC for the beta-binomial data is equal to the following, where V arPSU
is the between PSU variability (variance of the beta distribution) (Ridout et al., 1999) (see
Appendix A.1.2):
ICC =
V arPSU
p(1   p)
(5.1)
With this deﬁnition of ICC, we then calculate the design effect, which is the ratio of the
variance of the estimate of population prevalence under the survey to the variance of an
estimate of population prevalence under a simple random sample. In this paper, when
we refer to design effect, we are referring to what Kish calls DEFT 2 (Kish, 1995) because
our denominator is the variance of a simple random sample with replacement. Thus,
the design effect can be approximated by the following well-known equation (Appendix
A.1.3):
DEFT
2 (b p) = 1 + ICC [m   1]
5.2.3 Finite population setting
When the sampling fractions are non-negligible, one can incorporate fpcs into the cal-
culations. For the ﬁrst stage of sampling, express the ﬁrst-stage fpc as (1   n=N); this
is consistent with Stata’s method of analyzing the data. Stata assumes a simple random
sample of PSUs. In reality, our sample uses PPS sampling at the ﬁrst stage. Alternative
ﬁnite population corrections are described elsewhere (Wolter, 2007, chap. 8, eq. 8.7.6).
For simplicity and consistency with Stata, we employ the generally more conservative
ﬁrst stage fpc of (1   n=N) (a direct comparison of this approach and the most popular
79alternative fpc is described in Appendix A.1.4), although it would be straightforward to
change the ﬁrst stage ﬁnite fpc in the design and analysis. For the second stage of sam-
pling, we express the second-stage fpcs as (1   m=Mi) for each i, which is appropriate
because SSUs are sampled with equal probability.
We can predict the approximate variance of this estimator including fpcs as follows (see
Appendix A.1.5):
var(b p) 
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1
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
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We can then calculate the associated design effect (see Appendix A.1.6), where M = M=N
is the average PSU size:
DEFT
2(b p)  (1   m=M) + ICC

(1   n=N)m   (1   m=M)

Thus, the predicted ﬁrst stage fpc (1   n=N) and predicted second stage fpc and second
stage fpc (1   m=M) can be expressed as part of the design effect. Calculation of these
predicted fpcs does not require additional prior information over the standard method
for incorporating the ﬁnite population correction, which requires knowledge of the total
population size M and total number of PSUs N. If the sampling fraction is negligible
during both stages of sampling, the design effect simpliﬁes to the familiar expression for
the design effect of a clustered survey, i.e., 1 + ICC [m   1].
5.3 Sample size calculations
The variance of the estimator under discussion directly impacts the sample size required
to reach a desired precision, which is an important consideration at the design stage of
the survey. Here we present three methods for calculating the sample size for a two-stage
clustered survey. The ﬁrst does not incorporate any fpc (assumes an inﬁnite population).
80The second incorporates a single population-level fpc. The third is the method we pro-
pose, and it incorporates both ﬁrst- and second-stage fpcs.
As stated previously, to perform sample size calculations, we require prior information
about the outcome. For estimating prevalence, we require an assumed value for the
prevalence, p, and some measure of the intracluster variability of the outcome, such as
the ICC. If the prevalence is unknown, we can assume that it is equal to p = 0:50. The
ICC can be challenging to estimate in practice. If prior data are available, the ICC can be
estimated using an ANOVA estimator (Ridout et al., 1999). Otherwise, we recommend
surveying the literature to identify a reasonable value. To design the survey, one must
also specify the desired precision; this is generally deﬁned as a desired half-width L for a
95% conﬁdence interval with quantile q (example: 1:96 or tdf(0:975) where df refers to the
design degrees of freedom for the survey (Korn and Graubard, 1999, p. 62)). This infor-
mation is combined to calculate the effective sample size, keff. As mentioned previously,
the effective sample size is then multiplied by the design effect to yield the actual sample
size of the survey, kact.
5.3.1 Method 1: No ﬁnite population correction
For the ﬁrst sample size calculation method (denoted with a subscript 1), if no fpc is used,
we can determine an expression for m1, the number of SSUs required per PSU when
sampling n PSUs (see Appendix A.1.7):
m1 =
q2p(1   p)[1   ICC]
L2n   q2p(1   p)ICC
For this and all other methods, the per PSU sample size m1 should be rounded up to
the nearest whole number. Note that the quantile q used for the 95% conﬁdence interval
is left general. Because the method for calculating a conﬁdence interval in the setting
of clustered surveys uses a t-distribution with degrees of freedom equal to the design
81degrees of freedom (Korn and Graubard, 1999, p. 62), our effective sample size is also
a function of the number of PSUs sampled. When the design degrees of freedom are
large (around 40 or greater), it is standard to assume that z0:975  tdf;0:975 as this simpliﬁes
calculations. When sampling only a few PSUs, the design degrees of freedom will be
small, and it is thus inadvisable to make this simpliﬁcation. The consequence of using this
simpliﬁcation would be an underestimation of the total sample size required to achieve a
given conﬁdence interval half-width.
5.3.2 Method 2: Finite population correction in effective sample size
In the second method (denoted with a subscript 2), a ﬁnite population correction is ap-
plied while solving for the effective sample size. This method is used frequently in prac-
tice when conducting surveillance in low- and middle-income countries (Yansaneh, 2005,
p. 26)(World Health Organization, 2009a, p. 29). We can determine an expression for m2,
the number of SSUs required per PSU when sampling n PSUs (see Appendix A.1.7):
m2 =
q2p(1   p)M [1   ICC]
n[L2M + q2p(1   p)]   q2p(1   p)M [ICC]
5.3.3 Method 3: Finite population corrections at each stage of sampling
In the third method (denoted with a subscript 3), we incorporate ﬁrst- and second-stage
ﬁnite population correction factors into the design effect estimate. Using this method, we
candetermineanexpressionform3, thenumberofSSUsrequiredperPSUwhensampling
n PSUs (see Appendix A.1.7):
m3 =
q2p(1   p)M [1   ICC]
L2nM + q2p(1   p)   q2p(1   p)M [ICC]
 
1   n
N

+ 1
M

825.4 Simulations
We directly compare these three sample size calculation methods using a simulation
study, varying the size and distribution of the population, the intracluster correlation
coefﬁcient, and the desired precision. We focus on the selection of HIV clinics (which
are our PSUs) within a country for the purpose of estimating national HIV drug resis-
tance prevalence. For each simulation, we generate N PSUs with Mi SSUs in each PSUi.
We then simulated the outcomes using a beta-binomial distribution, for which PSUi has
prevalence pi drawn from a Beta(; ) distribution, and each of the secondary sampling
units (SSUs) in that PSU are drawn from a Bernoulli distribution with success probability
pi. To simulate data with a particular overall prevalence p and intracluster correlation
ICC, the parameters from the Beta distribution must equal the following (Ridout et al.,
1999, p. 138):
 =

1   ICC
ICC

p
 =

1   ICC
ICC

(1   p)
To simulate two stage cluster sampling, we randomly sample n PSUs using probability
proportional to size (PPS) sampling without replacement; then, we randomly sample m
SSUs from each selected PSU using simple random sampling without replacement. If m
is larger than the number of SSUs in the selected PSU, sampling stops after all available
SSUs are included. For each simulated cluster sample, we calculate the estimated preva-
lence, b p, which is the mean of the observed data since the overall design is PPS and the
data is self-weighting. If any clinics under-enroll, making the design no longer epsem,
mi may vary across clinics and the sampling weights wi for each individual will be equal
within clinics but not across clinics. The slightly more general formula below can be used
to estimate the prevalence:
83b p =
Pn
i=1 wib ti Pn
i=1 wimi
Following the Stata SVY documentation (StataCorp, 2013, “variance estimation”), an es-
timator of the variance can be written as:
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This variance has associated 95% Wald conﬁdence interval:
h
b p   tn 1;0:975
p
d var(b p); b p + tn 1;0:975
p
d var(b p)
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We ran 25,000 iterations for each of six scenarios. The conﬁdence interval (CI) width
reported is the average conﬁdence interval half-width over the 25,000 iterations.
Scenario 1 (moderate ICC, small number of large clinics): ICC = 0:01, p = 0:80, desired
CI width is 5% (L = 0:05). N = 30 clinics, each of size Mi = 100. M = 3000.
Table 5.1: Average CI width for sampling n = 15 and n = 20 clinics in Scenario 1
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 15 m1 = 25 0:0403 m2 = 22 0:0433 m3 = 18 0:0485
kact1 = 375 kact2 = 330 kact3 = 270
n = 20 m1 = 17 0:0427 m2 = 15 0:0458 m3 = 13 0:0496
kact1 = 340 kact2 = 300 kact3 = 260
84The per clinic sample size is smaller for Method 3 (our proposed method) than for Meth-
ods 1 (no fpc) and 2 (simple fpc), thus representing a great savings in cost and time. This
saving is quite sizable when only n = 15 clinics are sampled, requiring 60 fewer samples
overall than the simple fpc method The sample sizes calculated from Method 3 result in
conﬁdence intervals at approximately the desired 5% precision. Because they are larger,
the sample sizes calculated from Methods 1 and 2 yield conﬁdence intervals narrower
than the prescribed 5%.
Scenario 2 (moderate ICC, large number of small clinics): ICC = 0:01, p = 0:80, desired
CI width is 5% (L = 0:05). N = 100 clinics, each of size Mi = 30. M = 3000.
Table 5.2: Average CI width for sampling n = 15 clinics in Scenario 2
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 15 m1 = 25 0:0274 m2 = 22 0:0320 m3 = 14 0:0479
kact1 = 375 kact2 = 330 kact3 = 210
Again, the per clinic sample size is smaller for Method 3 (m3 = 14 for n = 15) than for
Methods 1 and 2 (m1 = 25 and m2 = 22, respectively for n = 15). Note that Methods 1
and 2 result in the same sample sizes for Scenarios 1 and 2 as they have the same ICC, p,
desired CI width, and, for Method 2, total population size. For Method 3, the sample sizes
are different for Scenario 1 (m3 = 18 for n = 15) as compared to Scenario 2 (m3 = 14 for
n = 15). The required sample size for Method 3 is smaller when there are many smaller
clinics (Scenario 2) as compared to fewer larger clinics with the same overall population
size (Scenario 1).
Scenario 3 (moderate ICC, moderate number of variable sized clinics): ICC = 0:01, p =
0:80, desired CI width is 5% (L = 0:05). N = 50 clinics. PSU sizes were drawn from a
gamma distribution (shape parameter equal to 2, scale parameter equal to 100. PSU sizes
below 50 or above 1000 were discarded. The PSU sizes were then shifted by subtracting
8545 from each to achieve some very small PSU sizes.) The simulated PSU sizes ranged
from 5 SSUs to 955 SSUs, with an average size of 180 SSUs. M = 8978.
Table 5.3: Average CI width for sampling n = 10 clinics in Scenario 3
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 10 m1 = 49 0:0415 m2 = 46 0:0426 m3 = 36 0:0477
kact1 = 490 kact2 = 460 kact3 = 360
In this scenario, the clinic sizes vary widely. Again, Method 3 (our proposed method)
results in the overall smallest sample size by a sizable amount while still achieving the
desired precision.
Scenario 4 (moderate ICC, moderate number of small clinics, low desired precision):
ICC = 0:01, p = 0:80, desired CI width is 15% (L = 0:15). N = 50 clinics. each of
size Mi = 30. M = 1500.
Table 5.4: Average CI width for sampling n = 5 clinics in Scenario 4
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 5 m1 = 13 0:1102 m2 = 12 0:1170 m3 = 9 0:1426
kact1 = 65 kact2 = 60 kact3 = 45
In this scenario, very low precision is desired 15%, resulting in very low sample sizes
for all methods. Method 3 still achieves the desired precision with the smallest overall
sample size.
Scenario 5 (high ICC, large number of large clinics): ICC = 0:2, p = 0:80, desired CI
width is 5% (L = 0:05). N = 100 clinics, each of size Mi = 100. M = 10000. Note: for
86n = 50, Methods 1 and 2 return negative sample sizes, indicating that there is no feasible
per-clinic sample size that would achieve the desired precision.
Table 5.5: Average CI width for sampling n = 50 and n = 60 clinics in Scenario 5
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 50 m1 = n=a n=a m2 = n=a n=a m3 = 8 0:0505
kact1 = n=a kact2 = n=a kact3 = 400
n = 60 m1 = 24 0:0338 m2 = 20 0:0349 m3 = 5 0:0509
kact1 = 1440 kact2 = 1200 kact3 = 300
In this scenario, the ICC is very high (0.2). Note that Methods 1 and 2 are unable to cal-
culate per clinic sample sizes until over n = 50 clinics are sampled. When n = 60, the dif-
ference in overall sample size between Method 2 and Method 3 is immense (kact2 = 1200
and kact3 = 300, respectively), though the differences in conﬁdence interval width are not
similarly extreme. The CI width for Method 3 is slightly above 5% for these simulations.
Scenario 6 (zero ICC, small number of large clinics): ICC  0, p = 0:80, desired CI width
is 5% (L = 0:05). N = 30 clinics, each of size Mi = 100. M = 3000. Note: simulated ICC
is 10 12 because ICC must be strictly positive for beta-binomial simulations.
Table 5.6: Average CI width for sampling n = 10 clinics in Scenario 6
Method 1 Method 2 Method 3
Design CI Width Design CI Width Design CI Width
n = 10 m1 = 33 0:0406 m2 = 30 0:0435 m3 = 25 0:0492
kact1 = 330 kact2 = 300 kact3 = 250
In this scenario, the ICC is effectively zero. Note that when the ICC is zero, we might
expect DEFT 2 = (1   nm=M). Alternatively, Method 3 predicts DEFT 2 = (1   m=M),
87which is not the design effect that would result from a simple random sample. Nonethe-
less, in this setting, Method 2 overestimates the sample size to achieve a conﬁdence in-
terval width of 5%, while the average conﬁdence interval resulting from Method 3 is
under 5%.
5.5 Discussion
We describe three methods for calculating sample sizes for probability proportional to
size (PPS) two-stage clustered surveys used for national disease surveillance. In all meth-
ods we assume that we know the actual prevalence and the ICC, thus these elements
must be estimated from previously available data. In Method 1, no adjustment for the
effect of a ﬁnite population is made at the design stage. The ﬁnite population correction
can be readily applied at the analysis stage, but the end result is overestimation of the
sample size, and thus a greater cost of the survey, in order to achieve the desired preci-
sion. In Method 2, a standard adjustment for the ﬁnite population is made at the design
stage. This is achieved by incorporating a ﬁnite population correction into the calculation
of the effective sample size. Method 2 results in smaller sample sizes than Method 1, but
in many cases the numbers are quite similar. The resulting conﬁdence intervals tend to be
narrower than planned for, but wider than the conﬁdence intervals yielded from Method
1. Finally, we present Method 3, which adjusts for the ﬁnite population correction at the
ﬁrst and second stages of sampling. These corrections are incorporated into the estimate
of the design effect using a formula derived in Section 2. The resulting sample sizes are
smaller than those from Methods 1 and 2, especially when fewer PSUs are sampled, but
the conﬁdence intervals seem to perform well; they tend to be at or slightly smaller than
the desired width.
Further, we observe that Method 1 returns the same sample size for all scenarios with
the same prevalence, ICC, desired precision, and number of clinics sampled. Method 2
returns the same sample size for all scenarios with the elements listed for Method 1, plus
88the same overall population size. In contrast, Method 3, our proposed method, returns
different sample sizes depending on the composition of the population size. The sample
size is larger for countries with few larger clinics (Scenario 1) than for countries with
many smaller clinics (Scenario 2). Method 3 performs well when the clinics vary in size
(Scenario 3) and when the desired precision is so low that the overall sample size is small
(Scenario 4). We also evaluated the methods in scenarios with high and low ICCs. When
the ICC was high (Scenario 5), Methods 1 and 2 return impossible sample sizes if the
number of clinics sampled are too few, while Method 3 returns a realistic sample size that
performs reasonably well. When more clinics are sampled in that particular scenario, the
sample sizes for Method 3 are drastically smaller than the sample sizes for Methods 1 and
2. Finally, when the ICC is effectively zero (Scenario 6), Method 3 performs well, even
though the predicted design effect does not reduce to the ﬁnite population correction of a
simple random sample.
We can identify a few limitations to this method. First of all, it adds a slight layer of
complexity to the sample size calculations; nonetheless, these are easily coded into user-
friendly calculators using software such as Excel. Another limitation is that the ﬁnite
population correction is a simpliﬁed way to analyze data sampled without replacement,
and there is a wealth of literature on more technically correct methods for analyzing such
data, especially for PPS sampling of PSUs (S¨ arndal et al., 2013, chap. 4). Nonetheless, one
of the major goals when prescribing methods to be used in the ﬁeld is to simplify wher-
ever possible. The simplicity of approximations vastly outweighs any risk of inefﬁciency
or the introduction of a slight theoretical bias. Furthermore, in practice one very often
uses the ubiquitous systematic sampling scheme for the sampling of PSUs, potentially
with implicit stratiﬁcation by geographic region; this approach does not lend itself well
to standard “without replacement” methodologies (Wolter, 2007, sect. 8.6).
On the other hand, we believe that thismethodology for calculating sample size fora two-
stageclusteredsurveyhasmanysigniﬁcantadvantages. Thegreatestoftheseistheability
to realize cost-savings at the design stage – and, in some cases, these savings may be sig-
89niﬁcant when compared to the standard method for incorporating the ﬁnite population
correction – and yet they retain their accuracy. For resource-limited small countries, this
can represent immense savings. For example, for the surveillance of HIV drug resistance,
each SSU sampled is a patient whose viral strain must be genotyped, which is an expen-
sive procedure. By improving feasibility, we increase the likelihood that these surveys
will actually be implemented in the ﬁrst place, which is important as they can provide
valuable information to national program directors. Outside of the HIV drug resistance
surveillance setting, this methodology could be applied to other national surveillance ac-
tivities in resource-limited settings, and the formulae can also be readily adapted for use
with continuous variables or stratiﬁcation.
906. Development of a viral load suppression measure
adjusted for non-retention for the surveillance of acquired
HIV drug resistance
Natalie Exner and Marcello PaganoAbstract
The World Health Organization is redesigning their guidance for the surveillance of ac-
quired HIV drug resistance in low- and middle-income countries. This paper focuses on
designing such a survey. The previous survey was a longitudinal survey of HIV-infected
patients during the ﬁrst 12 months of treatment, but this has been replaced by a cross-
sectional survey of patients on treatment for 12 3 months for reasons of feasibility. There
are important limitations of cross-sectional surveys. One of the key survey outcomes for
this survey is the prevalence of viral load suppression (VLS, deﬁned as viral load < 1000
copies/mL) among patients on antiretroviral therapy for 12 3 months. Because the pop-
ulation observable from a cross-sectional survey excludes patients who have died or have
been lost to follow-up, observed VLS has limited epidemiologic utility for national HIV
program managers. We highlight the importance of measuring 12 month retention to
assist in the interpretation of observed VLS results. In addition, we propose a novel ad-
justed VLS measure that incorporates data on site-speciﬁc retention by assuming that all
patients who have been lost to follow-up are not virally suppressed. We believe that this
adjusted VLS measure has improved utility for assessing changes in VLS over time within
a country, across countries, and relative to a global standard.
6.1 Introduction
In the last ten years, low- and middle-income countries have been able to signiﬁcantly ex-
pand access to antiretroviral therapy (ART) for their HIV-infected populations. Treatment
efﬁcacy is affected by HIV drug resistance (HIVDR) that is transmitted via infection or ac-
quired via drug selective pressure. As genotyping for HIVDR mutations is prohibitively
expensive in many settings, countries can implement sampling surveys to obtain na-
tionally representative estimates of factors associated with acquired HIVDR. Acquired
HIVDR (ADR) is deﬁned as any drug resistance mutation that emerges under the selec-
92tive pressure of ART (World Health Organization, 2012a). There are various ways that
a patient may develop HIVDR mutations, including suboptimal adherence to treatment
regimens, treatment interruption, inadequate plasma drug concentrations, or the use of
suboptimal drugs or drug combinations (World Health Organization, 2012a). National
program managers can use information from ADR surveys to identify gaps in service de-
livery and to assess the expected effectiveness of available ﬁrst- and second-line regimens
(World Health Organization, 2012a).
The newly revised WHO protocol for ADR surveillance in low- and middle-income coun-
tries includes a cross-sectional survey of patients on treatment for 12 3 months. The
primary outcome is the prevalence of viral load suppression (VLS, deﬁned as viral load <
1000 copies/mL) among patients retained on treatment (observable patients), and one of
the secondary outcomes is the prevalence of HIVDR mutations among patients with viral
suppression failure. Observed VLS is the primary outcome because it is a key indicator
of program performance at 12 months. Patients who are virally suppressed do not have
effective drug resistance (McMahon et al., 2013). In addition, viral suppression failure in
a patient may be attributable to either the existence of HIVDR mutations or to personal or
programmatic failures such as poor adherence or treatment stock-outs. These 12 month
viral suppression and drug resistance outcomes provide important feedback to national
HIV program managers.
The previous WHO protocol to study this issue was a longitudinal survey following a
cohort of patients receiving ART during their ﬁrst 12 months on treatment (World Health
Organization, 2012c). The WHO abandoned the previous protocol because of the logisti-
cal complexity associated with a longitudinal survey that requires following a cohort for
12 months and the long lag between survey initiation and availability of results (World
Health Organization, 2012b). In contrast to a longitudinal survey that requires a group
of patients to be assessed continuously over time, a cross-sectional study only observes
patients at a particular point in time; clearly, this is much less expensive than a contin-
uously ongoing study, but a cross-sectional survey excludes patients who are no longer
93receiving ART at the study site and therefore cannot be observed because they have died,
been lost to follow-up or have stopped treatment. This survivor bias can signiﬁcantly
impact the interpretation of the primary outcome. Without accounting for within country
or country-to-country variability in retention patterns, there are many important con-
founding factors, making it challenging to meaningfully a) assess changes in the national
estimate of observed VLS over time, b) compare these estimates against a global standard,
or c) compare estimates across countries.
In this paper, we discuss the epidemiologic limitations of observed VLS in the absence
of complete data on retention, and we propose a new outcome that attempts to correct
this bias by combining observed cross-sectional VLS with data on patient ART retention.
Retention needs to be estimated using a second site-speciﬁc sample survey of patient
records. This then leads to an adjusted outcome that has improved utility in that it can
be more meaningfully compared across time and to a global standard. This adjusted out-
come is akin to a lower bound of 12 month viral suppression because it assumes that all
patients who are not retained are not virally suppressed.In our experience, the percentage
of patients with documented transfer is very low in low- and middle-income countries.
The treatment of documented transfers is described in Section [sub:Retention]. The pri-
mary advantage of this framework is that it measures an outcome that is very similar to
that originating from a longitudinal study (i.e. prevalence of VLS among patients who
initiated treatment 12 months prior) using a cross-sectional study.
We also describe how the ADR survey framework can be used to develop a nationally
representative estimate of 12 month retention. Currently, 12 month retention is a recom-
mendedUNGASS/PEPFARindicator, thoughitssuggestedimplementationisviacensus.
Using a sampling framework can drastically increase the feasibility and acceptability of
this important indicator.
In Section 6.2, we provide motivation for the adjusted VLS outcome. In Section 6.3, we
provide a framework and the necessary formulae for the analysis of adjusted VLS. In Sec-
94tion 6.4, we provide formulae for approximating the precision of adjusted VLS to inform
survey design. In Section 6.5, we describe a simulation study to evaluate the robustness
of our results. In Section 6.6, we discuss the conclusions we can draw from this study.
6.2 Motivation for adjusted VLS outcome
The goal of this survey is to observe VLS patterns a year after patients have been placed
on treatment. The available primary outcome of this survey is VLS among observable
patients retained on ART for 123 months. Because this outcome is measured via a cross-
sectional survey, it has important epidemiological limitations. If one only observes those
patients remaining on treatment at a particular site, countries with the worst retention
may appear to have the highest observed VLS because the sickest patients have been lost
to follow-up or died. On the other hand, a country that makes a concerted effort to im-
prove retention may experience a decrease in observed VLS because these newly retained
patients may be failing therapy more so than those who were retained in the past. Thus, it
is not meaningful to compare observed VLS over time even within the same country if re-
tention patterns change over time1. Observed VLS from a cross-sectional survey provides
incomplete information about program performance if a measure of retention is not in-
corporated into the evaluation. As a result, we measure 12 month retention in a nationally
representative fashion using methodology consistent with an existing UNGASS/PEPFAR
indicator (UNAIDS, 2011, sect. 4.2). Furthermore, we propose an adjusted VLS measure
that incorporates information on retention; this measure makes two assumptions: (i) all
patients who are lost to follow-up or die are not virally suppressed; and (ii) all patients
who are documented to have transferred care to another site are assumed to have the
same rate of VLS and retention as other patients.
Using a simple law of total probability, an estimate of the overall prevalence of VLS can
be written as follows:
1This is an example of the Neyman incidence-prevalence bias
95Pr(V LS) = Pr(V LSjRetained)Pr(Retained)
+Pr(V LSjNot Retained)Pr(Not Retained)
= Pr(V LSjRetained)Pr(Retained) + 0
= Pr(V LSjRetained)Pr(Retained)
Thus, observed VLS, i.e., Pr(V LSjRetained), and retention, i.e.,Pr(Retained), can be mul-
tiplied to yield an estimate of the overall prevalence of VLS, adjusted for non-retention.
We recommend calculating adjusted VLS at the level of a site administering ART by mul-
tiplying a site-level estimate of unadjusted VLS (censoring documented transfers) and
a site-level estimate of retention. These site-level adjusted VLS estimates are then com-
bined across sites, weighting by site size, resulting in an overall estimate of VLS adjusted
for non-retention. In summary, we extract those who are documented transfers and as-
sume they behave the same as other patients. We then assume that those lost to follow-up
and those who die are failures. In this way, we have imputed or measured an outcome
for sampled patients who initiated therapy a year earlier. In fact, the adjusted VLS mea-
sure is very similar to one of the primary outcomes of the previous longitudinal survey,
HIV drug resistance prevention (World Health Organization, 2012a, annex 1, sect. 8).
HIV drug resistance prevention is deﬁned as as the proportion of patients who initiated
therapy who are virally suppressed at 12 months. Within this indicator is the inherent as-
sumption that all patients who have been lost to follow up or died have failed. Thus, we
can readily argue that adjusted VLS is measuring the same population quantity as HIV
drug resistance prevention, but adjusted VLS requires only cross-sectional information.
966.3 ADR survey implementation
6.3.1 Survey design overview
The proposed survey is a two-stage clustered survey of (1) sites administering ART in
the country, and (2) patients on treatment for 123 months during a pre-deﬁned survey
period lasting 6 months. The primary sampling units (PSUs) are the sites. The secondary
sampling units (SSUs) are eligible patients.
To perform the ADR survey, n of N total sites are selected using probability proportional
to size (PPS) sampling without replacement in which larger sites are thus more likely to
be sampled, and then the same number of patients are included from each chosen site.2
The sizes of the sites are estimated using available proxy information, such as the number
of patients on treatment during the previous year at those sites. Because these sizes will
likely differ from the actual sizes of the eligible population (i.e., patients on treatment for
123 months during the survey period), we refer to this type of sampling as probability
proportional to proxy size (PPPS) sampling. For the i 2 1;:::;n sites sampled, the PSU
sampling weight is equal to the inverse of the probability that the site is selected into the
sample SI, i.e. wPSU;i = [Pr(i 2 SI)]
 1.
6.3.2 Observed VLS
Once n sites have been sampled, eligible patients are consecutively enrolled at each of
these sites for the measurement of observed VLS. The target number of patients to be
sampled from each site is m, as determined by the desired precision of the observed VLS
outcome, but the actual number sampled may vary across sites because of differential
laboratory failure or under-enrollment, for example. Among the mi individuals sampled
at site i, b ti is the number of patients achieving VLS. Thus, the observed prevalence of VLS
2One such method for conducting sampling is PPS systematic sampling; the advantage of this option is
an increase in ease of implementation (Wolter, 2007, sect. 8.6).
97among patients retained on therapy at site i is b pV LS;i = b ti=mi.
In order to appropriately weight the estimator, it is important that the site screen patients
to determine the total number of eligible patients observed during the 6 month survey
period; we refer to the observed eligible population size of site i as Mi. The SSU sam-
pling weight, wSSU;V LS;i, is equal to the inverse of the probability that patients from site
i are selected into the sample. Since we assume that patients are randomly selected with
equal probability (no time trend over the survey period), wSSU;V LS;i = Mi=mi. The overall
sampling weight for patients with observed viral load data is wV LS;i = wPSU;iwSSU;V LS;i.
AnationallyrepresentativeestimateofobservedVLSprevalenceisaratiowithnumerator
equal to an estimate of the total number of patients in the country on treatment for 123
months who are still retained in care and are achieving viral load suppression (b T); the
denominator is an estimate of the total number of patients in the country on treatment
for 12-24 months who are still retained in care (c M). The point estimator and linearized
variance estimator (with ﬁnite population corrections consistent with those in Stata’s SVY
command) are as follows (Lohr, 2010, eq. 6.33) (StataCorp, 2013):
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A 95% conﬁdence interval can be calculated using a Wald-type interval for a proportion.
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p
d var(b pV LS)
The survey analysis can be readily modiﬁed for settings when the sites are stratiﬁed prior
to sampling or all sites are included in the sample StataCorp (2013).
6.3.3 Retention
In order to obtain a measure of retention for patients on treatment, we can perform a ret-
rospective chart review at the same n sites sampled. We list patients who initiated therapy
during a pre-deﬁned sampling window, and a random sample of these patients is selected
for assessment of retention. This sample can be obtained via systematic sampling (e.g.,
every 10th record beyond a random start point) (Lohr, 2010, sect. 2.7). 12 month retention
is deﬁned as the patient being retained on ART at exactly 12 months after treatment initi-
ation (UNAIDS, 2011, sect. 4.2). Patients who have stopped treatment, died, or been lost
to follow-up are not considered retained. Patients with documented transfer to another
site are excluded from the sample. The inherent assumption is that these transferred pa-
tients have the same prevalence of retention and viral load suppression after transferring
care as patients who did not transfer, and excluding them from the sample will properly
implement these assumptions.
The target number of patients to be sampled from each site is s as determined by the
desired precision of the estimate of 12 month retention. The number of charts reviewed
may vary across sites. Among the si patients sampled from site i (excluding documented
transfers), b ui is the number of patients retained on treatment at 12 months. Thus, the
observed prevalence of 12 month retention among patients at site i is b pRET;i = b ui=si.
In order to appropriately weight the estimator, it is important that the site determines the
total number of eligible patients for the retrospective chart review; we refer to the total
number of eligible patient records at site i as Si. The SSU sampling weight wSSU;RET;i
99is equal to the inverse of the probability that patients from site i are selected into the
sample. Since we assume that patients are randomly selected with equal probability,
wSSU;RET;i = Si=si. The overall sampling weight for patients with retention data (ex-
cluding documented transfers) is wRET;i = wPSU;iwSSU;RET;i.
A nationally representative estimate of 12 month retention is a ratio with numerator equal
to an estimate of the total number of patients retained on treatment for 12 months who
initiated during a pre-deﬁned sampling window (b U); the denominator is an estimate of
the total number of patients who initiated treatment during a pre-deﬁned sampling win-
dow (b S). The point estimator and linearized variance estimator (with ﬁnite population
corrections consistent with those in Stata’s SVY command) are as follows (Lohr, 2010, eq.
6.33) (StataCorp, 2013):
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A 95% conﬁdence interval can be calculated using a Wald-type interval for a proportion.
b pRET  tn 1;0:975
p
d var(b pRET)
The survey analysis can be readily modiﬁed for settings when the sites are stratiﬁed prior
to sampling or all sites are included in the sample (StataCorp, 2013).
1006.3.4 Adjusted VLS
At each of the n sites sampled for the survey, we can estimate the site-speciﬁc adjusted
VLS prevalence as the product of site-speciﬁc observed VLS and site-speciﬁc 12 month re-
tention. We then weight the site results by the number of patients who initiated therapy at
each site (Si for site i). The adjusted VLS measure can be estimated as a ratio with numer-
ator being an estimate of the total number of patients in the country retained on treatment
for 12 months with viral load suppression (b V ); the denominator is an estimate of the total
number of patients who initiated treatment during a pre-deﬁned sampling window (b S).
(Note: this is equivalent to b S calculated for the retention denominator.) The point estima-
tor and linearized variance estimator (with ﬁnite population corrections consistent with
those in Stata’s SVY command) are as follows (see Appendix A.2.1):
b V =
n X
i=1
wPSU;iSi^ pV LS;i^ pRET;i
b S =
n X
i=1
wPSU;iSi
b pADJ =
b V
b S
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
A 95% conﬁdence interval can be calculated using a Wald-type interval for a proportion.
b pADJ  tn 1;0:975
p
d var(b pADJ)
1016.4 ADR survey design
Prior to implementing the survey, countries must determine a suitable design that will be
a compromise between desired precision and logistical/ﬁnancial feasibility. Guidance on
how to calculate sample size requirements to achieve a certain precision, for the observed
prevalence of VLS, b pV LS, is described elsewhere (see Chapter 5). The same procedure
can be used to calculate sample size requirements to achieve a certain precision for the
retention measure, b pRET. Given the sample sizes identiﬁed for the viral load suppression
and retention portions of the survey, it is useful for countries to predict the precision of
the adjusted VLS measure, b pADJ.
With some assumptions, we derive estimates of the variance of the adjusted VLS measure
that can be used to predict the expected conﬁdence interval width resulting from a survey
with a particular combination of sample sizes for VLS and retention. These approxima-
tions assume that site size, site-speciﬁc prevalence of observed VLS, and site-speciﬁc re-
tention are independent. Sensitivity to these assumptions is evaluated in our simulations
in Section 6.5. For the derivations and simulations, we assume probability proportional to
size (PPS) sampling, in which the actual site sizes are known, although we acknowledge
that generally this information will not be available prior to site sampling. In this case,
the predicted variances below should be multiplied by an additional design effect due to
disproportionate weighting, often expressed as 1+cv2(weights), where cv() indicates the
coefﬁcient of variation (Park and Lee, 2004, eq. 2.2).
For an inﬁnite population, the variance of b pADJ can be approximated using Equation 6.1,
requiring the parameters for the survey design (n sites sampled, m VLS patients sampled
per clinic, and s retention records sampled per clinic), an estimate of the prevalence of
observed VLS (pV LS), an estimate of the intracluster correlation coefﬁcient for observed
VLS (ICCV LS), an estimate of the prevalence of retention (pRET), and an estimate of the
intracluster correlation coefﬁcient for retention (ICCRET). Note that all of these elements
are already required for the design and implementation of the surveys for observed VLS
102(b pV LS) and retention (b pRET). When a subset of sites are sampled in the absence of stratiﬁ-
cation, the predicted variance is as follows (see Appendix A.2.2):
V ar(b pADJ) 
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
ICCV LS +
1
m
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
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2
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(6.1)
For a ﬁnite population with N total sites, M =
PN
i=1 Mi total patients eligible for viral
load suppression testing, and S =
PN
i=1 total records eligible for retention estimation, the
variance of b pADJ can be approximated by Equation (see Appendix A.2.3):
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(6.2)
The corresponding predicted conﬁdence interval half-width using a Wald-type interval
for a proportion is:
tn 1;0:975
p
V ar(b pADJ)
1036.5 Simulations
6.5.1 Simulation set-up
We evaluate these methods by simulating data within a hypothetical large country and a
hypothetical small country. In both cases, we assume that the national prevalence of VLS
amongretainedpatientsispV LS = 85%, andthenationalprevalenceof12-monthretention
is pRET = 85%. Site-speciﬁc prevalence of VLS, pV LS;i, is drawn from a Beta(V LS; V LS)
for i = 1;:::;N sites in the country. The parameters of the beta distribution are the follow-
ing, where ICCV LS = 0:0043 is the intracluster correlation of observed VLS:
V LS =

1   ICCV LS
ICCV LS

pV LS
V LS =

1   ICCV LS
ICCV LS

(1   pV LS)
Similarly, site-speciﬁc retention, pRET;i, is drawn from a Beta(RET; RET) for i = 1;:::;N
sites in the country. The parameters of the beta distribution are the following, where
ICCRET = 0:0476 is the intracluster correlation of 12-month retention:
RET =

1   ICCRET
ICCRET

pRET
RET =

1   ICCRET
ICCRET

(1   pRET)
The assumed values described above are identical to those used in the proposed ADR
surveillance guidance. Their justiﬁcation is described elsewhere (see Chapter 4).
To simulate the patient outcomes of the Si eligible records that can be reviewed for re-
tention in a site, we assign Mi = SipRET;i as retained, and we assign the remaining
Si(1   pRET;i) as not retained. Among the Mi retained patients, we assign MipV LS;i as
virally suppressed, and we assign the remaining Mi(1 pV LS;i) as not virally suppressed.
104To simulate two stage cluster sampling, we randomly sample n of N sites using proba-
bility proportional to size (PPS) sampling without replacement; sampling is proportional
to the number of eligible records at each site, Si. For the observed VLS outcome, we
randomly assess the VLS outcomes of m retained patients from each selected site us-
ing simple random sampling without replacement. If m is larger than the number of
retained patients in the selected site, sampling stops after all available patients are in-
cluded. Sampling for the retention outcome proceeds similarly, with s patient records
being sampled from each selected site. For the purposes of this simulation, m and s are
selected to achieve conﬁdence intervals of 5% around b pV LS and b pRET (see Chapter 4).
For each simulated cluster sampled, we estimate the adjusted VLS prevalence, standard
error, and 95% conﬁdence interval as using the formulas provided in Section 6.3.4. We
repeat the simulations 10,000 times. We calculate the true value of the adjusted VLS out-
come, which is pADJ =
PN
i=1 SipV LS;ipRET;i

S. We report the average point estimate from
the 10,000 simulations. We calculate the simulation standard error, which is the standard
deviation of the 10,000 simulated prevalence estimates. We report the average estimated
standard error and average conﬁdence interval (CI) width. The average conﬁdence in-
terval width should be compared to the predicted CI width as calculated by Equation
6.2.
Unlike the proposed ADR surveillance guidance, we do not incorporate adjustments for
laboratory failure, the proportion of patients on ﬁrst-line regimens, documented transfer,
and disproportionate weighting as these are not features of the simulation. Details of how
to accommodate these design features is described elsewhere (see Chapter 4). Brieﬂy, the
design effect is multiplied by an inﬂation factor to account for disproportionate weight-
ing, and the sample size is inﬂated by dividing by the expected proportion of eligible
patients (eg. divide by 0.90 if 10% laboratory failure is expected).
1056.5.2 Large country
We simulate a large country, with N = 2000 sites and an average of approximately 200
eligible records per site. This hypothetical country is intended to be similar to large coun-
tries in Sub-Saharan Africa with generalized epidemics. The site sizes are sampled from a
truncated gamma distribution scaled to have mean 200; simulated sizes ranged from ap-
proximately 40 to 1000 patients per site. The proposed design requires sampling n = 20
sites, m = 12 observed patients for VLS assessment, and s = 21 patient records for reten-
tion assessment. The predicted CI width by Equation 6.2 is 5.87%.
To challenge the assumptions of the derivations, data are simulated in a variety of ways.
(1) Site size (Si), site-speciﬁc observed VLS (pV LS;i), and site-speciﬁc retention (pRET;i)
are mutually independent. (2) pRET;i is independent of pV LS;i and Si, but Si and pV LS;i
are sorted so they have perfect positive rank correlation; this corresponds to larger sites
having better VLS among retained patients. (3) Same as setting (2), except Si and pV LS;i
have perfect negative rank correlation; this corresponds to smaller sites having better VLS
among retained patients. (4) pV LS;i is independent of pRET;i and Si, but Si and pRET;i are
sorted so they have perfect positive rank correlation; this corresponds to larger sites hav-
ing better patient retention. (5) Same as setting (4), except Si and pRET;i have perfect neg-
ative rank correlation; this corresponds to smaller sites having better retention. (6) Si is
independent of pV LS;i and pRET;i, but pV LS;i and pRET;i are sorted so they have perfect pos-
itive rank correlation; this corresponds to sites with higher VLS having higher retention.
(7) Same as setting (6), except pV LS;i and pRET;i have perfect negative rank correlation; this
corresponds to sites with higher VLS having lower retention.
The estimator has little to no bias in the settings we investigate. The estimated standard
error using the variance estimator in Section 6.3.4 is close to the simulated standard error
in all settings, but it tends to be a slight underestimate. The average CI width is roughly
similar to the predicted CI width in all settings. The average CI width is especially large
in two settings; these settings are when site size is negatively correlated with retention
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Truth Estimated Simulation SE Estimated SE Average CI Width
pADJ b pADJ V ar(b pADJ) d var(b pADJ) Predicted 5.87%
(1) (Si ? pV LS;i ? pRET;i) 0.716 0.716 0.0282 0.0281 5.89%
(2) (+Si;+pV LS;i) 0.727 0.727 0.0284 0.0280 5.86%
(3) (+Si; pV LS;i) 0.704 0.704 0.0291 0.0286 5.98%
(4) (+Si;+pRET;i) 0.754 0.754 0.0270 0.0266 5.56%
(5) (+Si; pRET;i) 0.673 0.673 0.0300 0.0295 6.18%
(6) (+pV LS;i;+pRET;i) 0.716 0.716 0.0308 0.0301 6.30%
(7) (+pV LS;i; pRET;i) 0.716 0.716 0.0269 0.0262 5.47%
(Setting 5) and when observed VLS and retention are positively correlated (Setting 6).
The average CI width is especially low in two settings; these settings are when site size
is positively correlated with retention (Setting 4) and when observed VLS and retention
are negatively correlated (Setting 7). When retention is independent of both site size and
observed VLS (Settings 1, 2, and 3), the predicted CI width performs well.
6.5.3 Small country
We simulate a small country, with N = 50 sites and an average of approximately 20 eligi-
ble records per site. This hypothetical country is intended to be similar to small countries
in Latin America with concentrated epidemics. The site sizes are sampled from a trun-
cated gamma distribution scaled to have mean 20; simulated sizes range from approx-
imately 4 to 90 patients per site. The proposed design requires sampling n = 20 sites,
m = 8 observed patients for VLS assessment, and s = 9 patient records for retention as-
sessment. (Note that small sites will under-enroll patients.) The predicted CI width by
Equation 6.2 is 6.01%.
We observe a slight bias in the mean point estimate, with the maximal bias being 2.0%
(Setting 5). For all settings, the estimated standard error using the variance estimator in
Section 6.3.4 is close to the simulated standard error, but it tends to underestimate the
107Table 6.2: Small country simulation result
Truth Estimated Simulation SE Estimated SE Average CI Width
pADJ b pADJ V ar(b pADJ) d var(b pADJ) Predicted 6.01%
(1) (Si ? pV LS;i ? pRET;i) 0.700 0.701 0.0281 0.0279 5.84%
(2) (+Si;+pV LS;i) 0.720 0.720 0.0278 0.0276 5.79%
(3) (+Si; pV LS;i) 0.697 0.703 0.0283 0.0281 5.89%
(4) (+Si;+pRET;i) 0.750 0.742 0.0257 0.0254 5.33%
(5) (+Si; pRET;i) 0.659 0.679 0.0281 0.0284 5.94%
(6) (+pV LS;i;+pRET;i) 0.712 0.710 0.0286 0.0282 5.91%
(7) (+pV LS;i; pRET;i) 0.714 0.713 0.0262 0.0258 5.41%
standard error slightly more than in the large country setting. The average CI width is
below the predicted width of 6.01% in all settings. The mean conﬁdence intervals have
similartrendsinrelativewidthasdescribedforthehypotheticallargecountry(i.e., widest
for Settings (5) and (6), narrowest for Settings (4) and (7), and moderate for Settings (1),
(2), and (3).
6.6 Discussion
The measurement of VLS among HIV-infected patients retained on ART for 123 months
using a cross-sectional study has severe epidemiological limitations. It excludes patients
who have died or been lost to follow-up since ART initiation. Thus, because of the con-
founding, it is not meaningful to compare measures of observed VLS over time or across
regions if mortality or retention rates have changed. We describe the importance of col-
lectingdataonretentionandincorporatingitintothecalculationofwhatisakeyindicator
of national HIV program performance. We describe an approach for developing a more
epidemiologically meaningful measure of VLS in HIV-infected patients. In this approach,
representative data on retention is combined with representative data on observed VLS.
For patients who die or are lost to follow-up, we assume that they are not virologically
suppressed. WerefertothismeasureasadjustedVLS,althoughitisakintoalower-bound
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We develop formulae that can be used to approximate the variance of adjusted VLS under
a set of simplifying assumptions (Section 6.4). These formulae assume PPS sampling, and
they should be supplemented by an additional design effect factor to account for the
expected disproportionate weighting due to imperfect prior information on site size (see
Chapter 4, suggests multiplying by 1.50). These formulae can assist program managers
when they are determining the necessary sample sizes for the VLS and retention portions
of the ADR survey.
In Section 6.5, we describe our simulation study, assessing this outcome in a hypothetical
large and a hypothetical small country under a variety of different assumptions. In small
countries, the point estimate can have slight bias. This is not surprising as the point
estimate is calculated as a ratio estimate, which is known to be slightly biased but is
used because of its lower mean square error (Lohr, 2010, sect. 4.1.2). The standard error
estimator tends to slightly underestimate the variability, but it seems to work well in
all of the different simulated settings, regardless of country size and of the correlation
between site size, prevalence of observed VLS, and retention. The predicted conﬁdence
interval width is similar to the observed conﬁdence interval width even when some of
the assumptions are severely violated.
We can identify a few limitations to this method. It makes the strong assumption that all
patients who are not retained on therapy are not virologically suppressed. In the absence
of data on missing patients, this is likely the most reasonable assumption available. Data
from a study in urban Malawi reported, among lost patients, 30% had died (Tweya et al.,
2013). Among those who were still alive, 44% had stopped taking ART entirely. Thus,
for these segments of the population, assuming that these patients are not virologically
suppressed (with death deﬁned as a virological failure) seems reasonable. On the other
hand, for the remaining 56% of living patients who reported still taking ART by sourcing
drugs from other sites, using alternative ART sources, or making brief ART interruptions,
109the assumption that none of these patients are suppressed may be overly pessimistic. This
highlights the limitation that the proposed method is unable to detect undocumented,
or ‘silent,’ transfers out of the site. This limitation stems from the larger challenge of
properly estimating retention in resource-limited settings, and it is also a limitation of
the previously used longitudinal survey. Thus, while it affects the interpretation of this
measure, it is not a failure of the method itself. An additional limitation is the increased
complexity of the analysis formulae and the approximation formulae, although these can
be readily coded into any statistical software package or spreadsheet-based program.
Overall, we believe that this adjusted VLS measure has increased epidemiological util-
ity over the observed, on-site VLS measure, and, in fact, it is very similar to the HIV
drug resistance prevention measure previously described for the longitudinal acquired
drug resistance protocol. To achieve a VLS measure with improved utility, we highlight
the importance of collecting representative data on retention for the interpretation of ac-
quired drug resistance outcomes in patients on therapy for a ﬁxed amount of time. The
beneﬁt of the adjusted VLS measure is that it ﬁts into the existing design-based survey
analysis framework, requiring only small modiﬁcations to the variance estimator. This
measure can be calculated from survey data collected on observed VLS and retention at
no additional cost. Because it can be compared within countries over time, across coun-
tries, and to a global standard, it is an important and useful addition to the acquired HIV
drug resistance surveillance guidance.
1107. Evaluating conﬁdence interval methods for binomial
proportions in clustered surveys
Natalie Exner and Marcello PaganoAbstract
In survey settings, a variety of methods for constructing conﬁdence intervals for propor-
tions are available; these methods include the standard Wald method, a class of modi-
ﬁed methods that replace the sample size with the survey effective sample size (Wilson,
Clopper-Pearson, Jeffreys, and Agresti-Coull), and transformed methods (Logit and Arc-
sine). We describe these seven methods, two of which have not been previously evalu-
ated in the literature (the modiﬁed Jeffreys and Agresti-Coull intervals). For each method,
we describe a formulation that does and does not adjust for the design degrees of free-
dom. We suggest a deﬁnition of adjusted effective sample size that induces equivalency
between different conﬁdence interval expressions. We also expand on an existing frame-
work for truncation that can be used when data appears to be more efﬁcient than a simple
random sample or when data has zero standard error and/or a point estimate of 0 or 1.
We compare these methods using a simulation study modeled after the 30x7 design for
immunization surveys. Our results conﬁrmed the importance of adjusting for the design
degrees of freedom. As expected, the Wald interval performed very poorly, frequently
failing to achieve the nominal coverage level. For similar reasons, we do not recom-
mend the use of the Arcsine interval. When the intracluster correlation coefﬁcient is high
and the prevalence p < 10% or > 90%, the Agresti-Coull and Clopper-Pearson intervals
perform best. In other settings, the Clopper-Pearson interval is unnecessarily wide. In
general, the Logit, Wilson, Jeffreys and Agresti-Coull intervals perform well, though the
Logit interval can be too wide. The Wilson interval performed best when a non-unimodal
distribution was assumed for the simulations.
7.1 Introduction
A very important and useful inferential tool is the conﬁdence interval. If the outcome
of interest is discrete, a complication arises when one attempts to calculate an exact pre-
112determined level of conﬁdence (see Brown, Cai, and DasGupta, 2001, for an overview).
When dealing with surveys, the data analysis must adjust for any clustering, stratiﬁca-
tion, or weighting used in the design. The standard and popular 95% conﬁdence interval
for a proportion in a survey setting is a Wald-based interval. In the independent and
identically distributed (IID) setting, it has been extensively demonstrated that the Wald
interval performs poorly for proportions, especially when the proportion is close to 0 or
1 and/or the sample size is small (Agresti and Coull, 1998; Brown et al., 2001). Coverage
can be below the nominal 95% level. Also, the Wald interval can have limits below 0 or
above 1, which is inappropriate for a proportion.
In the IID setting, other conﬁdence interval methods for proportions exhibit more desir-
able qualities. Intervals constructed using the Wilson (quadratic), Jeffreys (beta binomial)
or Clopper-Pearson (binomial) methods cannot have limits outside of the 0 to 1 range.
Also, these intervals, along with the Agresti-Coull interval (modiﬁed Wald), tend to have
coverage closer to the nominal 95% level, though the Clopper-Pearson interval can be un-
necessarily conservative. The general conclusion is that the Wilson and Jeffreys intervals
provide the best balance of conﬁdence interval width and coverage, with the Agresti-
Coull interval also performing well when the sample size is sufﬁciently large (Brown
et al., 2001).
It is reasonable to infer that the Wald interval would also perform poorly in the complex
survey setting when the expected proportion is close to 0 or 1 and/or the sample size is
small, and this has been demonstrated in a few simulation studies (Korn and Graubard,
1998; Sukasih and Jang, 2005; Feng and Sitter, 2008). A variety of alternative methods for
conﬁdence interval construction for proportions have been described, including modiﬁ-
cations of standard methods replacing the sample size with the survey effective sample
size or transforming the proportion to a different scale. Literature on the topic is largely
limited to conference proceedings (Kott et al., 2001; Curtin et al., 2006; Rust and Hsu, 2007;
Feng and Sitter, 2008) and a publicly available masters thesis (Feng, 2006), with very few
reports appearing in peer-reviewed journals (Kott and Carr, 1997; Korn and Graubard,
1131998; Gray et al., 2004, being notable exceptions). We intend to remedy this situation
in this paper where we assess a number of methods, including some that have not been
previously applied either in simulation studies or in practice.
In addition, we discuss the existing framework for adjusting these intervals for the sur-
vey design degrees of freedom. The design degrees of freedom, denoted dfdesign, is tra-
ditionally equal to the number of primary sampling units minus the number of strata
(Korn and Graubard, 1999, p. 62). While there is no formal theoretical justiﬁcation for the
design degrees of freedom, empirical evidence from the Wald interval suggests that ac-
counting for this design feature can improve the performance of the conﬁdence interval
(Korn and Graubard, 1998). For each interval method in this paper, we describe alter-
native formulations with and without a degrees of freedom adjustment. We describe a
novel method for incorporating the design degrees of freedom into the effective sample
size that induces equivalency between different expressions. We also provide an in-depth
discussion of truncation, a procedure by which data expected to be no more efﬁcient than
a simple random sample is truncated so that the design effect is equal to 1. We describe
our recommendations for handling truncation and the related concept of ‘degenerate data
to improve logical consistency in the framework.
The goal of this paper is to summarize the methods available for conﬁdence interval con-
struction for proportions in complex surveys, study approaches for incorporating the de-
sign degrees of freedom into interval construction, describe a logically consistent frame-
work for data truncation, evaluate the methods using a simulation study based on the
popular 30x7 survey design, and provide practical guidance based on the performance of
the intervals. In Section 7.2, we describe the conﬁdence interval methods considered. In
Section 7.3, we discuss our framework for truncation and handling ‘degenerate’ data. In
Section 7.4, we describe our simulation study and the results. In Section 7.5, we discuss
our conclusions.
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7.2.1 Method categories
We divide the conﬁdence interval methods we evaluate into three categories. The ﬁrst
category includes only the Wald method. The second category is a class of modiﬁed
methods, in which the sample size is replaced by the survey effective sample size; the
surveyeffectivesizeisrelatedtothedesigneffect, whichquantiﬁesthedeparturefromthe
ideal of a simple random sample; this category includes the modiﬁed Wilson, Clopper-
Pearson, Jeffreys, and Agresti-Coull intervals. The third category considers methods in
which the interval is constructed on a different scale, using a Wald-type method, and then
the endpoints are back-transformed to yield the ﬁnal interval; this category includes the
Logit and Arcsine transformations. All intervals described can be calculated from basic
elements produced by typical statistical output, including the appropriately weighted
point estimate, b p, and the estimated standard error, c SE(b p).
7.2.2 Design degrees of freedom
For each method, we describe two alternative formulations: one that does and one that
does not adjust for the design degrees of freedom. Adjustments for the design degrees
of freedom can be made by replacing the standard normal quantile with a t-distribution
quantile with dfdesign degrees of freedom. Alternatively, the effective sample size can be
replaced by the degrees-of-freedom adjusted effective sample size, described below.
A key element for modifying IID conﬁdence interval methods for the survey setting is cal-
culating the survey effective sample size. The effective sample size is the sample size of a
simple random sample that would yield the same precision as the survey under consid-
eration. The effective sample size reﬂects the either gain or loss of precision attributable
115to the survey design. The effective sample size is:
neff =
b p(1   b p)
[ c SE(b p)]2
(7.1)
Korn and Graubard (1998) suggest the use of the degrees-of-freedom adjusted effective
sample size (henceforth referred to as simply the adjusted effective sample size). The ad-
justed effective sample size is equal to the effective sample size multiplied by a deﬂation
factor that reﬂects the difference between the actual sample size, nact, and the design de-
grees of freedom. When constructing a two-sided conﬁdence interval of level 1   , the
adjusted effective sample size suggested by Korn and Graubard (1998) is:
n

eff;KG = neff

tnact(1   =2)
tdfdesign(1   =2)
2
where tdf(p) indicates the pth quantile of the t distribution with df degrees of freedom,
and neff is deﬁned as in Equation 7.1. Heuristically we argue that for ﬁnite samples
the distribution of the estimator, although asymptotically normal, may be better approx-
imated by a t distribution. We recommend using a slightly different formula for the ad-
justed degrees of freedom:
n

eff = neff

z(1   =2)
tdfdesign(1   =2)
2
where z(p) indicates the pth quantile of the standard normal distribution. The motivation
for using this formula will be described in greater detail later.
7.2.3 Standard method
The ﬁrst method described is the standard Wald-type interval, also called the normal ap-
proximation or linear method. This method, which is based on the normal approximation
to the binomial distribution, produces a conﬁdence interval that is symmetric around the
116point estimate, and it can produce intervals with endpoints below 0 or above 1. For a
95% conﬁdence interval, with b p equal to the appropriately weighted point estimate, and
c SE(b p) equal to the estimated standard error, the conﬁdence interval is calculated as:
^ p  z(1   =2) c SE(b p) (7.2)
We can show that the above interval is equivalent to:
b p  z(1   =2)
q
b p(1   b p)=neff (7.3)
This representation in expression 7.3 resembles the IID Wald method with the sample
size replaced by the effective sample size. We refer to either of these conﬁdence interval
methods as the Wald method.
To adjust for the design degrees of freedom, one can replace z(1   =2) in expression 7.2
with tdfdesign(1   =2). Alternatively, one can replace neff in expression 7.3 with neff.
These intervals can be shown to be equivalent. We refer to either of these conﬁdence
interval methods as the Wald, adj. method. Note that these intervals are not equivalent
if the Korn and Graubard adjusted effective sample size (n
eff;KG) is used instead. Thus,
our proposed version of the adjusted effective sample size induces consistency between
the expressions.
7.2.4 Wilson method
The ﬁrst modiﬁed method we describe is the modiﬁed (or ad hoc) Wilson, suggested by
Kott and Carr (1997). For the IID setting, the Wilson interval, also known as the score
or quadratic interval, is constructed by solving the following quadratic function (Wilson,
1927):
jb p   pj
2  z(1   =2)
2 [p(1   p)=n]
117This is equivalent to utilizing the asymptotic distribution of b p to set the interval. To mod-
ify the interval for the survey setting, we can replace the sample size n by the effective
sample size neff to produce the following formula for the upper and lower bounds of the
interval:
b p +
z(1 =2)2
2neff  z(1   =2)
r
b p(1 b p)
neff +
z(1 =2)2
(2neff)
2
1 +
z(1 =2)2
neff
(7.4)
We refer to this method as the Wilson method.
To adjust for the design degrees of freedom, Kott and Carr (1997) suggest replacing
z(1   =2) in expression 7.4 with tdfdesign(1   =2). Alternatively, one can replace neff
in expression 7.4 with n
eff. These intervals can be shown to be equivalent. We refer to
either of these conﬁdence interval methods as the Wilson, adj. method. As before, these
adjusted intervals are not equivalent if the Korn and Graubard formulation of the ad-
justed effective sample size (n
eff;KG) is used.
7.2.5 Clopper-Pearson method
The second modiﬁed method adapts the traditional Clopper-Pearson interval, also called
the binomial or exact interval. The Clopper-Pearson interval uses the binomial distri-
bution, and in the IID setting, the coverage of the Clopper-Pearson interval is always at
or above the nominal conﬁdence level (Clopper and Pearson, 1934). The limits of the
Clopper-Pearson interval can be calculated using the quantiles of an F or beta distribu-
tion. Using the notation of Korn and Graubard (1998), the lower and upper limits in the
IID setting are deﬁned as:
118pL =
1F1;2(=2)
2 + 1F1;2(=2)
pU =
3F3;4(1   =2)
4 + 3F3;4(1   =2)
where 1 = 2x, 2 = 2(n   x + 1), 3 = 2(x + 1), and 4 = 2(n   x), n is the sample size, x
is the observed number of successes, and Fnum;den(p) is the pth quantile of an F distribu-
tion with num and den degrees of freedom. To construct the modiﬁed Clopper-Pearson
interval, the sample size n is replaced by the adjusted effective sample size n
eff, and the
observed number of successes is replaced by b pn
eff. The adjusted effective sample size
is used because the Clopper-Pearson interval does not otherwise account for the design
degrees of freedom. We refer to this method as the CP, adj. method.
To maintain consistency with the rest of the paper, we also evaluate an unadjusted
method, though no such method appears in the literature. For the unadjusted method,
the sample size is replaced by the effective sample size neff, and the observed number of
successes is replaced by b pn
eff. We refer to this method as the CP method.
7.2.6 Jeffreys method
The next modiﬁed method is the Jeffreys interval, which is constructed from a non-
informative Beta(0:5;0:5) prior for binomially distributed data (Brown et al., 2001). In
the IID setting, the Jeffreys interval can be regarded as a mid-p version of the Clopper-
Pearson interval, and its bounds are always contained within the bounds of the Clopper-
Pearson interval, making it less conservative than the Clopper-Pearson (Brown et al.,
2001). In the IID setting, the lower and upper limits are deﬁned as:
pL =Beta1;1(=2)
pU =Beta1;1(1   =2)
119where 1 = x + 0:5, 1 = n   x + 0:5, and Betashape1;shape2(p) is the pth quantile of a Beta
distribution with shape1 and shape2 degrees of freedom. To modify the Jeffreys interval,
the sample size n is replaced by the adjusted effective sample size neff, and the observed
number of successes x is replaced by b pn
eff. This modiﬁcation was ﬁrst suggested in the
appendix of a paper (Gray et al., 2004). We refer to this as the Jeffreys method.
Alternatively, the sample size can be replaced by the adjusted effective sample size be-
cause the design degrees of freedom are not incorporated otherwise (Curtin et al., 2006).
In other words, the sample size n is replaced by the adjusted effective sample size n
eff,
and the observed number of successes is replaced by b pn
eff. We refer to this method as the
Jeffreys, adj. method. To our knowledge, neither the modiﬁed Jeffreys nor the adjusted
modiﬁed Jeffreys intervals for surveys have been applied in simulations or in practice.
7.2.7 Agresti-Coull method
The Agresti-Coull method was developed to have the simplicity of the Wald interval but
with performance more like the Wilson interval (Agresti and Coull, 1998). In their paper,
the authors demonstrate that the midpoint for a Wilson interval is a weighted average of
the observed prevalence and 1/2. To modify the Wald interval to more closely resemble
the Wilson interval, a constant is added to the number of successes and two times that
constant is added to the number of trials. To construct the interval in the IID setting, the
bounds are as follows:
~ p  z(1   =2)
p
~ p(1   ~ p)=~ n
where ~ x = x + c, ~ n = n + 2c, and ~ p = ~ x=~ n. For a 95% conﬁdence interval, the authors
suggest letting c = 1:962=2 = 1:92, but they propose that setting c = 2 may be easier to
understand by non-statisticians because it is akin to adding two successes and two fail-
ures to the data. In this paper, we use the former, more theoretically-motivated deﬁnition
120in which c = 1:92. Note that the Agresti-Coull interval can have bounds that are below 0
or above 1.
Similar to the other modiﬁcations, the Agresti-Coull interval can be adapted to the survey
setting by letting ~ x = b pneff + c, ~ n = neff + 2c. We refer to this as the AC method.
Though this modiﬁcation has been suggested previously (Curtin et al., 2006), it has not
been applied in practice or evaluated in a simulation study, to the best of our knowledge.
The Agresti-Coull method can be further modiﬁed to adjust for the design degrees of
freedom by letting ~ x = b pn
eff + c and ~ n = n
eff + 2c. We refer to this as the AC, adj.
method. Note that this is not equivalent to constructing the interval using a t-quantile,
tdfdesign(1   =2), in place of the Z-quantile, z(1   =2). The two methods will only be
equivalent if we use the Z-quantile and let ~ x = b pn
eff + c and ~ n = n
eff + 2c, where
c = c
n
z(1 =2)
tdfdesign(1 =2)
o2
. We do not suggest using this revised constant c in order to gain
this equivalency.
7.2.8 Logit method
The third class of methods consists of transformed methods, in which variance-stabilizing
transformations, commonly used for binary data, are applied to construct the conﬁdence
interval. The point estimate is transformed to the new scale, and a Wald-type interval
is constructed around the transformed point estimate, with the delta method being used
to determine the transformed variance. The logit-transformed conﬁdence interval can be
constructed in the following way (Rust and Rao, 1996):
log

b p
1   b p

 z(1   =2)
c SE(b p)
b p(1   b p)
(7.5)
The above limits are on the log odds/logit scale, and one must apply the function
exp()=[1 + exp()] to convert them to the standard risk scale. The limits on the logit scale
121can be re-expressed using the following equivalent formulation:
log

b p
1   b p

 z(1   =2)[neffb p(1   b p)]
 1=2 (7.6)
We refer to this as the Logit method.
To adjust for the design degrees of freedom, z(1   =2) in expression 7.5 can be replaced
with tdfdesign(1 =2). Alternatively, one can replace neff in expression 7.6 with n
eff. These
intervals can be shown to be equivalent. We refer to either of these conﬁdence interval
methods as the Logit, adj. method. As before, these adjusted intervals are not equivalent
if the Korn and Graubard formulation of the adjusted effective sample size (n
eff;KG) is
used.
7.2.9 Arcsine method
The arcsine-transformed conﬁdence interval (Hogg and Craig, 1995) can be constructed
in the following way:
p
b p  z(1   =2)
1
2pneff
(7.7)
The above limits are on the arcsine scale, and one must apply the function [sin()]2 to
convert them to the standard risk scale. We refer to this as the Arcsine method.
To adjust for the design degrees of freedom, z(1   =2) in expression 7.7 can be replaced
with tdfdesign(1 =2). Alternatively, one can replace neff in expression 7.7 with n
eff. It can
be shown that these approaches produce the same conﬁdence interval limits. Again, the
expressions conﬁdence limits are not equivalent if the Korn and Graubard formulation of
the adjusted effective sample size (n
eff;KG) is used.
1227.3 Truncation and degenerate intervals
7.3.1 Truncation
In settings where it is expected that the survey will only increase the standard error rel-
ative to a simple random sample (design effect ¿ 1), such as clustered surveys, Korn and
Graubard (1998) recommend using a procedure called truncation. If the observed effec-
tive sample size is greater than the actual sample size, they recommend setting neff (or
n
eff;KG) equal to nact. In other words, the observed design effect is less than 1, so we set
the design effect equal to 1. Since this is equivalent to treating the data as if it resulted
from a simple random sample, the logical next step would be to apply the standard IID
conﬁdence interval methods to the data, adjusting for weighting as necessary. In reality,
for many formulations of the conﬁdence intervals, after truncation, we are not left with
the standard intervals. In this section we discuss these inconsistencies and recommend
a revised framework to increase logical consistency. For all methods described that do
not adjust for the design degrees of freedom, truncating the effective sample size neff at
the actual sample size yields the equivalent IID conﬁdence interval. For methods directly
using the estimated standard error in the calculations (Wald and Logit), truncation can
be achieved by checking if the estimated survey standard error is less than the simple
random sample standard error, i.e., check if c SE(b p) <
p
b p(1   b p=nact; if so, the estimated
simple random sample standard error should be used for all calculations. Alternatively,
since we present the Wald and Logit intervals with equivalent formulations using the
effective sample size, neff can be truncated as described above.
For the methods described that do adjust for the design degrees of freedom, the truncated
intervals do not always readily reduce to the standard IID interval. Consider the adjusted
Wilson (Wilson, adj.) method. We have two equivalent formulations for this method, one
using a t-quantile with the effective sample size, and the other using a Z-quantile with the
adjusted effective sample size. Following the instructions of Korn and Graubard (1998),
123wecouldeitherusetheformulationwiththeeffectivesamplesizeandtruncateneff, orwe
could use the formulation with the adjusted effective sample size and truncate n
eff. These
two approaches lead to different intervals. For example, let neff = 60, nact = 30, b p = 0:10,
and dfdesign = 10, thus the observed DEFF = 0:5. The resulting conﬁdence intervals
are described in Table 7.1. As noted previously, the two intervals are equivalent in the
absence of truncation. For this example, the comparable IID interval is (0.035, 0.256). We
see that truncating the adjusted Wilson interval with the t-quantile leads to a conﬁdence
interval that is wider than the IID interval, while truncating n
eff returns the standard IID
interval.
Table 7.1: Results of Truncation Example
Adjusted Intervals Not Truncated Truncated
Wilson, adj. t-quantile & neff tdf = 2:23, neff = 60 tdf = 2:23, neff = 30
CI = (0.042, 0.219) CI = (0.030, 0.283)
Wilson, adj. Z-quantile & n
eff Z = 1:96, n
eff = 46:4 Z = 1:96, n
eff = 30
CI = (0.042, 0.219) CI = (0.035, 0.256)
The same phenomenon occurs with all other adjusted intervals that have two equivalent
forms, one with a t-quantile and the effective sample size, and the other with a Z-quantile
and the adjusted effective sample size. For this reason, when applying truncation to an
adjusted interval, we argue that only the adjusted effective sample size n
eff should be
truncatedbecausetruncatingtheunadjustedeffectivesamplesizeneff leadstoconﬁdence
intervals wider than the equivalent IID intervals.
7.3.2 Degenerate intervals
We now discuss the behavior of each conﬁdence interval method in the settings that can
yield degenerate intervals. A degenerate interval is a conﬁdence interval with zero width;
this can occur when b p = 0 or b p = 1, or this can also occur when c SE(b p) = 0, which happens
124if, for example, all sampled clusters in one-stage cluster sampling have the same observed
prevalence of the outcome.
In settings with degenerate data, Korn and Graubard (1998) suggest that either the effec-
tive sample size, neff, or the adjusted effective sample size, n
eff;KG, should be set equal
to nact. To align this with our discussion of truncation, because the estimated variance is
0, the survey effective sample size is inﬁnitely large, and thus a reasonable approach is to
truncate it at the actual sample size. For the class of unadjusted methods, we recommend
truncating the effective sample size. For the class of adjusted methods, we recommend
truncating the adjusted effective sample size, n
eff. Consistent with the previous section
on truncation, if the effective sample size, neff, is truncated in the adjusted formulations,
we will return intervals wider than the comparable IID intervals.
Brieﬂy we discuss the behavior of each conﬁdence interval method in these degener-
ate data settings as it is important for evaluating their relative merits. We discuss only
the adjusted methods because the key results are the same. We start with the setting of
c SE(b p) = 0but b pisstrictlybetween0and1. Inthiscase, allmethodsaretractable, butsome
lead to degenerate conﬁdence intervals. In practice, we would prefer a non-degenerate
interval that reﬂects the sample size through the conﬁdence interval width. The modi-
ﬁed Wilson, Clopper-Pearson, Jeffreys, Agresti-Coull, and Arcsine methods do not lead
to degenerate conﬁdence intervals in this setting as long as the adjusted effective sample
size is truncated at the actual sample size. The Wald and Logit methods lead to degen-
erate intervals when the standard error is zero. In this setting, we recommend using the
alternative formulations for the Wald and Logit methods expressed as functions of the
adjusted effective sample size; then, the adjusted effective sample size can be truncated
at the actual sample size to yield non-degenerate intervals.
When the estimated proportion is equal to 0 or 1, some of the methods lead to degener-
ate conﬁdence intervals, and one of the methods is not tractable. The modiﬁed Wilson,
Clopper-Pearson, Jeffreys, and Agresti-Coull methods do not lead to degenerate conﬁ-
125dence intervals in this setting as long as the adjusted effective sample size is truncated
at the actual sample size. The Wald method will always lead to a degenerate conﬁdence
interval, even if the adjusted effective sample size is used and properly truncated. Simi-
larly, the Arcsine interval always produces a degenerate conﬁdence interval; interestingly,
this degenerate interval will be located slightly above 0 (or slightly below 1). The Logit
method is not tractable when the estimated prevalence is equal to 0 or 1 because of the
b p(1   b p) term in the denominator of the conﬁdence interval arm. Korn and Graubard
(1998) suggest substituting the truncated Clopper-Pearson interval (observed b p and nact)
for the Logit. In theory, any of the non-degenerate conﬁdence interval methods could be
substituted here, or an alternative method for degenerate data such as that suggested by
Louis (1981) could be used.
Overall, we prefer a method that never results in a degenerate interval, which can be
achieved for many of the intervals if the adjusted effective sample size is properly trun-
cated. We provide a suggested framework for truncation in these degenerate data set-
tings.
7.4 Simulations
7.4.1 Set-up
To assess the performance of the conﬁdence interval methods, we performed a simple
simulation study modeled after the popular 30 by 7 design used by the Expanded Pro-
gramme on Immunization to estimate immunization coverage (Henderson and Sundare-
san, 1982); in this design, 30 clusters are sampled with probability proportional to size
and 7 children are selected within each cluster.
For our simulations, we generated 1000 primary sampling units (PSUs) with sizes drawn
from a gamma distribution with shape parameter equal to 2, and scale parameter equal
to 100 (mean size 200). We simulated the outcomes using a beta-binomial distribution, for
126which PSUi has prevalence pi drawn from a Beta(;) distribution, and each of the sec-
ondary sampling units (SSUs) in that PSU are drawn from a Bernoulli distribution with
success probability pi. To simulate data with a particular overall prevalence p and intr-
acluster correlation ICC, we determined that the parameters from the Beta distribution
must equal the following (Ridout et al., 1999):
 =

1   ICC
ICC

p
 =

1   ICC
ICC

(1   p)
We consideredprevalence values p = 0:01;0:02;;0:99, andintracluster correlations ICC =
0:005;0:010;0:050;0:100, and 0:150, with the last resulting in a design effect of 1:9. To sim-
ulate two stage cluster sampling, we randomly sampled n = 30 PSUs using probability
proportional to size (PPS) sampling with replacement; then, we randomly sampled m = 7
SSUsfromeachselectedPSUusingsimplerandomsamplingwithoutreplacement. 10,000
simulations were run for all combinations of n, m, p, and ICC.
For each simulated cluster sample, we calculated the estimated prevalence, b p, which is
the mean of the observed data since the data is self-weighting (Lemeshow and Robinson,
1985, eq. 1). We also estimated the variance using a standard estimator for unequal prob-
ability with-replacement two-stage sampling, simpliﬁed for the PPS setting (Lemeshow
and Robinson, 1985, eq. 3) (Lohr, 2010, eq. 6.15):
d var(b p) =
1
n(n   1)
n X
i=1
(b pi   b p)
2
where b pi is the observed prevalence in the ith selected PSU. Then, for each sample, we
calculated each of the conﬁdence intervals described above: (1) Wald, (2) Wald, adj., (3)
Wilson, (4) Wilson, adj., (5) CP, (6) CP, adj., (7) Jeffreys, (8) Jeffreys, adj., (9) AC, (10)
AC, adj., (11) Logit, (12), Logit, adj., (13) Arcsine, and (14) Arcsine, adj. We summarized
127the results for each method by reporting the conﬁdence interval coverage, which is the
proportion of simulations for which the estimated conﬁdence interval contained the true
value p. We also calculated the average conﬁdence interval width.
7.4.2 Results
Simulation coverage results are shown in Figure 7.1 for p = 0:01 to 0:99, n = 30 PSUs,
m = 7 SSUs per PSU, and ICC = 0:15. We do not report results for the other ICC values
because the relative performance of the methods was consistent across the simulations.
In general, the methods perform the worst when the ICC is large, so we report the results
for the largest ICC considered.
7.4.3 Adjustment
From Figure 7.1, it is apparent that for all seven conﬁdence interval methods, the adjusted
version has superior coverage than the unadjusted version. With the exception of the ad-
justed Clopper-Pearson interval, all versions that are not adjusted for the design degrees
of freedom have coverage below the nominal 95% level, whereas the adjusted versions
have coverage near or above the 95% level. Thus, we only consider the adjusted methods
henceforth.
7.4.4 Conﬁdence interval coverage
When contrasting the individual methods, we see that the adjusted Wald interval cov-
erage tends to fall below the nominal level when p < 0:25 or > 0:75. Coverage drops
precipitously when p < 0:10 or > 0:90. The adjusted Wilson and Jeffreys intervals have
coverage very close to the nominal level, though the coverage drops for p close to 0 or
1. The adjusted Agresti-Coull and Logit intervals have relatively stable coverage close to
the nominal level. The adjusted Clopper-Pearson method is further above 95% than the
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Figure 7.1: Conﬁdence interval coverage probability versus true prevalence of outcome (0.01 to
0.99) for n = 30 PSUs, m = 7 SSUs per PSU, and ICC = 0:15. All methods are shown with
unadjusted and adjusted intervals. (a) Wald, (b) Wilson, (c) Clopper-Pearson, (d) Jeffreys, (e)
Agresti-Coull, (f) Logit, (g) Arcsine.
129other methods. The adjusted Arcsine method performs well for moderate p, but coverage
drops precipitously as p approaches 0 or 1.
7.4.5 Conﬁdence interval width
To simultaneously assess conﬁdence interval width and coverage, we plot average cov-
erage versus average width in Figure 7.2 for each of the seven adjusted methods. The
behavior of the methods changes as a function of the prevalence, so we show separate
plots for prevalence values averaged over the ranges 1% to 10% in Figure 7.2(a), 10% to
25% in Figure 7.2(b), and 25% to 50% in Figure 7.2(c). The most desirable methods lie
closest to the upper left-hand corner (narrowest width with the highest coverage).
For p between 1% and 10% in Figure 7.2(a), the Arcsine and Wald methods have the poor-
estcoverage. Thisislikely attributabletohow theseintervalshandledegenerate data. De-
generate data produces degenerate intervals for both the Wald and Arcsine intervals. The
Logit, Jeffreys, and Wilson intervals all have coverage slightly below 95%. The Agresti-
Coull and Clopper-Pearson intervals are the only intervals with coverage above 95%, but
they are also the widest intervals.
For p between 10% and 25% in Figure 7.2(b), the Wald and Arcsine intervals again fail
to achieve the nominal coverage level. The Jeffreys interval has coverage barely below
the nominal coverage level, and it is the narrowest interval on average. The Wilson in-
terval performs very well with the narrowest width among the methods achieving the
average coverage level. The Agresti-Coull and Logit intervals are slightly wider with
slightly higher coverage. The Clopper-Pearson interval is quite a bit wider than the other
intervals.
For p between 25% and 50% in Figure 7.2(c), the performances of the intervals are similar
to each other (note the x-axis scale), though the Clopper-Pearson interval is quite wide.
The Wilson and Agresti-Coull intervals perform the best. The Logit, Jeffreys, and Arcsine
130l
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Figure 7.2: Average coverage vs. average width plot. n = 30, m = 7, ICC = 0:15
131intervals are all slightly wider. The Wald interval performs very poorly, having the lowest
coverage and still being wider than the majority of the intervals. The Clopper-Pearson
interval is signiﬁcantly wider than the other intervals.
7.4.6 Truncation
To assess the effect of truncation, we performed a set of simulations in which the adjusted
effective sample size was truncated if it exceeded the actual sample size. Because this is
most likely to occur when the ICC is small, we show results for ICC = 0:005. Figure
7.3 compares coverage for the adjusted Wilson with and without truncation. The effect of
truncation is a moderate increase in coverage because it increases the width of conﬁdence
intervals that are narrower the comparable IID conﬁdence interval.
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Figure 7.3: Conﬁdence interval coverage probability versus true prevalence of outcome (0.01 to
0.99) comparing adjusted Wilson with and without truncation for n = 30, m = 7, ICC = 0:005
1327.4.7 Non-unimodal simulation
The beta binomial prior is a rich family, but it is mostly a unimodal family, except for the
uniform member. To investigate a richer prior, we generated PSU means from a mixture
distribution of three betas. Each component beta distribution had an ICC of 0.005. The
means we used were 5%, 15%, and 45%, with weights 20%, 40% and 40% respectively,
resulting in an overall trimodal distribution. The overall mean was 25% with ICC = 0:15.
We summarize the results of 50,000 iterations in Figure 7.4 for n = 30 PSUs and m = 7
SSUs per PSU.
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Figure 7.4: Average coverage vs. average width plot for mixture distribution
In this scenario, the Wilson interval performs the best, being both the narrowest and with
high coverage. The Agresti-Coull, Logit, Jeffreys and Arcsine intervals also perform well,
although the Arcsine coverage is a bit lower and the Logit and Agresti-Coull intervals are
abitwiderthantheWilson. TheWaldintervalperformspoorly, havingbothlowcoverage
and high width. The Clopper-Pearson is much wider than the other intervals.
1337.5 Discussion
In this paper, we describe an extensive evaluation of seven methods for constructing con-
ﬁdence intervals for proportions using survey data. We classiﬁed the intervals into three
categories: (1) the Wald interval, (2) a class of modiﬁed methods, and (3) a class of trans-
formed methods. To the best of our knowledge, this paper contains the ﬁrst application
of the modiﬁed Jeffreys interval and the ﬁrst description of the modiﬁed Agresti-Coull
interval. All methods described require very few parameters to calculate just an esti-
mate of the prevalence, an estimate of the standard error, the design degrees of freedom
(if the interval will be adjusted), and the actual sample size (if the interval will be trun-
cated). Thus, these methods can be readily applied by researchers with limited statistical
expertise, an aspect which is highly relevant to people analyzing the types of surveys that
would emerge from a 30x7 cluster design.
For each method, we describe two formulations: one that does and one that does not ad-
just for the design degrees of freedom. For many of the intervals, we express the adjusted
version using either a t-quantile with the effective sample size or a Z-quantile with the
adjusted effective sample size. We note that these versions are only equivalent when our
proposed version of the adjusted effective sample size is used. From our simulation re-
sults, we conclude that it is necessary to adjust for the design degrees of freedom in order
to achieve nominal conﬁdence interval coverage levels.
Considering the seven adjusted intervals described and the simulation results, some clear
recommendations emerge. The Wald interval should be avoided entirely because it fre-
quently fails to achieve the nominal coverage level while still being wider than the other
intervals when 10% < p < 90%; in addition, it can produce degenerate intervals or inter-
vals with bounds beyond 0 or 1. Similarly, the Arcsine interval performs poorly across
all simulations, partially because it can produce degenerate conﬁdence intervals. For
25% < p < 50%, the Arcsine interval is also wider than many of the other intervals. Thus,
we do not recommend use of the Arcsine interval.
134Among the remaining intervals, when p < 10% or p > 90%, the Agresti-Coull and
Clopper-Pearson intervals perform the best, although it is worth noting that the other
intervals only narrowly fail to achieve the nominal coverage level. Though complete
simulation results are not shown, for less extreme ICC values, these other methods do
achieve 95% coverage. For all intermediate prevalence values and for the mixture distri-
bution example, the Logit, Wilson, Jeffreys, and Agresti-Coull intervals perform well. The
Wilson and Jeffreys intervals tend to be narrowest. The Logit interval tends to be wider
than the other intervals. The width and performance of the Agresti-Coull interval varies
across the different prevalence ranges.
We also expand upon an existing framework for truncation and the handling of ‘degener-
ate’ data described by Korn and Graubard with the goals of increasing logical consistency
and making clear practical recommendations. If truncation is to be used, we demonstrate
the importance of truncating the adjusted effective sample size, rather than the effective
sample size, so that intervals reduce to their standard IID equivalents. In addition, we
describe how each of the seven intervals performs when the standard error of the data
is equal to 0 and/or the point estimate of the data is equal to 0 or 1. In these scenarios,
we propose a framework in which the adjusted effective sample size is truncated at the
actual sample size, thereby avoiding degenerate intervals for many of the methods.
There are limitations to our work. Our simulations studies did not address many of
the other relevant factors in surveys, including stratiﬁcation, disproportionate weight-
ing, missing data, and so on. Furthermore, the simulations were constructed to resemble
the particular setting of the 30x7 survey, which does not generalize to all other settings.
Nonetheless, the results are consistent with the large body of literature describing meth-
ods for conﬁdence interval construction for proportions in the IID setting, so we believe
that the recommendations would not change signiﬁcantly if more extensive simulations
were performed.
Another limitation is that we do not apply all possible methods for conﬁdence interval
135construction. There are further adaptations of the Wilson interval described in the liter-
ature, including the use of a continuity correction (Korn and Graubard, 1999) or drop-
ping terms that are Op(n 3=2) (Kott et al., 2001). Preliminary evidence in our simulations
suggested that these intervals did not perform as well as the standard modiﬁed Wilson
interval. Other modiﬁcations of the Wilson interval include the Andersson-Nerman inter-
val and the Model-based Wilson interval (Kott et al., 2001). We did not investigate these
intervals because they require calculations of additional quantities beyond the point es-
timate and the standard error. We believe that this makes the intervals less appealing to
practitioners and leave their further investigation to others. The Breeze interval is another
interval suggested for use in survey settings (Breeze, 1990). It is based on the Poisson dis-
tribution, so it is only appropriate for small (or large) b p, and it is not expected to perform
well for moderate p. There are transformations, besides the logit and arcsine functions,
that have been suggested. Korn and Graubard (1999, p. 66) describe the use of a log trans-
formation , although this interval is not guaranteed to remain within the 0 to 1 bounds.
The likelihood ratio interval is obtained by inverting the likelihood ratio test H0 : p = p0
(Feng and Sitter, 2008). This interval was not included in our simulations because an
iterative algorithm is required to ﬁnd the bounds, which we again believe makes the in-
terval less appealing to users. Finally, the class of replication-based methods, including
the bootstrap and jackknife, comprises an important category of methods for the analy-
sis of survey data (Rust and Rao, 1996). These intervals are interesting, but we excluded
them because of the computing complexity.
Our work has important practical implications because it addresses basic questions that
are not fully described in the literature. We reiterate the importance of avoiding the Wald
interval, but we also provide a variety of viable alternatives that are operationally simple
to calculate. Among these intervals, the modiﬁed Jeffreys and modiﬁed Agresti-Coull
have not been evaluated previously. We also provide a more structured framework for
handling the design degrees of freedom, data truncation, and degenerate data with the
goals of inducing equivalencies and increasing logical consistency.
136A. AppendicesA.1 The use of the ﬁnite population correction in survey
design for national disease surveillance
A.1.1 Estimating Survey Variance in an Inﬁnite Population
In the ﬁrst stage of sampling, n PSUs are sampled without replacement using probability
proportional to size (PPS) sampling into a set S deﬁning the indices of the sampled PSUs,
and m SSUs are sampled using simple random sampling without replacement from each
selected PSUi into a set Si deﬁning the indices of the sampled SSUs.
wPSU;i = [Pr(i 2 S)]
 1 PSU weight
=
M
nMi
wSSU;i = [Pr(j 2 Siji 2 S)]
 1 SSU weight (equal 8j 2 Si)
=
Mi
m
wi = wPSU;i wSSU;i Overall weight
=
M
nMi
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m
=
M
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 w
b T =
X
i2S
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c M =
X
i2S
wim Denominator
=
X
i2S
M
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m
= M since PPS
b p =
b T
c M
Prevalence estimator
The following is derived using a result from Lohr (2010, p. 229). Let T =
PN
i=1 Mipi. We
make the assumption that site size (Mi) and site prevalence (pi) are independent.
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A.1.2 Estimating the Intracluster Correlation Coefﬁcient
We can show Equation 5.1 using standard formulae for the Beta distribution and the Beta-
Binomial distribution Gelman et al. (2004, pp. 576-577) and additional notation from
Ridout et al. (1999). The PSU means are sampled from a Beta distribution with parameters
 and .
The grand mean is:
p =

 + 
The variance of the PSU means (pi) is:
V arPSU 

( + )
2 ( +  + 1)
The intracluster correlation (ICC) is:
ICC =
1
 +  + 1
We now verify that Equation 5.1 is consistent with the known ICC of the Beta-binomial
distribution:
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A.1.3 Estimating Design Effect in an Inﬁnite Population
For the second method, we consider the design effect for a binary outcome estimated
via a two-stage cluster survey in an inﬁnite population. The denominator of the design
effect is the simple random sample variance with replacement. A simpliﬁed approach
to calculating the simple random sample variance is to calculate the unit variance of a
beta-binomial random variable and divide this by the overall sample size (nm).
V ar(b pjone unit sampled) =
( +  + 1)
( + )
2 ( +  + 1)
=


 + 


 + 

= p(1   p)
We can then demonstrate that the design effect in an inﬁnite population is the following:
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141A.1.4 Comparing First Stage fpcs for PPS Sampling
Here we assess the properties of the ﬁrst stage fpc of Wolter so it can be compared with
the simpler ﬁrst stage fpc used by Stata.
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Interestingly, this represents the proportion of patients in the population attending clinics
that were sampled, which is not the same as the proportion of patients in the population
sampled.
ES [fpc1] = ES
"
1  
1
M
X
i2S
Mi
#
= 1  
1
M
N X
i=1
ES [I(i 2 S)Mi]
= 1  
1
M
N X
i=1
nMi
M
Mi
= 1  
Nn
M2
1
N
N X
i=1
M
2
i
= 1  
Nn
M2ES

M
2
i

= 1  
Nn
M2

V arS(Mi) + ES(Mi)
2	
= 1  
Nn
M2
n
V arS(Mi) + M
2o
= 1   Nn
M
2
M2   Nn
V arS(Mi)
M2
142= 1  
Nn
N2  
Nn
N2
V arS(Mi)
M2=N2
= 1  
n
N
 
n
N
V arS(Mi)
M
2
= 1  
n
N
 
n
N
cv
2(Mi) cv
2() coefﬁcient of variation
We can see that the two fpc formulations will be equivalent when Mi is constant across all
i. When the PSU sizes are not equal, we can see that the above formulation will result in
greater variance deﬂation. Thus, the simpler (1 n=N) formulation is more conservative.
A.1.5 Estimating Survey Variance in a Finite Population
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A.1.6 Estimating Design Effect in a Finite Population
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A.1.7 Sample Size Calculation Methods
Derivations for all sample size calculation methods. Note that these methods can return
negative numbers; these should be viewed as impossible (n=a) sample size designs.
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The corresponding predicted conﬁdence interval half-width will be:
tn H;0:975
p
V ar(b pADJ)
Note that the design degrees of freedom are n H where n =
PH
h=1 nh is the total number
of sites sampled, and H is the total number of strata. If no stratiﬁcation is used prior to
site sampling, H = 1.
146A.2 Development of a viral load suppression measure ad-
justed for non-retention for the surveillance of ac-
quired HIV drug resistance
A.2.1 Derivation of adjusted VLS variance estimator
This section outlines the derivation of the variance estimator for the adjusted VLS mea-
sure b pADJ = b V =b S, with notation as deﬁned in Section 6.3. Methodology follows Stata’s
section on variance estimation in the SVY manual (StataCorp, 2013), and it applies a re-
sult from Goodman (1960, eq. 7) for the variance of a product of independent random
variables, referring to the independence of b pV LS;i and b pRET;i. Recall that b pV LS;i = b ti=mi
and b pRET;i = b ui=si. b ti and b ui are independent because they are taken from separate and
unrelated samples (the former from incoming eligible patients and the latter from eligible
patient records).
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A.2.2 Derivation of predicted variance in an inﬁnite population
In this section, we outline the derivation for Equation 6.1 for the predicted variance of
b pADJ for an inﬁnite population (no ﬁnite population corrections). In order to derive this
equation, we assume that sampling of PSUs is PPS (proportional to the total size of the
eligible retention records, Si). Thus, Pr(i 2 SI) =
nSi
S and wPSU;i = S
nSi, where S =
PN
i=1 Si. Let V =
PN
i=1 SipV LS;ipRET;i. Simplifying assumptions are made to yield results
148that limit the amount of prior information required to predict the variance. Among these
assumptions, it is assumed that VLS and retention are independent from PSU size Si.
First, we provide important results about estimating the between PSU variance for ob-
served VLS, retention, and adjusted VLS. First, it can be shown that the between PSU
variance for observed VLS and retention can be expressed using the following formulae
(see Chapter 5).
V arPSU;V LS = ICCV LSpV LS(1   pV LS) (7.1)
V arPSU;RET = ICCRETpRET(1   pRET) (7.2)
Available data suggested no evidence of a correlation between site-speciﬁc VLS and site-
speciﬁc retention (World Health Organization, 2012a, table 9). If we are willing to assume
their independence, we can estimate the variance using the following formulae involving
the between PSU variance of VLS, V arPSU;V LS, and the between-PSU variance of reten-
tion, V arPSU;RET (Goodman, 1960, eq. 6).
V arPSU;ADJ = p
2
RETV arPSU;V LS + p
2
V LSV arPSU;RET + V arPSU;V LSV arPSU;RET (7.3)
To derive the predicted variance for adjusted VLS, we use a result from Lohr (2010, p.
229) and Goodman (1960, eq. 6) for the variance of a product of independent random
variables; the assumption of independence is justiﬁed for reasons stated in Appendix
A.2.1.
A.2.3 Derivation of predicted variance in a ﬁnite population
In this section, we outline the derivation for Equation 6.2 for the predicted variance of
b pADJ using ﬁnite population corrections. We proceed using the same notation and many
of the same results as Appendix A.2.2.
149V ar(b V ) = V arSI

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h
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(7.4)
(Goodman 1960)
Deﬁning V arPSU;ADJ as the between PSU variance of the pV LS;ipRET;i terms
Assuming m; s same for all PSUs
Assuming independence of Si; pV LS;i; and pRET;i
Assuming Si=S  Mi=M
Replacing V arPSU;V LS with ICCV LSpV LS(1   pV LS) by Eqs. 7.1,7.2
Assuming that
N X
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1
Mi
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::: (7.5)
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150If ﬁnite population corrections will be used during the survey design,
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(7.7)
V ar(^ pADJ) = V ar
 
b V
S
!

V ar(b V )
S2 Using Eq. 7:7 (7.8)
The corresponding predicted conﬁdence interval half-width will be:
tn H;0:975
p
V ar(b pADJ)
Note that the design degrees of freedom are n H where n =
PH
h=1 nh is the total number
of sites sampled, and H is the total number of strata. If no stratiﬁcation is used prior to
site sampling, H = 1.
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